var title_f31_0_31744="Location of retropubic midurethral sling";
var content_f31_0_31744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retropubic midurethral sling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31744=[""].join("\n");
var outline_f31_0_31744=null;
var title_f31_0_31745="Red macular lesion of VIN";
var content_f31_0_31745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar intraepithelial neoplasia (VIN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Red macular lesion as a manifestation of VIN.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christine Holschneider, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31745=[""].join("\n");
var outline_f31_0_31745=null;
var title_f31_0_31746="Apical 4 chamber color Doppler diastole";
var content_f31_0_31746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical four chamber view with color flow Doppler during diastole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is the apical four chamber view with color flow Doppler during diastole. There is physiolgic flow (tagged red) into the left ventricle (LV) that extends from the right superior pulmonary veins (RSPV) to the apex of the LV. This color signal is used to position a pulsed wave Doppler sample volume so that quantitatable signals of flow can be obtained from the pulmonary veins and from the mitral leaflet tips.",
"    <div class=\"footnotes\">",
"     RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31746=[""].join("\n");
var outline_f31_0_31746=null;
var title_f31_0_31747="Docusate and senna: Patient drug information";
var content_f31_0_31747=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Docusate and senna: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8115?source=see_link\">",
"     see \"Docusate and senna: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/52/5955?source=see_link\">",
"     see \"Docusate and senna: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doc-Q-Lax [OTC];",
"     </li>",
"     <li>",
"      Dok&trade; Plus [OTC];",
"     </li>",
"     <li>",
"      Geri-Stool [OTC];",
"     </li>",
"     <li>",
"      Peri-Colace&reg;  [OTC];",
"     </li>",
"     <li>",
"      Senexon&reg;-S [OTC];",
"     </li>",
"     <li>",
"      Senna Plus [OTC];",
"     </li>",
"     <li>",
"      SennaLax-S [OTC];",
"     </li>",
"     <li>",
"      Senokot-S&reg; [OTC];",
"     </li>",
"     <li>",
"      SenoSol&trade;-SS [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to docusate, senna, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, upset stomach, or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11255 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31747=[""].join("\n");
var outline_f31_0_31747=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015296\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015295\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015300\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015301\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015303\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015298\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015299\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015304\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015305\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8115?source=related_link\">",
"      Docusate and senna: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/52/5955?source=related_link\">",
"      Docusate and senna: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_0_31748="Hetastarch: Pediatric drug information";
var content_f31_0_31748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hetastarch: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"    see \"Hetastarch: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19187?source=see_link\">",
"    see \"Hetastarch: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hespan&reg;;",
"     </li>",
"     <li>",
"      Hextend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hextend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Plasma Volume Expander",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"      see \"Hetastarch: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &lt;1 year: 7.5-15 mL/kg/dose has been used in one small study (Boldt, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;1 year: 10 mL/kg/dose; the total daily dose should not exceed 20 mL/kg (Brutacao, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Volume expansion: I.V. infusion: 500-1000 mL (up to 1500 mL/day) or 20 mL/kg/day (up to 1500 mL/day); larger volumes (15,000 mL/24 hours) have been used safely in small numbers of patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukapheresis (Hespan&reg;): I.V. infusion: 250-700 mL;",
"     <b>",
"      Note:",
"     </b>",
"     Citrate anticoagulant is added before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Initial dose is the same but subsequent doses should be reduced by 20% to 50% of normal",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 6% (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hespan&reg;: 6% (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in lactated electrolyte solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hextend&reg;: 6% (500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Sodium chloride infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Administer I.V. only; infusion pump is required. Change I.V. tubing or flush copiously with normal saline before administering blood through the same line. Change I.V. tubing at least every 24 hours. Do not administer Hextend&reg; with blood through the same administration set.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F179082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hespan&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Cimetidine, diltiazem, doxycycline, enalaprilat, ertapenem, nicardipine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amikacin, cefamandole, cefoperazone, cefotaxime, cefoxitin, gentamicin, ranitidine, theophylline, tobramycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, cefazolin, doxycycline, ranitidine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hextend&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, amikacin, aminophylline, amiodarone, ampicillin, ampicillin-sulbactam, atracurium, azithromycin, aztreonam, bumetanide, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexamethasone sodium phosphate, digoxin, diltiazem, diphenhydramine, dobutamine, dolasetron, dopamine, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, erythromycin, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, furosemide, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, inamrinone, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, lorazepam, magnesium, mannitol, meperidine, methylprednisolone sodium succinate, metoclopramide, metronidazole, midazolam, milrinone, morphine, nalbuphine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, palonosetron, pancuronium, phenylephrine, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, ranitidine, rocuronium, succinylcholine, sufentanil, sulfamethoxazole/trimethoprim, theophylline, thiopental, ticarcillin/clavulanate, tobramycin, vancomycin, vecuronium, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, diazepam, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature of 25&deg;C (77&deg;F); brief exposure up to 40&deg;C (104&deg;F) does not adversely affect product. Do not freeze; do not use if crystalline precipitate forms or is turbid deep brown. In leukapheresis, admixtures of 500-560 mL of Hespan&reg; with citrate concentrations up to 2.5% are compatible for 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood volume expander used in treatment of shock or impending shock when blood or blood products are not available; does not have oxygen-carrying capacity and is not a substitute for blood or plasma (FDA approved in adults); Hespan&reg;: Adjunctive use during leukapheresis to improve granulocyte harvesting and increase the yields (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hespan&reg; may be confused with heparin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, circulatory overload, heart failure, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, intracranial bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, pruritus (dose dependent; may be delayed), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amylase levels increased (transient), metabolic acidosis, parotid gland enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding, bleeding time prolonged, clotting time prolonged, dilutional coagulopathy, disseminated intravascular coagulopathy (rare), factor VIII:C plasma levels decreased, hemolysis (rare), plasma aggregation decreased, PT prolonged, PTT prolonged, thrombocytopenia, von Willebrand factor decreased, wound hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (indirect)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, pulmonary edema (noncardiac)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, flu-like syndrome (mild), hypersensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Hypotension, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hetastarch or any component; severe bleeding disorders, renal failure with oliguria or anuria (not related to hypovolemia); and fluid overload condition (eg, congestive heart failure, pulmonary edema). Hextend&reg; is also contraindicated in the treatment of lactic acidosis and in leukapheresis.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients allergic to corn (may have cross allergy to hetastarch). Use with caution in patients at risk from overexpansion of blood volume, including the very young or aged patients and those with CHF or pulmonary edema. Use with caution in renal impairment; potential for circulation overload. Hextend&reg; contains calcium, lactate, and potassium. In presence of renal glomerular damage, hetastarch may leak into urine and increase specific gravity. Use Hextend&reg; with caution in situations where electrolyte and/or acid-base disturbances may be exacerbated (renal impairment, respiratory alkalosis). Use caution with hepatic impairment; transient elevations of indirect bilirubin reported. Use with caution in patients previously or concurrently receiving other anticoagulant drugs. May temporarily increase serum amylase concentrations; elevation persists longer in patients with decreased renal function.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anaphylactoid reactions have occurred. Infusion of large volumes of hetastarch or use over an extended period of time (days) may result in transient alterations of blood coagulation by hemodilution (decreased Hct and plasma protein values) and a direct inhibitory action on Factor VIII which can result in reversible von Willebrand's-like syndrome and/or a Factor VIII deficiency. Avoid administration of volumes &gt;25% of total blood volume or &gt;20 mL/kg in less than 24 hours and extended use. Consider replacement blood products if clinically indicated; if coagulopathy develops, it may take several days to resolve. In patients undergoing open heart surgery, increased bleeding has been reported; use is not recommended as cardiac bypass prime while patient is on bypass or in the immediate period following bypass discontinuation; bleeding risk decreases within hours. Avoid use in patients with subarachnoid hemorrhage; significant clinical bleeding and death have been reported with extended use of hetastarch over a period of days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Volume expansion: capillary refill time, CVP, RAP, MAP, urine output, heart rate, if pulmonary artery catheter in place, monitor PWCP, SVR, and PVR; hemoglobin, hematocrit; for leukapheresis, monitor CBC, total leukocyte and platelet counts, leukocyte differential count, hemoglobin, hematocrit, prothrombin time, and partial thromboplastin time",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hetastarch is a synthetic polymer which acts as an oncotic agent to produces plasma volume expansion; effect is approximately same as 5% albumin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of volume expansion: I.V.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24-36 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Molecules &gt;50,000 daltons require enzymatic degradation by the reticuloendothelial system or amylases in the blood prior to urinary and fecal excretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Smaller molecular weight molecules  are readily excreted in urine; ~33% of dose excreted in first 24 hours in patients with normal renal function",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hetastarch is a synthetic polymer derived from a waxy starch composed of amylopectin, average molecular weight of Hespan&reg; is 600,000 kDa (range: 450,000-800,000 kDa), average molecular weight of Hextend&reg; is 670,000 kDa (range: 450,000-800,000 kDa); each liter of Hespan&reg; provides 154 mEq sodium chloride; each liter of Hextend&reg; contains the following electrolytes: Sodium 143 mEq, chloride 124 mEq, lactate 28 mEq, calcium 5 mEq, magnesium 0.9 mEq, potassium 3 mEq, and dextrose 0.99 g",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boldt J, Knothe C, Schindler E, et al, \"Volume Replacement With Hydroxyethyl Starch Solution in Children,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1993, 70(6):661-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/0/31748/abstract-text/7687142 /pubmed\" id=\"7687142 \" target=\"_blank\">",
"        7687142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brutocao D, Bratton SL, Thomas JR, et al, &ldquo;Comparison of Hetastarch With Albumin for Postoperative Volume Expansion in Children After Cardiopulmonary Bypass,&rdquo;",
"      <i>",
"       J Cardiothoracic Vasc Anesth",
"      </i>",
"      , 1996, 10(3):348-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/0/31748/abstract-text/8725415/pubmed\" id=\"8725415\" target=\"_blank\">",
"        8725415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13350 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3B792D9370-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31748=[""].join("\n");
var outline_f31_0_31748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179043\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179044\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059235\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059230\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179025\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179010\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059238\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179082\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059232\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059237\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179084\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179081\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059242\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059229\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059228\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299443\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220790\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179020\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888219\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059234\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059227\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059240\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059241\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059243\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=related_link\">",
"      Hetastarch: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19187?source=related_link\">",
"      Hetastarch: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_0_31749="Epidemiology of pediatric HIV infection";
var content_f31_0_31749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of pediatric HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31749/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31749/contributors\">",
"     Susan L Gillespie, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31749/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31749/contributors\">",
"     Mary E Paul, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31749/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31749/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/0/31749/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiology is the study of the determinants and distribution of disease. The epidemiology of pediatric human immunodeficiency virus infection (HIV) will be discussed here. Diagnostic testing for HIV infection in infants and young children, the natural history and classification of pediatric HIV infection, and HIV infection in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35525?source=see_link\">",
"     \"Diagnostic testing for HIV infection in infants and children younger than 18 months\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1737?source=see_link\">",
"     \"The adolescent with HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840561#H18840561\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOBAL HIV/AIDS STATISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the joint United Nations Programme on",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    (UNAIDS), 34 million people worldwide were estimated to be living with HIV or acquired immune deficiency syndrome (AIDS) at the end of 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/1\">",
"     1",
"    </a>",
"    ]. Most reside in the developing world, with approximately two-thirds in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/1\">",
"     1",
"    </a>",
"    ]. The annual rate of incident (new) HIV infections is believed to have peaked at &gt;3 million in the late 1990s and was 2.5 million in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 12 percent of these infections (330,000 cases) occurred in children younger than 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Developed countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States and other developed countries, the number of children newly infected with HIV has decreased dramatically. This decrease is a consequence of the success of interventions to prevent mother-to-child transmission (PMTCT) of HIV. These interventions include early identification of HIV infection in pregnant women through routine antenatal testing, provision of antiretroviral medications to both the pregnant woman and her infant, delivery by elective cesarean section when indicated, the complete avoidance of breastfeeding, and the widespread availability of educational programs addressing HIV infection, prevention of HIV perinatal transmission, and HIV counseling and testing services [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) estimates that the number of infants born with HIV each year in the United States dropped from 1650 in 1991 to fewer than 200 in 2004. At the same time, new pediatric AIDS cases and AIDS deaths also have plummeted, in large part due to powerful combinations of antiretroviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840582#H18840582\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'HIV infection treated with ART'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prospective surveillance in the United Kingdom and Ireland also documented dramatic improvement in the prognosis of children with perinatally acquired HIV who were treated with antiretroviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/4\">",
"     4",
"    </a>",
"    ]. Mortality, progression to AIDS, and hospital admission rates all significantly declined in this cohort of 944 children, including those who acquired the infection in a developing country.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, 330,000 infants and children were newly infected with HIV worldwide, more than 904 infections each day [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/1\">",
"     1",
"    </a>",
"    ]. Although access to care and treatment services for HIV-infected children in resource-limited settings is expanding, it is estimated that in 2011 only 28 percent of children in need received antiretroviral therapy and 230,000 children died from HIV and AIDS, joining more than 4 million children already claimed by the epidemic.",
"   </p>",
"   <p>",
"    More than 90 percent of children living with HIV in developing countries were infected through mother-to-child transmission during pregnancy, around the time of birth, or through breastfeeding. In order to reduce the number of infected children, increasing emphasis has been placed on PMTCT programs with the use of antiretroviral medications in the pregnant woman during pregnancy and at delivery and starting immediately after birth for the exposed infant. Although these programs continue to scale up on a global basis, only a portion of HIV-infected women in resource-limited areas have access to them. UNAIDS estimated that in 2011, about 57 percent of pregnant women living with HIV in low- and middle-income countries received antiretrovirals for PMTCT, including antiretroviral therapy for their own health. This represents an increase in coverage of antiretrovirals for PMTCT from 45 percent in 2008 and 15 percent in 2005. Despite these gains, coverage of antiretroviral medicines to HIV-infected pregnant women for PMTCT in low- and middle-income countries varies greatly. Seven low- and middle-income countries had greater than 75 percent PMTCT coverage, while 15 such countries had less than 50 percent coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. It is hoped that with continued expansion of PMTCT, this mode of transmission may become rare in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR HIV ACQUISITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behaviors that increase the risk of HIV acquisition include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Having unprotected sex with an infected person",
"     </li>",
"     <li>",
"      Having blood-to-blood contact with an infected person",
"     </li>",
"     <li>",
"      Injection drug use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, infants may be exposed during pregnancy, birth, and breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exposure through sexual contact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual intercourse is the major route of transmission of HIV throughout the world. The precise risk of HIV transmission from one act of sexual intercourse with an infected person is not known. Although some people have had multiple sexual contacts with an infected person without acquiring HIV infection, others have become infected after one sexual encounter.",
"   </p>",
"   <p>",
"    In general, the risk of acquiring a sexually transmitted infection is proportional to the number of different sexual partners. However, for some women, a steady male partner who has sexual contact outside the primary relationship is the only source of HIV exposure.",
"   </p>",
"   <p>",
"    Several biomedical interventions have the potential for radically changing the patterns and rates of HIV transmission. Randomized controlled trials in several African countries indicate that male medical circumcision reduces the risk of heterosexually acquired HIV infection in men, and the World Health Organization (WHO) recommends male circumcision as part of a comprehensive HIV prevention package. The effect of male circumcision on HIV transmission is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=see_link&amp;anchor=H14#H14\">",
"     \"Neonatal circumcision: Risks and benefits\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pre-exposure prophylaxis against HIV infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link&amp;anchor=H7740894#H7740894\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exposure through blood or blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct exposure to HIV-infected blood is an efficient way to transmit HIV. Exposure to HIV-infected blood may occur nosocomially through a tainted blood transfusion or through needlestick accidents suffered by healthcare workers, or in the community through the use of nonsterile razor blades for ritual scarring or traditional healing.",
"   </p>",
"   <p>",
"    Compared with industrialized nations, countries in sub-Saharan Africa experience more transfusion-associated HIV transmission because of a higher prevalence of HIV infection in donor populations, a lack of HIV antibody screening in some areas, and a higher residual risk of contamination in blood supplies, despite antibody screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8230187\">",
"    <span class=\"h2\">",
"     Exposure through injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of illicit drugs is increasingly associated with transmission of HIV worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link&amp;anchor=H14#H14\">",
"     \"The global human immunodeficiency virus pandemic\", section on 'Injection drug use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exposure through pregnancy, birth, or breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertical transmission of HIV can occur at any time during gestation and delivery, and through breast milk in the postpartum period. More than 95 percent of HIV-infected children worldwide have acquired the virus via vertical transmission. The rate of vertical transmission of HIV varies from approximately 20 to 30 percent in the absence of antiretroviral therapy. Although it is known that HIV can be transmitted early in gestation in utero, most transmissions (50 to 80 percent) are believed to occur during the time period near or during delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of antiretroviral therapy in HIV-infected pregnant women and their infants has virtually eliminated mother-to-child transmission, lowering the HIV transmission rate to less than 2 percent in some parts of the world. Prevention of new vertical HIV infections is one of the most powerful methods available to reduce the global impact of HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall rate of perinatal HIV transmission is approximately doubled in populations where breastfeeding is the norm compared with areas where breastfeeding is uncommon among HIV-infected women. The WHO guidelines emphasize that expanded antiretroviral treatment for mothers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infants during pregnancy, delivery, postpartum, and the breastfeeding period could reduce the risk of vertical transmission to 5 percent or less in breastfeeding populations. Risk factors for and prevention of HIV transmission through breastfeeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WHAT DRIVES THE EPIDEMIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemics are the result of complex interactions between biology and the",
"    <span class=\"nowrap\">",
"     environment.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Increased travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/AIDS",
"    has followed the routes of trade and commerce and the movement of labor, goods, and services. These are routes of legitimate commerce, as well as illegal activities, such as trafficking in humans and illicit drugs.",
"   </p>",
"   <p>",
"    Migrant labor plays a particularly important role in southern Africa, where the mining industry attracts workers from all over the region. Most miners live in single-sex dormitories, often far from their families. They may contract HIV through sex with prostitutes and subsequently transmit the virus to their wives, who may in turn transmit it to their infants during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     War and instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;War and instability may affect the spread of HIV by altering the routes of trade and commerce. The presence of a military force may increase exposure to HIV through commercial sex, casual and consensual sex with other soldiers or civilians, or rape in times of conflict. In addition, war and conflict often weaken or destroy public health systems, legitimate commerce, safe food supplies, and stable social arrangements.",
"   </p>",
"   <p>",
"    To the extent that war and conflict restricts movement within a country, cross-border migration, and trade, they may also slow the spread of HIV infection (eg, as occurred in Sierra Leone) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/8\">",
"     8",
"    </a>",
"    ]. In such situations,",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    prevention efforts are a critical part of the reconstruction and normalization process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cultural norms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultural barriers often prevent women from taking necessary precautions to protect themselves and their infants from HIV. Domestic violence reduces women's control over their exposure to HIV. In cultural settings where supremacy and violence are regarded as a man's right, women can seldom question their husbands about extramarital encounters, negotiate condom use, or refuse sex [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/9\">",
"     9",
"    </a>",
"    ]. In a study from Soweto, South Africa, women who reported having been physically or sexually assaulted by an intimate male partner were more likely to be HIV infected. A high degree of male control in relationships was also associated with increased risk of HIV infection among women [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31749/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Poverty",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIDS tends to disproportionately affect the politically and economically disenfranchised. All over the world, the prevalence of HIV is increased in communities where people are poorly educated and living in poverty.",
"   </p>",
"   <p>",
"    It is often poor, uneducated women and children who are most susceptible to HIV. Millions of people are vulnerable to HIV because they do not know how it is transmitted or because their life choices are constrained by poverty. Poverty may force women to turn to prostitution or transactional sex (sex exchanged for gifts and favors) as a source of income.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stigma and denial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many regions, denial and silence regarding HIV is the norm. There is a reluctance to admit that a fatal disease spread by behavior that is thought to be immoral is prevalent in the community or country. Certain groups are blamed or stigmatized when explanations for the transmission of HIV are limited to factors such as sexual promiscuity or drug use, but fail to consider the larger issues in disease transmission. As described above, it is not necessary to have multiple partners to acquire HIV, nor is everyone who has multiple partners HIV infected.",
"   </p>",
"   <p>",
"    Denial, silence, stigma, and misinformation create an environment conducive to the spread of HIV and undermine prevention efforts. Inhabitants of communities where HIV is stigmatized are less likely to take advantage of testing and counseling. Fear of disclosing her HIV status may prevent an infected woman from feeding her baby formula to prevent HIV transmission through breast milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGRESS IN PROVIDING PEDIATRIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continued emphasis on prevention of new pediatric infections through prevention of mother-to-child transmission (PMTCT) programs and expansion of care and treatment services for HIV-infected children is critically needed.",
"   </p>",
"   <p>",
"    Globally, there are a number of barriers to implementing pediatric antiretroviral therapy on a wide scale. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of infrastructure",
"     </li>",
"     <li>",
"      Lack and loss of health professional capacity",
"     </li>",
"     <li>",
"      The relatively high cost of some pediatric formulations of antiretroviral medications",
"     </li>",
"     <li>",
"      The perceived complexity of treating children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Without treatment, approximately one-half of children with vertically acquired HIV infection will die by the age of two years. Fortunately, antiretroviral coverage for children is increasing. The United Nations Programme on",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    (UNAIDS) does not provide estimates of the number of HIV-infected children receiving antiretroviral therapy. UNAIDS estimates that 356,400 children were treated with antiretroviral therapy in 2009, increased from 275,300 in 2008. The Baylor International Pediatric AIDS Initiative provides care and treatment to approximately 50,000 HIV-infected children in Africa and Romania.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462158546\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States and other developed countries, the incidence of human immunodeficiency virus infection (HIV) has decreased as a consequence of successful programs to prevent vertical transmission of HIV, including HIV counseling and testing services for pregnant women, antiretroviral therapy providing alternatives to breastfeeding, and educational programs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Developed countries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New cases of HIV and HIV deaths among children continue to occur in resource-limited settings, particularly sub-Saharan Africa, where access to care and treatment services for HIV and programs to prevent mother-to-child transmission of HIV are limited. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Developing countries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 95 percent of HIV-infected children worldwide have acquired the virus through vertical transmission, which can be prevented by the use of antiretroviral therapy among HIV-infected pregnant women and their infants. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Exposure through pregnancy, birth, or breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biomedical prevention interventions, including male circumcision and pre-exposure prophylaxis, may play a significant role in curbing the acquisition of new infections through sexual contact. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Exposure through sexual contact'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"       \"Pre-exposure prophylaxis against HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factors that contribute to the persistent epidemic of HIV include increased travel, war and instability, cultural barriers that prevent women from taking precautions to prevent HIV, and stigma and denial. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'What drives the epidemic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Without treatment, approximately one-half of children with vertically acquired HIV infection will die by the age of two years. Continued emphasis on prevention of new pediatric infections through expansion of programs that prevent mother-to-child-transmission and provide treatment services for HIV-infected children is critical. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Progress in providing pediatric treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     UNAIDS: 2012 report on the global AIDS epidemic 2012. Available here: www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31749/abstract/2\">",
"      American Academy of Pediatrics Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics 2008; 122:1127.",
"     </a>",
"    </li>",
"    <li>",
"     CDC: Perinatal HIV Transmission 2007: file://www.cdc.gov/hiv/topics/perinatal/overview_partner.htm (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31749/abstract/4\">",
"      Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019.",
"     </a>",
"    </li>",
"    <li>",
"     WHO: Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2010: www.who.int/hiv/pub/2010progressreport (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     WHO: Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach, 2010 version: www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     Pizzo PA, Wilfert CM. diatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents, Williams and Wilkins, Baltimore 1998.",
"    </li>",
"    <li>",
"     UNAIDS. 2004 report on the global HIV/AIDS epidemic. Joint United Nations Programme on HIV/AIDS. December, 2004. www.unaids.org (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     World Health Organization/London School of Hygiene and Tropical Medicine. Preventing intimate partner and sexual violence against women: taking action and generating evidence. Geneva, World Health Organization, 2010: file://www.who.int/violence_injury_prevention/violence/activities/intimate/en/index.html (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31749/abstract/10\">",
"      Dunkle KL, Jewkes RK, Brown HC, et al. Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet 2004; 363:1415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5962 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31749=[""].join("\n");
var outline_f31_0_31749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H462158546\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOBAL HIV/AIDS STATISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Developed countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS FOR HIV ACQUISITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exposure through sexual contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exposure through blood or blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8230187\">",
"      Exposure through injection drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exposure through pregnancy, birth, or breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WHAT DRIVES THE EPIDEMIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Increased travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      War and instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cultural norms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Poverty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stigma and denial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGRESS IN PROVIDING PEDIATRIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462158546\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35525?source=related_link\">",
"      Diagnostic testing for HIV infection in infants and children younger than 18 months",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=related_link\">",
"      Neonatal circumcision: Risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1737?source=related_link\">",
"      The adolescent with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_0_31750="Arteriovenous malformation gluteus";
var content_f31_0_31750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83576%7EDERM%2F83577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83576%7EDERM%2F83577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxjVfA9xAHeyl80D+Bhg4rkriCWCUxTxtG46hhjFfSE9jG/ReDXN6/4atdQQpPEC38LL1FerDE9GTKlY8PA7YpwXnBrqtW8H3dm7m2bz4wM46NXOTQvAxWZSj+hFd0JqWxi0QqvH8qU/d4PTkUqryeelLt4+p/I1smIYBx+v401uTx096kwSfTsfrTG7ik5CIyOcUAdRTj7UoHHvUR1Y2Kq9s05AB15FG3bjjNSKuFz610xJGYw3H4U3nNOIJIzxinHbRcCMHjtinrGCAc8+lBz02j2pyg8NkjHeiKATnvkZxTlHHDdsmnFSAD06daI0HJPHWtEiRGQkk8DmoyTxuODjjFSsQW3YO04JphUAtx64pMEREZxSwp2yM9Ce1K/JyRkH0pIRnPOPoKy+0iuhNyGGCB2qRu5kBJUYP17UzJzwckinBTkry3OGGetbogam0rz3GDQEJUFcnPH409UDHAADEgYPagKRtA47MO1CAcY2EmGB3jg/NypHemxggtu4cn5T7+tSBRjJV8Nw3OB7UpjPDyj5ScnHemAzqDx16AdmFCgMzKccgH0Gae7q+6VVCKwIAU8A+9ChWO44YAZ69TTBgkDyMwUDj5skfoKdHGS4SMnawzu9PrQuAwGcH75APanFM5b5gvBA3Z470E6jPJQKDJkrwQRxnnmkCCQ70XainI9T+FT5G/HLADI7cU3zWDRIBxGfkPdR6fSgLsjJBkfyy23OcZyfwpnKq46HqnHNTcsX3DCj7pA4pqfKuGKkxgEDHX1oBDo96YeNjlfnU4+96gU9gijjDMp8zKgdD2pJGbIjRWaKMkDJwcHtSNkEAnO1s5XqF9Kq4rCoc7idylWG3jGB349PeieMLKfL2oR86gNyB6fWpI3YsxGZDB8wf/AGe2fWoBL8+/ezMhLKO2PT6Urodh6lZIZIyXJPzKzYUHHakVAc7HVT1C56H0pFEfltlOrblGTjHtT59iqjZBUAOrfxfQ0eYCPuIVlO0scoOpHr+FE5J2uvLMu9Tn+LvxSrG0jOCZAyjeMMOB3+tNO+SMqNxSI7tuOQPSi40rCuMtkJIzON4xxg96TYwRoiPlJ8xVU5/WnTAKfMQDDDfGq8gL0IPp3pzDyFxEWTBDBsfwkdDUrUBrQJAm0ffbEi7W3ZU9RXR+H/COo6gFmLC3jYnY753EfSrvgfw8Lmc3Ui+ZED+6yuNwr2LSbFIowxGT0Ga8jGZj7J8lPc9XB5f7X3p7HFaV8N7HYv2gSXLD+8do/IV0lt8PtJSHyzYxsg7HJrsLG2O8EDit+KFQnPavFqYytN3cmev9TpU9FE8i1T4daZKD9njaGQAgEEkfQg9q8q17w7daBdj7SjvbI+6OUDCnPGCexr6glgDSNwc1yPiywimtLgSRrIhUhlI4YeldmEx9SErTd0cuMy+DjeGjPnBGJmO1EMS5dVIzle4BprqpGd5AJLK208D0xV3VLRbG8mtg7L5Mm9VI+9GemD61RbiU+VveMHcWHdT7dq+jUrpNHzzTTsSInlgvGpZ48SZYDZ7j37cVATsdj91iAyjb8pHofpVg4i84mKTMUnRj/Cf0/wAaI40JKSCR0jGM4A2qTwev5U2rgUZoCD8qMrLllBPbvUH2dj8o9N4XPJHt61qiaUFVZ2dYi2B12g9T/jTSfLcFSJBEcb0XaQnTg1nKmmx8xlPaMigMq56nDZI9jip7S2iDgzfcVwH7EA96v27LCwmkQFg5Rt65DIwxkj1/GmNEFLCX7sDCNnGCAvY+/eoVKK1ByJZBbxBYGBmCMSSOA0Z5ByOc0FhbSRKFJiiO8oDgnPqe/p9OKbGoWNjjjhGSQHHI65/kKbJIwRFnfcY8xhT/AAJ7HuOa0sRuOQAoXt4wggcFjgtkHpjsB/OikYOyIzEqpDRHaRg4H+Boo5UFz6PkUdBVOa183JH8q0njPOBQIscnmvk4yse1KJz82njPK1n3ugW1yv72BH4xyM12Xkg8npTXhQj5QCa2jVaMHC55Zf8AgKxlO6NHjPqh6Vi3PgB1yIblvo65r2trYEYwMmoxp6nJIH1rojiZLqZukeA3fg3UoBlBHN/unBNYd5p13ak/abeSPHqvFfSc2lp/czVG60eOVCrRhgfUVrHFt7k+zZ83EZIp2zvXseseBrC4ywhEbn+KPiuN1LwRd2xZrRxKB/CRg4rqpVYye5nKLRyOMig5Ax1qxc20tsxSeF43H94YqDHGOprsvYgiOT26U5ck/wBKcwxwKQ7twwAcVIDivCncD7elHPKjGM0pBI3DApCp2g5PrWggC/LhjyRxTyw45+XPakAXbzwcGkYk9Rx6VSYgPTA6Y6CkkHHzHkGpETKgrw3c561E4Gcdc0m9AIn9xinIuUJwMrRjPPTFPUEKOP8A9VZRd5FMeu3Z354PvUmFMeTkEHn3pFUAbTjGemeo9aEbYfkXIxtJ/rWybIYJGz7xnIPc9aVQTuUMBn5SD6+tKiggN1YnB4pynkPJyx4K9PxqgsNdnZVVjznoR0PvQw9ThhzweKf8jvh2OD1PvQqAMdu0npjHX6UrhYYhOMAZ7428ZpQhdcgqAWztHalHYg7WOTxTkyoO04bHGBmi4DmTBbZJtZV+6wwfpTCDtXcW2jsOwpy4P323DOcD0qRBvO+NNxQ42jJJqriG4MSptHmEAknrwe1NZSr/ALphxyMelaUOm6izZhtrmUkYJEZAx6Cp08M6q6f8g+fI4AOACP8AGpdSK6jUJdjEDjHVm643DoDUgOEUbkdEBXk88+1bUfhfV1cZspgD7Aj8aoXWk39ohE9lKAD94oelL2iezHyPqirC7BShAZWGCT0H1NRIu9icEIgO5gat2FlNckC3ikkZSUKKp5q9/YepRKss1lcADK4EZyfSnzrZsXK+iMklFmBOcAbTg9R/jUhIVw0ZUBFAPH8NPe3kiVtyOC3yMHXBGe5oEbYLGItHHxnt7cVV0JoauVL7HUpGeD3x3xSyqodkjUIq85JySp96UQsjAsjgjqDkde9WLDT7q/uFhtYzKwO0jGOPrQ5JLUEm3oVNhMf8ICD5T0Z6Qg7mMbDjGWHUj/61eg6T8PpZ3D3c59kVd2B6ZNdJZ/DfSnAQq7t3JY1xzx9GPU6Y4SrJXseNBVVseaSqnJwOce9dDoHhi71BJLj/AFdnCpPnEf6wY6AV3lz8NtNt7q3TdKVZvuHkEZzXTa9DDY6H5ECrHHs2YUYwK5cTmKStT3LpYVyfvLYy/DNssVrCiABQuAPau5sIhLGqhTgd64/RseSvOMV1Ol3XkqQxPNfPVJOTufTUIpRsjrdNjVE+70ps04MzEAq3T6VUtbxgnHGaglkDOSeCfeskzWK11L4wy5IHA5JrlvEtzFHHKWGRtPA9+la098sUZyeg45ryz4keJPsVuTGw86Rto7498e1dVCDnJRRx4mqoRbZ5r4qlgk8Q3LiVvLjCxOqDk4GOPxrGUgAgrhgNrEHJPpx2/WpW+zTOjvKxkdiNwGNp7NnvzQiwZijniZduUZg3zZ/vD1FfYQjypI+Vbu7kIdsr87OFyjMTjI7A+uKfgbVwpAQbSG4GD0z60twF/dxAGNdhVs8jdnjJ/wA4p8eH3CQSfMNqEYKhu4Y9SAP5VQmIVEssZlQbUIgO448vPQn19c05Ytm5njQBcwsCeG/2h7+9LEq4dJZIXeVSjFicAjkNnt6U1SxLQvGrM8YkwxGOORz2pepL1HsZbjygCuXTb84PzEHgfU9KjSFjdqAJMuvlAsAcN6EenYUSBnyZHV8oHBA/T19qHePJ8vKOFDrtGRkHkA/T86TERuQqGVwcSYUleVLA8k5709JWnKmNJYkcbAQBhXHPH6VP8/mstvJHKrfvgp4XPfAPB78UiI3myCKZn3fvmVlzhh7Hk/h6UDIY4ht3IwdZl2hPusHHRiDx9e1FDbjP5iMZHT95HIrYOR6A+9FS7gfSkkhVQvBPehVYjNRxnc2Sc/Wrsa7gCMDPWvkWe62hiqSBT0hYtnr7U4Y3YPH0q3FjGRikIgEHOD+dPEITrUxByciliUk5J+WjmDlQ1og6jsBVW4txtxwBWiwAUnvVbqSapTJ5LmPLZ7gSQMVn3FiHPygYropDjJJBz2qrhXPbHtWiqMl0zkdS0SG5UrNCjqexWuP1LwLZvuNvut39jkV6+8CnAA/GqNxZJyRxW9PEyjszF0l1PAdV8JajYguqCeMd4+o/CsBkIJG3B7g9a+h57JVJNct4g8L2uoqzeWI5j0kQYNd1LGp6TMZUWtjx9lwO47U4FjnPJAxXR6j4U1K1lbZEZ0HQp/hWPNYXcLMJLaZPqprvjNPVMxcWtypjlSQPelC/LgAdM0MjIxyCD6HingqRg9R1rRMREcd/wpjDjk8VLnnjp6UxxnOBxUS2BERADDB3Cpl4I7kHp7VEAPwqwgz7Y5+tRTepTF25YcKB0604KQDuUZzjOavWGlXmpOFtIC65zv7fnXX6T4CaXB1CcknkpF0/OlVxNOl8TKhRnU+FHDRo5xGoMhcfdAyRj0rf0vwhq2p4ZYxBGwwWl4J/DrXq+i+F7OyRVtrdUPc4yfzrpraxCLtAGa86rmvSmjsp4G/xs8w0/wCGUWB9ru5Wb0jAArat/htpSt80cshP96Q16Pa2QznjNXFtQp+bjntXFLH1ZdToWFprSx503w20mTBe2/JjToPh7pMJG21U445JNegz7UyNwFU5ruNRg4J9qj63VfUr6tDsctH4K0mEbhYwjAxyM1aj0qytxhIYU9MKBVu/1I5CR8/0rJmmaTJkY59BR7WpLdi9lCPQsStBEcblI9jUEtxbFsbhmqbYIPymo/IVs/L071RorLdGrBJDJwhXjjBqz5ETkoyBgetYib42wsSmrEV3JCwLIBk4wDzRr0M58rNzTNMtYIsRQooJPAXFaK2SuDwprGivbgYC/KPfmr0Uty2CJQD9KiTk3uOEoRQ660i2cZeFCfQqKrR6BahcrDGB3+UVdE06jEmHX9RVyBxtByCp7is3UnHqdEVTl0MWTQraeNo5II2jIwQVBFZ1voUGmziOOJUjJ42riu1hQBuACKnezjuUKsvX25FQ68rWuX7CCfMkU9I09fLJCj5quPpLQy7kX5TyauaNH5TeU3LKePcV0xtUaHJXk9hWTqApcr9Ty/WoSmsW6EHhCR9c1meJrR7nTZiudyrk11fjO2EGp2UqggNlST2qNrRZbORcZ3KQQaanchqy0PLdKvNiKO5rpra5DbfT3NcneW8mn380Lr91uD7VcguiVyvFRqdUJ2R2TXrKo2kYH6VB/baQrIzjLsNqcZCnuTXOC9wDubAxWVqd98h2kmqjG45VkkafiLxOIbeSQuCVGSehNeKa7qlxql408zZC5CKeig10eqo95PjkgGuZ1yOO2KQxHL53N/hXpYWPI+Y8bF1efToMjkZs7cO7jI+Xnip/LDQg5G94wVA7ODyAarQbkQMFy0bBgeowfX2q0qm2dZVIjmVtxB/hU+3cGvpKbulc8qQiQSTdF3vOhIXqCynt+tAYGSRoDsLqHAb7px1B9PanmJ4HZyQGt3DlRwdp/iB9ORQiBXeQHCK+4tuHKk+lXYlhuRRhf3mQJFI4KHPP1pl0zwEiNj5o+dXwOATyD71aCwLAAFDlWKsW5G1uhX3qsISDuEsQO/yn3DAYdif5UCsRKCk20OVJbg4wdrdf/wBVWYvtCRBTlY43yC2PutwMj6Y/Cmuf3GCxYY8tx3DAnHPf60Yt5LaNVU+YyFJF64YdMc85HNK4mLJ5UWTuXzEJSVUywx2b6e3rTFjUBpg8bbH2BnJy2ec/p+tSBTlF2BGZTE4A3Hpwcen/AOunO9vJglnDspUsuMM69Dg9OMflmkxELlNgOApiBXlevXHHUZ9feipDKzRx/MpZ0MTfKTtx3Ge9FAH0ZboASOM1eQbV461DHAS24irioAADXyN0exrcrBSSOeTVqEY4PegxjqacCCcnj0xUt3LRMc4x1JoVwDzTYwdhbvR1PepNE0PIBU8844FV5eRjGPpVlEDYxmlaLHXvTTIkzOmXC/MwyKqg7TnGM1oSxZ4IzSC0JGT1q00LYqrKudvamyqxHA+lWxZBWz1zUwtwFpXQ9zBki5Ixz15qq9pv5INdM1srD7tQPbDGapTJaaZzb2YHJBz24qtNYqeqA/hXTmyZsn+EVXltcfdq41GiXFM5C60OzuBie1hYHrlRmua1TwDay7nsnML9QvVa9Nls2PXmqktqF9a6IYqcNmZyop7nhGseG9Q0zc00JkT+/HyKwyOf519DzQKVIcAqfauQ8R+EtOvP3kI8i5Y8FO/1FdkcapK0jF0n0PKbeCSeRY4Y2kc9FUZJrvPDXg2QlJtTUs3BWHsP96uz8H+ErbTIgUj3St96Rup+npXZ22lhcErXJWxrtaB10cIm7zMPTNGWKNUCKoHRVXAFbcdksSgKvPcitaK22qDgH6Vdite+OnWvMnUcjuUFDoZVnEfMxjoKviFY+f4qeSkfzNtGR0rNur9ATszmpV2VKS3LwnWIFifwqldapITiP5f51mSzs2dzde1V2YdcnNbQp9zmqVU9izNM7j5pCTVcI5J659aQOAB3NXYGAB31vZIxU29Sk9kCMs2aqyWvPyVubVZcYyDUDRqucjgUiVN3MYRE5U8VPHBleBmre0FgcZq/DEpGUHHcUG3NpqZq2fG7Gcd6hlgyQCO9dNBbKIwP0qpdWvPAy3tQmZydyBIwEAUDp3q1DHtAOMmkgt5GZcgBcZ96vIioSDUNitqJHH5hGR83TFC27RM23O30NW4YwzAqeOlXVjUghgAfasZG8HYzI90TKVztPUelaUDMy5Tt+FMWDBGOPWp1jMeNxPpWMjthUurANwYSRkh15rq9GnW6g7+h9jXLn5hjOPpVjRL37Je+U7fu5On1qGOorrQl8d6W02lSyRgmSLEg/CuW0y9EsMeD25zXp9yBPZOp+ZWH6V45eRPpWq3Fq5xGW3x/7vpQtzOHvxaZH4w0UXtubi3IW4XkccH2Necs0kTsrqysv3lPUV6jBqCt8kuB2zWVrulW96C7BUkx8rr1x710cvMDXKjze4vCmdpOMc81kXeo5OAc11WpaIycEA+4zXNanp0UCFyM1cIO5y1KltzGvNQWGIlDuYe1co7tczmR+Sx59qn1S4EsrIpO1T6113gHwt9sKXl+pEG7McZ4Le/0rtpSjGXvbI4+V1XaJS0DQb3VUHkQHyZYijyseMg8V2umfD5Nwe9u5JZGTY6hRgj2zzXe6fYBIVCqAgHAAwBV+FFjcArk1VXM6stIaI9PDZVC156s57T/AAVpsQH+iI527d0nzEj3zWq/g7TZo2EllAVYYIC4z6V1FlGGO3bweTV426AKRx9a4niard+Z/edrwdJe6oo8c8S/De3ZJZNPkeCVwAQeVOPbtXm2s6fLZXU9vdrCsjRhgxBAJH90+v8AOvpu+C7SODivM/iJoYvbQTxR7p4Tu2ngMvcV6eCx8udQqvQ8rHZcox9pBWPJHhVEfBGTH5qSltpAB5471Du4kkZCrvtkUAjAI9R/SrTlovL2ynEMpQMFBBU9ef0qpGgaFRldiSeW+3qd3TGfwr3Xc8IlyTMQSJCAJlCE/MepH5ZpJxEk05cOgO2RECn15we31pTHsWFJGRTG7QkFSAAT1p8ixDG9nVomMMhB4I7dfcfrSEyEuGSTJKoQJUYnuD90en1oqXc7qizcNE/lsqgkOnp6cdfeii6Cx9RW65XaTzipShxx270RqME/5NPAYtkDA9K+Mue44kMihm2nj+tDJxwOB2p7hcjPWlClW4/Wi5PKxu7BCqOo5p6kBeRmlKgKTjnpQeQBii5SJY8HAGKew2g5HJpFBHGMCkGMnOc9s0AREY++M1Igz83p0FIQFYZ5zUw5b5QMU0yZajcHHbNRlCASepqaUc8dRTUG75u5pNhFdSLHy4qIrjmrbxgDPQCodykjA496EypajNmR6D0qCWPj0FXc57VUnwTgUcwJFKZlVSKzbglshRjPetGSLeaa0WFPFVFiZz91iGMvIcAdvWqVhbvc3HmuMseg7Crl4v2m9KdY4j+Zrd0OxXAZh1PpVSnbQ3oU0/eZb0y0CIoIGTWvDajgHr2q5BZhFVgBz2NWBbnJIA9q5ZSNvQrC2Ea4wAxGaqX8ghtnZWw2cVq3SkRqx4JGK5rW5CI0VerEmlHVhczJ5mlOBwBWXNKfOwvODVu+kMEACjk81m2ili8jn6ZrpgrHPZyV2SOTu/2jUiLkcfnQQd24VIo3fdrVNmUooUqoXp+XemsGVgE+UntUgXYwIOT0NPZwSVZcr6+lXe5EU0TW5JQZPPf2qeNOOVqOBAoDAHHcjvWnFGpRWH4VLE1Zmc9v8+AMY5zV61VQMAZBHWrAg3rnHI/DFWI7b938g+lTzFX0Fhty6bl7d6bcWJYArnf19j9KswF4iGUcDqK0JpImhB6fxDPY1PMZ6mVFa/ugw5J4NNktmOABzWxa7Gs/M6nnpUwj+4Sv1qeYvzMaOFo3HX1rTitwxVwCQ+D9KsPAuCT1PIOKuaei+W4fBAOV/wAKzmzVPQy2tSXU89amFszKTjCjpWtJFkqNuAO4pz4WEjaMYyvtWbdzaEjnZUxx0P8AKsrUCVbepwynIroBEJCzOMBj09KwtWQRucfdxSsdkXc7LRb9JrNctnIzXK+P9LW4ijvLUfvoSWIHde4rP0jUjbJLCWIKn5fpU9xrySBo5GGMYNVyanOotS5kcPNdqqbxxkdM1UbWFRcOQBUviGGIPJJbuuxjkKO3tXCatcPCrHdge9bxiyKlVWNjVtfjVWZnArzLxLr73bmKIkL0JqDWdVaZvLjJbPFZ9nb7XWWYFgH2lCM9u9dlKlKo+WB5tSpqWvCmmDUdYhSX/VD94Qf4gK9x0WBYwpwB2AxivM/AUBa4E5jYRIjJvxxknpmvTLcnAVTzWeMgqMvZxPRy2PMuZnTQzqFCryR1q1aJvkL44HQVkadGXYBmPWuls1RFx3rgvY99SjTVkaVonyEqMDvmplty4J3HaeKfaAOvoBV7aojwgzijmMXVMO7hVI2DYz61x2uYEUnOcA8V2ussu0jgY615z4oulggkKjLH5QB3J4ralLUxryXs3c8m8WWYsdUu3gVVhmhWcLjjOeePqKyrljLh5WceZEHVyBscjGRWv4uuhNr0aRsri1iFuTjIz3/WsJJP3SFI1EaFo25IJz6/0r7Gn8KbPjJbkqJ9tmuVhDKhTzcngqV759KZHG07SKGZfOjWTB+bOO/H0qxuSKO2SQ7pEZossOSO2R7elQxyTWkyvC7xvE5h8yMYG09cfXvVmYsTiff5JwsqE7TIRgqOpzxn0opknlLwzEywTAbuh2npgUUgsfVAbbgMfwpFlHI5x602UgL29qgyxGCfyr4o+g6EoJdgMnGasqVHYbvrVZW2Dp06Um7+Lr60C3Le4FeOc8U5Qo4YdKhV/lUDk9OKnJ2p0z70CFctjGTinpjy8EdKgEnGSKkicN0HTrQFgKk8g1JboWPXilA6YXvUyZAOOMdTRcHEY6ZO0du4pdpXjj1p4fbk5wTUcj5y3f1qGwSsRzZf5R06/jVfb1BJzVgZboahkbHSqTBoa5IOOhqIR7zkjNS7GeQccU8nahJHAoDYheNQB0ArK1aYpbSMnAUE5q/IXlbA+7WH4rk8ixjiAAMjhf1pp6g0N0W2Dou77zcn6111pbBVTYuAKwNCi2xoSM9K7CzwAPepmzthGysWIUYsFqzJEQ5LdDzTIzggDIFPOWbbngjP/wBasWU0JJHvtyOMqc4rivEimO5XGQRXeMUS2kdyF+XqeK4bWCbi5Zm6kVUVdmKdjA1BzJFnjPSqcKsyhVOAKt3wCYRep9aiyqpgZ4611wRjKSWiGjKsELjNWo0yNqYB+lVBGNxcd+lWoWPAwOO9a2M2xJQQcq2R3FOgjLNvAb0Ip20EkevXirqqRGM4APGaCk0MiPkZWQ4J5GTmti0dduME+g6VmhA0y9yBgcVpW0WD8x5pO7MptF2PLLhlBHtV61XMYBA3DsTVaBkUBe9WYxtcHArOSsZJ3LDWm5O3rx2qvNa4G3kHrzWnZsJJMMq+YvIION1Pu0WTCDILHjtzUKRbRQsIy0IXoc4INbMdsIocMN3qD1os7JBGGwy4+Vvc1ekYOMkZ244rNvUqLvoZDxAYyTjOQKs2EBfCZUZP5ClnQuBs2nb6dasaapjR2OeflA9Kzkzbl0uWgFlChcDaccVFPGiKdo3fXtUqSKoIHGeevIrLv5SCCoOTxwalF04tspXMZSTcqn8DWRrSBY1YjNbalzFgknnoayvEGBbMcdBnOaq50rRnnuuXi2zJIDgElTXO3erFiCj9K2bvR311MGdofm3IQMjFNbwFblNpvLk54zwMV0KUbambU3JqBw2ra0LdGLSAjr1rg9X1efUd62wbylGWPoK9pb4R2F2+64vLwgc4LDH8qqXPwj02DiC9ugSpU5I5zXTRlRb996ehyVMNXlsjxNLWKOKWRHZpE2EOOik9a7Pwj4QutZlM907RWYm3iQDDTHvj0Fb/APwrYQX8KyXxltjtV024Yge9enadbRW+Io02RooVVHYCu3EY6nTpqOH6mVDBSlK9XY5TxBp8Wk6Rb21rEkUSMCFQfzqlYXA4re8eRk2DMhxgDBFcNYXZI2k814kpNyuz1KfuaHa29zslyT8uP1rZtLwEqN2DXFJckRqT90ng5q5FfqgA3fMKlnWqiPRrK6GQC31zWobxUhIBFed22tDaOQSOOtOu/EKouS4BA6UJXJnZm34i1JbS2aa4ysQ7k8GvHNe8XwTPPJZr5k8YxGW+5Hk43H1PoKg+IXi37VDJZQzsQ/VQcce9cLb3ClpB91Ghwyge/Fe1l+GhL35ni4/FSd6cS3NI8aXETtMp80SMwP3lJB/nzmmyxwRm4VC7gYmQIcgjjl/1NJaLPdTLHHtxLHghzu6dj6VLB5TN5QLqksO0Oeu4dVB9D6egr392eOyMMBLNhpGcEShx8x6f16Ut0/kyzRRhUR496hjv2+oJHcEU63kJ8oN5RZ4jCVYYGR796LYlhAMq5bMe0EHHbkntmmSyOTE7TlfvTRBgD2I46+tFK/mRxRyByQsjQOFXkY7deRwKKWvQZ9Qk7vvDmolyMjnGaA568mmPJ82OcYzXxZ77Jy27GegqQgkcDp6VUjfJAFXYiQMnGPQVRm3ZjkYKMsKk3Bx16VUm5zjt2pglOAMY74qRliTluOnarNrtAzj7wqirksFrQUZKhRgUh3LyrgZHSnKu7I7d6YrYAUfjSyNtRsY6VDAq3Dkcd6ah+XtUZOWYnvzTd2B1oBa6EvUEZ6elRcb/AFzQX+Tv7UyNgrc0IqxaQAd6JgNgXuaZGTJINowPerMIDyYxzRcViqse1RxXJa6DfazBEBlI/T1Ndbrdytlakry5HygfxGsTSLQLKZZvmmc7ic8Vp0EtWaml2xVFRRkDHNdDBEw2jFQWbwxEBsYHf1rUWePaCSNuOPas2jpVa2w+NACcgNnp7VI6qF35HHIrHvdat7ZmPm5YDgDnFc7da5PNkISAaSg2KUnI2dX1FZQVQnjgDt9awJWPzZPUdaryXQUbpSWPYCqNzeMx+Va1jCxEnfRFa7YtdEqPu01HBJGPyFRSSyOwBAAP51ZtY5CCRWyIcLIZDjOefxFSRSoWIUjPeraxPIBu/lUbWaB1IVlbPOKtSuRytbluBM43Y5qRomVh1K0Q7rcDehdfXHNW4ZRcOAgHPYjmqIV0yW2i/d4ZSQecjqKh8zZJsHU8VfVCOM8k8ZqldWrmYSAMOxHSlcztqaFllm4GcCtCC4C/KwGRVCyzHGHU/KR0qeSB42MvJGKzkUoamtbsjMhQjcOfpWtJbrLFubcSBlgPX1Fcvay4QnOCeR6iui06U3Fq+w8qOfX8BWHUJpxV0S2k+QV5OM9ewolnbG4DPPXPFMgkSKVyoQbh05qOcFxyRj+6KGiabux/mfJuQcDqD2p1tclEw6n1qpGpDhc/Kewq0YMoCAc+orFo7FsSeYXzggk+lVZUlOAvI7ZqSFXR8A5H8qmfeF6CjY3hGzK8duSvoR1rn/FLFbR0HJIwK2ri5KLknOD24rB8RyG709ygw45x6Urm0abvdlDQ7LMR2rtwNv5VuRWQC5Kgv3HXFQeGWSeyjdc4IzW7Em8jkbfQd6G9QWhV+zKYtpDcCqF1aCGJnYdBnkc10kaBmx6VQ8SDbp7kYyR6UJhz62PNBmbUHY9B09qtRZExB6VUT5HdgADmpI33S5qrmnL1H67ai6sJFxnI4FeRXVtJCzFBhgSPyr2MzLtwc56VwfiKzFvfyHH7uQ7gapq6uc8kzl4btwpBwOMGmT3mxc7846c4pLxFVmKnoaxLuUYwfxAqFuZ8zLeoa40QQwSlmx8wIxtNc/q3iK8mjMfmFV7kdTUF1IqgljgViXEnmOSPu10U0lqzlr1pbXGNIzOWLEknqant5WDISTgHHXoKrYNPQEDB6da7cLVanY4ZK6NawdZLmBpGKxiQj5STgVcitozbxPI8YVZiDz8+DnGfr+dZsAfawTIKEP05q+ynzp2CHcyibhgByOv146V9FSk2cc1ZiT5XCt5YME2wDgYB9/xpZURDcSLhZY9r8Lj2x9KfPE7TGNSxWSPcp2gkjHNPYrLNGCqus8Owr6EDitd0QyEDb5sHmghD5itnG44HH6dRRSyFJfskrMGDZicZ+6QODnvRRsB9KpIq53Gk3Alu9VScdTkGmmXPyg4zXxaWp9A3oSrJsYBq0YJdyEDnHSsZW+fLc1ft5Nyrt69qt6IyXvaj7iVlyV4NRrLnDHGafcqCnP3u9VoQAjA/QUlsU2XYD82ffNbECEjqfUVhwv5fDEHFbUMxaAnPUZHsKlktakqSEN174xRNN1Hc1BGy7evPWkkbcvHJFYs2GyHIHYd81XMhY46UksgJ4qMEszccVa1RnsyRXLNx93pUqKC/0qIAIhwME1YiXCj1q4xFKRah4XpU0sqW0LSuQEAzmq0lzHbwmSd1VI/4ia4/Vtan1B9sWUtx90ev1pqndhzFu7vWurj7RdMqRj/Vg9h9KRdZggz5UbO3qTgVhmIuwMxLH0zViKDJ4TFbcokzXOv3LkeUiKPpmmNeXdycs7EenQVDbQDPPP17VdSFR92lypFcxDHFI2C2KlMO1eaeR5fUmo2fdkkkD3pWKvJkLQs3IXiqswZM8c1b8/BKkjHrUUkqjocn3qrIS5r6laCTaxMoJb1rYs5Y9mCMe9ZP2iMt8+FFPWWInKuw+lHQ0dlubhePjBFWrO1iuBluD/OucE5Lheq+tXILtlI2N096h3Q1FS0TOikt41TAwSKiWAZ27COetV7G9aVwHI4roLIrOQNmSvqODRzEyg6e5nIhAwy7lzjjqK07ewE8LvGzSoPvBFOV+orSgtYpHUSxn0BTj8KW4s0tT5sTSK/97oRRzHPzcxhIPLLQSodxORjuPWtONwIDGwI7ZxWTqly4dXBbdnGUHb6VJFKQi+XMrLjIyeaZuqbaFuLdopnI4B5wO9WLa6lt1V1z71XVjzmROT69KlM4EZQMrDGMg1EkOSexpiZGmgYLjfnvx9avzASQ71GT3rnbS+8rEb/c6gHqK3orhGjEaMN33s9qzbM1Ts7lRZDESNwLnk1bFwXhGDg9Kz1gxOzucZ/Wr9uEAOGHNYvc7bRSRNAd4ywIxSzHHJHNKMchQOeearSS/PsINIqCu7opXMTSK/p2xXPzEo0kcoO1gQK6icE8L6ViaqivCc4De9K52QldWKvgydV00Ix+ZCV49jXWW0yjacAr646V5t4aujb3t5Fu/wCWmcfWuwtbzKjLAY9aVzOcNdDoDKN+QeTVfWYxNpc6cZCk1lG92tkvk+wqeS83wMjnKMpHNVFXMpU+WzPNRIfMfP8AeOakJ2xjPT+VU70mLUZo2+XLZppuDsKtzx+dO50rVaDrm428jKsOorJ1W5SePa6g/XtS3VwWBzkGsO8mPOSMflRzGVRGVqcSgNtJGPWuM1GUh2+bjvXYy2F/qZK2du75/jPA/Oqknw41e4Ul7i3iXqepwK0hC+p5tSXRHnF5OZWCg5Ga0tL8LarqIV4rYxxN0eT5f0rvfDfgu206cy3LC6mB+VtuFUeoFd1Z20aAF1BNasinhnN3keeaJ8MlcbtSuWY/3IuB+ddXbfDfQkxi0Zz0+Zya7KBQxHA2+1aduyAbcAmlzuOx2RwcFujho/h7pI4Fq23GD+8PT0p83w60eZFBt/uKVXa5GAa9EgVQeR1p1xEqnKjmrWLrLaRp9TpP7J4xrHw9S2QPYO/yKVCMeefQ155LA1kFSeRkubeUR7NvIQ56V9PT26yx4IrzH4haCZrG4a3wswXIOOuK9fB5hKT5Kh5mMy5RXNA8lAMqnOAkThmHTI7Y9+vFFWGTzndXzIsseQCPmDDj86K9qzPFPf8AzNvJIx71WecEkcjB4qGV+w9KqTOyyADp6Gvjkj2mzQlueQcZJ64rQtJMoGyMH9KwB8y524q9ZSY7nB9qqSEmbM7F8rn3qKMcYY59KSNg2PXFPIGO3FZ7Gis0DNuVQMVpxSFLfaTk9M1jMfnyOBjNWreXpkkUdBSTRrwEcA+lF04WMkHBquJQTkHrUV/MNgFZNajuIsuTkYOKfG24gDHNZIuFE+wt83XHtVpJMhwB09a0jEmWmppsN7qFOMdaku7qO2tGmlOxUHT1qjBNzlj0HX0rnNY1E6ldERkm3jPyj+8fWtYxM27sZfXsuozky5ESnKR9h7n3oSImiFAij1NWY0IOW4B6VqkkMWG3AYZ5Hc1fBA2qgz+FRRhW+VQRnrV+CBhgipbsUkRrHKxxjFTpHInpViEtkjOafMpyMAZ+tSN6FZ1O3NY2pTHkJyR1rXuzhCpzg+lY88YYkDC+9UlcqMramas7fNgkgcmnq5dQQeD60+e3CnC/jUkaJGoj6Me9DNG7q5TkhcH5j17VNDb8ZYnFSurbe9NAkC880D1aJV/d4AGRSlsHgc+1SxbmX5Vz2NCRb3+YVTWhmtxIb1kbA69x6V0+jayVRQxBx3rl7mzKNuXkDtUtqGSQFO/as5Q7GqtNano0WrjYMtnJ7HGKtTXBvYyi5LAHgfzrjIAXRex6jFXLa7khIG75geves+Vow5YrY6SOyUwHP1G4fpTrixt/s4cgFQA3/wBas2PXHKkSHJPByOtN+3vLGVU4XOQvUUm2hR5k7lZ5FUuBgZOcelRyjJDJ6VFdoT8wyAepqmZdrABjt9TTSubWvqi4JA4IY5YdM0yC9nt8BHJjPO30poTe25emKVoDtDHBOO1Jx1NIpdy4dUbABkwf7pNXrbUQVAUnd165FcxcRMuHK/jVvTy7fdHOOlZSgbRiuU6yHUWbG75we1XUnjYKdoVs4HNc5EWQYIIOK0rQggFuR2NZWsJvqi1cTDzAQSvPTtWdqUccycnPvWhMqlRuwR2JrG1GQxL8xwG4FQ0a05X2OCnY6frMqn7rE8jtW9b6unl4JA9yararpltO5Jy07YJcHpT7DSo4woC72H8T1SWht7RdS29+0gGxWI9hT1nuiuAAF6/MatQ2zBRx+BqcRDGSBVbEufMrHIa9pt5dOJrZR5g6jPWsCaPVIAftFlMR6qMj9K9NKDHQ+xqrfTQ20DPNhVHp1JotfUXPZHlv2hppREkTmU/wEHNa+m+HhNMr3Q3ledvateIG5nMrBVYngDsPStyyg2JxWkYKO5y1KjnoiKCxhgRVxgDoBWV4onSK3WGHh5Dz9K32GRniuC8TXJOsOhPEShevc81omZ+z7kKADaB1+tXlb5QB2rFScBqvwXKuAR2oTudtJWN6yfcPXFXoVJcEVj2d0iE5OKvQ3aFwQSM+lVY6Ym3Du34Ppmpw5YNkZxzWfBcDBDMcnp7UPcBJQB+OTU8o7aj5pdo3AnaeK57xDtlhbpjHSte8mQ5VMHPQVk63b29rdrbXdy20Aee6Jnyz3AHfAqoaPQyr8vLZnh2uWc1tfOjB0WOY/I6kEhugB9O9FaXxDhuYvFF5BdzPdOsUcsUhOQ8e3KEZ7Y/KivraD5qcW+x8bU0nJI9HLccHrVSY8DJNOST5Qf09KZK+Wr5RHpXJoXwNueKt2xwcZ4FZyuM89PX0qbzdrAdRTY4mzC/GcnipfO+as62l3gkMcEdKmV+oPGKyZurFzcCp/vHpU1udvLfSqUbYOOo7VZMgC47+9A3YtByGyKq3cpBHcU3zx64NV7liw/pQkTJ2Hk9CKtQSDac4z2rOt3LPgg49aklnWCOSR8BUBOauJlN6WK3iC+MaraQsQ7jLkdQPSqlqNqDHWshJnubgyycs53ZNbtlHvwAMitV3JgXLZCRuPersab29TUcIAUKw5NXLdVQAniqNUiS2iCyc4HfitBnVFAj69KpO425X71SwAyLyc1EikluyWCTy9xP3iaSadWUksBjjNQ3Eewdeo6elZ0jCNAoz1oRUoqWpPcSvj1rNfhvmJzVliTioJ1CtzycU/InroRKSZAerZ609Rly2eaaDgAgd6kCKThDTHsS2+MHIpZNueFpBlVxim+bkgbcn1oHG7J4yQ67R8wNWURWO5lCPnp61WUOeVAOBzUvnOwXaeRxQ2Vy66Fh4d6so6EVVjiMb/NwAau20u84PynpSyhJFwp/OkGqRJDJt27myM1JJsK5U8+xqpDwcOygjjmo5VZJgVPB60uo+VSLg3c7myD0qxBKIgTvyMZx3FZzSuqlQMjHHvUNpO7zMpPApSiZpG/uZ4zz8prOWFxIwzu54FX7d1C7eh9TUypGJFLDj1pbBCbi7WIoVaBeASO9Qw3MjTgMuB71t+SJIeOPQDvVC4j8iQkjjPXFZyZ10nGW61HBPNTDgU6ztysx24yvSmW4EzAxnOK0VBjKnGD796llTXLoWgElTO3BXr7VKkAyTn5T7cVXhnXc3zcnhhV23kDMQh47g9hWbVzDVCMh+zlHUkg/erj9bmee9S1GQF+ZsetdpPLvRU6EcA/yrhoH8zU7yVznMpQZ9qzSuawnZNlyCzxtUD5j6itmC1jRQSucVTgfDg4OegrWQ7lByMema1UbGLm29RqwqU4AAqNrYMcdPepGLNKQMbfSpTjBLNjihoam0ZF4UgBPRRzk1w+p3r6heZziFD8oH866HxfeLDbMFPJ+UH1zXFRTYAAOWP6VcI9RqbZv2BXCkcEV0Nou8AnrjtXN6a6rjccmuisDuYKM8gc5rRoi+tx13GsaFjXkeu3Ql1e7f1fAP0Fev6kPkdCeMV4Zq2V1C4X0c4qWtCpz0THwSsZjnp0rWil8uMc8mubhm2tk8NnpWglyCOTSRrCtY145yzk7sZ4rTs5QDkt3rlVuMHgg4q5HdsQQrUcx1KpfqdjBdfNwePrTzMHO7NcxFekDk9asrfYQnPHajmuV7SxqzXGCfm57H0q3q6S3sQubrw/c3E5XO6KcRrLx1IPPNchdaoIsPuAwQeao+N7ux1TVWni8U6WiSFWeKSVxs4wVBA6VrRjzyUTz8XiNNDi/G8t5c+KXuNWtmtZ2Co8KsMRpt+RRyccDrRWZqsYtZLmGK+hvPIdZFnhLMjA9FBPpnFFfWU4pQSR85KTuz08TAqSxPHYdqI5crgmqME3cng0kkh5Oea+SPQTuaUZIyrYx6U+Rjt4HSqUExIBzUzSAjrSbNYMuWjkDg8GrnmnPIyBxWVCQBjNWlm+XGak1TNWOUbCenbFOaX7uT1rLWUgc04y5Of5UJCbsXlfLkg02V+uBz2PpVYSHnikRizc800rA9S3G/K46isXxBeEqtuv8AGcn6CtJyV6dfSuUv5xPf3D54B2gfSmjKRoaaAck10NsxQADpiuf0nleBW/ZpuCsc1siqcS9Bu3Ix6VoqVIG7gHpVVFYqNoGBVuPiElhyentUvRnSx4XGTnipbQbm+Vjx3qHzP3WOMDrRFIRhhwBzmnczsXrrbtweTWXOF+YkYOOlWJJNzjkEnnNVbs4I55NBKTW5X3NwFPGKZJGSfvnjt61JwBnluM5oID7ufTmmlcHOxWc44HSnQjcQemKQq2CMD60+AFCoYkjPFUoh7TQtIVAORwaeYBuG0DJIPFRupmUKMAjmplx5mO4HWjlJjUsP2sqMCaigyqtnkg5q243NheSaFg3IGIw3p61LRpCdiEkFMr96noSy88Yqdrckcde9IEIXGOlTYuU+xTI/eFt2MfrV1IXMauQOO1VZAG4HUdKu6e7GHy3PK9KG7A3pceIhImMf/WqGGJUkche+DxUgcxsSat21uXVWOcntmnuYSk0INxUEKOKuQsp+8v8A9agQ8YBOaZPbsoO0nPXmocQjNPQ1bd12rGCBjnP1qHUI1khABIJ5zVOGQ4CsD8uDkU+SdXk2gnketYs76FN3uiOwiMSF85A/Wr810ksewA7h/n8ay7uRosKSAW4IBp1tMrIuAFPrig6qlPm95kH23yJwWkJ9wOtbmnXscq4zgjlWJ/Sue1JASTtJOPyqvpN+YpCjLjnqaJIJUeeN0dbf3LYLZAGOcdq5TRv3kckjc5lZv1rRuroOrKGzuH61gaBcYs2DH5ldwfzNRGOpxTTijpLVx5nzDgHvWtbuXPoB29a5u2uAG6jPp2rXspwJM/LyOB05rZIyZswkHcWOMjp0ptzCSACT+NMVl2cEgfyNQ3d2FgJcgspocTKEmnocT4zAFw5JG0Rgge+a5FHwxz0zWx4oufNnmyxOdp/WuaMpZcjseau1jSEmtzo7efbHuJ/KtrTr0pJGdwzXJW1zmLBOat2t4okG78jVWuXGSO3vZvMIPOG/WvIPF9g9vqdyFAVlO7GfWvRbfU45EUORweK57xjbi9IuVA3DhwO4HQ0nHQzqPTQ8re7Ibk896lS9PrxTta04ljLBnI6iuZluZICQ3UVi1bczVQ6yG+UnGTmrK34Uferg21UjOBzUEmrSYwD+tLluP29up38mshRye9RSeII1GDJwBmvOptSmf+Kqjyu5+Zj+dNQsJ4lne/8ACdfYGmEdlZXxkwNtym4LjuKqDxusjMZPDPh9iR3tj1/OuJ6U5H289x2zXVhnaaRyVJOW5099qa31+blLe3tI5IxEYLZNsagDnA9T1oqG7tbBYhHp1+b6QFCyi3MZGRk7SSc46HpRX0dOV46HHJK52lvc44B49KtNcHIPpXMQ3ylhnj0q4Lrd3NfJnab8U3JyeDUrzdCM1gw3gzjPX1q0tyOpbp2oGpWNuCc8ckVcEwJAB5xXOpddOQauRXYA5I4pGikbqzAjB5pEl+c5zisqObnjOOvWraSAYJFNPQrmNJG55bOakQ4PWqaOCOOtSRyYPNND5ie6kCQs5PIGa4pHLAtnkkn9a6PXJwthKc87CK5eL/VR8d6Zle7On0pfkB5Ga6Ky4KqOlYGmsPIUj0rdsXPl5xyORVxOyC0NuAhU5+lTTuPJwo5/lWfLOfJ+Tgjnmp7eXfFjuetF7mrg4q5XMrFyD3NXLckxkZwwORntVWZcEgkY9aga5Kyqkbbsjmi9jWNO6uPe6KykA56r9aRpixyTVFyVYEn5ie1Tj5kwOnfNCZlWs2OacmQf3SO1TrhiMcHrn1qizBBkkVLas0h46VojkloTLuMgUHA/nVryh1br6VGPl5/ipyM5Jzhj+VWZXuyNHfexA57AVbhGZATk5Gaiji+fd0Udc81p2cbIMsmBxtbHWi9imTQx4IwMkVcjiBQq3HGRSWUSJhn+VuT7mrYjWNtzEHcPyrNtCjpuVZo+uB1qu1u+CwrQdlI+X7vqaSVlEXyjJI5qLlJs527Kwt8y4J74qotyyuCrECrWoMzTHH5ntVRY1AYlck0I7eW0bmrbMbjAJ4Bya14n2IA2QcYPFY2jLl34H1z2rdZdw2MOT/hSuYThcWBsncc8U+c5GSTmkeJ1OV6Yp0eNp3/gfSncxtZjbVEdip4LZyPWo7mBIgTGfmz3psmY5MpywI/CpLx8BnZskioe530J66GZcMW+bGcDkCn2skZXAZQ304pbfZIj5c7sdh96qRUwOWUDDcA0mrI9OPvKxcvTII9x+6BzXOebtuDtBIJrba5EsAQ9e/PJqk0CZJx1qGbU7QTTHGU4DEnOKytPuFR7uIn/AJaEj8avzfJjPSuZlnMWsSKPuuo/CiO55eK7m9De+XLhia17e+JCkHkdOa5GSYHqeaW3v9j7S3HarTszml7yPQYb+RmwOvrSyv50Tgk5/nXK2mphRy2K07LUEeMgsNx961duhmlbU5TxITFcTqwONgYfnXOJcBHYM2UYcV0vjM4ZLgcpjY49vWuElnCO0Dkgr90+orOUrMlu+puQzgNgHjsc1dikDAbiM9B7VyH2427YYgp2qympDg76pTRKkddHcbHGD0qS5uleJ88gjmuUi1VMn58CmXWrqsfDAde9UpDdRbFPWzPbOZIf3qE8qOorhNYu1mkb5Np7jGK6HU9eWMMM5PYZrjtRvTcys7DGT2pNX1Oecl0Krv6VEWyeaaTmkzUszFJ5ozSZzSUgHKFLqGbapIBb0HrXq9zpFvoN1q+oWuiwkQCCw0qKWMyrdSPyZcHhyR6eteTqrOyqoyzEKB6k16NqWmafpmk3UbXWq3F7odzbJJN9o2oN+S6wr/DjGAT3rWjHmmkJvQzfG9nFpvihxaQC33RRPNDH92GZkBdB9CTxRUPibSRpesSrbTPNBMqXUEkxy7JIgYbv9rnBPtRX0lFe4jlluc/FflTyeK0rbU9wALiubNKGx618pY6zrxdd1bmrEN+MYYj8a5CO6kTvnHSpftjZzRYDskvRx8wNXIbz5R6Vw6X2MfNzVqLVGHBIFKw0zvYLo8EN9avxXgzya4O21MFRliD9a0Y9Qzg55HvSQ7nbRXWQckY9akF2u3GefWuSTUSc849qlXUMoR6d6tC5jT126zbMueCKzEnz5Sg9azdU1DKY3CmpPiWEj6UXKjqzv9FYmMZPFdTYqG6DHFcXoc3yjPrXY6fIqpx941rHY6YyZdkRcZ5yKZbSkOwPaiUneDnr1qGRtjcHr1pW1OtVE1YsXUoKsCeR6VQj3bS4xvapHkVjgnB9aiik+c470WuxqbSBeoLZzxVpAwDMfQ1Cfk5FKZjwF6571aRyTbbuijcszNtFX9PJGB/dqFmVuuCe59Kswsq4IIHr71S0Im21YtABmJB5+lPjUqcE7h9aRFO0YPJq5aR5ckrkAen61TZEdCe2jZgGcEDjjFXVBCthCUVgvI6mrcCLnALMMgfd61JDb+YY18xizy7tuOw7k1DDnJLWGU5J2kjGOO3vSSrvdmU7kHGT/StGOIzN+9JZt5VcAfNj+lQm2kOwhW/iI2ngc1DJUk2Zs+VYHOTUavlcEAkitBockKGJkUkNkYPT+VU4dxPlleMccVJukrGZdQ73OB+dV3jCJ1HTNa18QqnHPU4rMuCCpI49QaDZNtD9IYhMKoLZyfpXTWyAksTwBgD3rk9InHnMADnpXX2MZWLbJwRz9c1nJjmtCfYDFkgCqNyixthcgnpWvwOAACOef1rMvMSMTnnBq09DninzEMS70Vf73Ofeqtxh2bBORVzTwXGMYwCSe1MuoRGcP0YcGmzope7Ixd2zc4Gcn8M0qMJskg89aWZVWTA4U8j6VA5KqwjyFAHI6E1DPWik0E9uscudu04qYKNvz9aLYmULvO4n1qSd1X5cdqgVSbWhkahtVW/MVwmragsWrx4PzMCOK7DVpNyOV6V59r6qQXQZeM7s/wA6WzODEN8prG5Ugc8VUmuCnOeKz9Niv9QQfZLWVx034wPzNac3hrW9m4LDnHQvTszkTbQlvqa9C/IrRs9UVZdwfmuP1HRNdtsubJ3x3iINc7carc2cm2YSQyDs6kGndrcHJpanrl5eRXURWQg5GDXnPiAPaTlQ26LqhzyPasQeJJg+Wc4zS3euQ3MW18k/SqfvIy57O4175iMM3FQfbjFwrjb6Gsi5udzHaeKpu5NSkRKp2N2TVSn8YqhcarK+QGPPc1mHk0lWZOTZK8zuck5qInNFI3ShakiGkNLSU7AFFLtJ6VIsLMOMfnitadCc9kK6Q2JGd1C5GSACK9ltbTX5bJ49X8J2F9c3QjaWZr1U+0FB8jMobk4POMZryuG0aLZJIF2jDbGOM88g+ma73XrPTNf1J9WtPEmn2lrNsby7lmSa1wANiqOoGDjFenSwns0ub9f0M+e5n+MNP15LuTVdetRGbiRY3aNgyIQMKmFOBgDABorY1bVNNurTxHPFeBk1NYLaCFl+eVowpM7joucH8TRXqUb8tmrGErJ6HkWaXNJRXyJ2C0uaTNFAC5oBOaSigCQSMOlWI7x1xyaqUUDNSPUWHDE81aj1MjjPFYWaVWNAGrcXXmHk5q+J8xxsD92ucyc1pwybocdTSGnY9F0K6G1cHPFd3p8gKK3tXkXh28OQp7HivRdKuw1sOa0gzZM3pbjBzmmNOTnFUwwbFWdgIBzzirsdEXoAyw69aQyFNq/rU0SbVy3TtTflkbGMkUdS3IkYkIp/SkjIaQBu/wClNk3kbfSn2eBksfwqiLaDRGVX5h1NOs/nlw5wnvTizN944A6CoIMl9o69c0XGo6XNiHbvCgkgdK29OUNIpPIxnnofasO3QAAnnNa2nTeW6jdlffv3q7HNPyOjhg5VWBCsGljKnqOhFSgrClmS43Lk88DBPSqQuVMa7HZQqZH1Pb8arzX0X7llG5xncp54/wAanlMldm8gdWgZAM5ZuvBqQ3CR2SNtLbk4C9Qc1i2l7mFFhb5wrfMehzQtyIh5gdg2Bk/0FTKI4Ru9TRkcuCXIUA/dzjIxnGapSy+aAYx5Ywu32OahMoZ8ylSwyyDrVK7kHmfIzFmwME4waix1xVhLg7upyT1A7HNZWpSFAQpPIpVnwTk/Meu3nBqtdkbTnr2FDRutGN0R3NygzgswB969EtnIQ/OMEDFcFpIAiklH3lwF+vrXUwXJ8kqOWIDfQ96hRuKrLmRr5LMdpymeTnpTRbfISmCG796q29yoX5c57kVIbkKWKsGXO1eOfrVcrOdya2LNqFi+UKNoU596pamq+SMkFlHA9+aWO5lJd87Oihsdc1Ru7pyj5HA7VXKTGTTuZg8wyAnp/CD6VKyKjsuBt54Hc0kCmWUs3Azx9KJSBIre+KhxPRjiCO0idjvOAo9aguzjdnrSyXZj/d5B55xWTq98EiZicVElYv2rkzK1m6CRv83AFUNB0Y38n2u+z5J5SMjG73PtVbT4JNb1MlgfskRycfxn0ruBAVh2IOcYAHaphHmdyKkk9OgB47aLZEioijAAGKy7q+mZiA+F6cdamZWeZgWyF4P1qOeCNGycYx1rpUbmTajoisrhlwzs7dueRVfUtMtdQgaK9tUlUj+IVdtlRfnH16VS1C+3/uoCcjq1U1ZGcnz6I808U+Azbo9xpDllAJ8hzz/wE1wccE8rERQzORwQqE4r3fyXmkUF9w6mrtvbxQIAVVT6KP1qORPY5pUNT58ksrqMZe1nX6xn/CoGicZyjjH+ya+iJI42Jxz6ZNZlxbI5YNGD7kdaPZGbpNHg3ekINey3vh2xvFKT2sZJ6FRgj8RXLar4F8sM1nKwPZZOR+dHspESg4nBYz2qaOBioYg4zitGXTpbOd0uIirIN+D/ABDPY1YEVuoZVMqv9+Elcgn0PoK9HD4JW5pM55T7GW1mVUMzBVOQD15Hb/69IkADL5vCnI9wfetBJHiLbYwGcYC4yM9/x/lTGfYh5+ZhncvI+v49/wBK7Vhqa6Ec7I4YU3ElkRkBzv5yfpUsUWETy1+dXAJBBxx1x3+vSkLeYvUKjjadw5UjsPxoB8whCGMpO0njr71vGCjsiWxwkCygT52Ow3knsTyc+vWvWb7UpdPl1+10zSLBG0qOCexQ2oYzQEgO3qc5zkc15IgO9QqoDIdnJ4BzgE+3vXeX0+h+HNaFtLqfiL+1dPjFv9pt3UDpnC7uQnPes6q5rIqLMnx+p/4Ssu5WLzYYJUhK7PKVowfLwOBgnH6misjX7uC51WWa1ku7mDAG69IaZmIyxYj36e1FbQVopENXZyVFFFfJnWFGaKKADNLSUCgBaKKKAFpaaOtLQMdVi3cgEVXp8OTIoB5JApAa+jXBju1GeDXpGiT/ACAV53c6fJZski5wCM12OhTb0GD6EVUdGaw2O4t9rEc4FXY8AZ9KzLVi8SMDzVyLcN2T1ra5rTLXml+B0FQvKInAzio4iQ+4dKZcgyOoGPrQbLc07eRXFMbasvPTNVVBjUDNWSiuFJJHOaCkkJelcgICQaICNnzHbkYxUZKngnvgVJJhNqgZ54zQtGW/hsX7eTGA+QF6GrKTMSRuCAnqf6VS3ExgHBA6YqSM54zwPWtLo5XGzNdp5DFy4J6fhUcb5OAc896qo3lxHJOc9aPMy2cYzQ9DFbl+3lCb0LHaD8tPnuwDhCOvNZbTjftIzk9ahun2jcMc571D1NYxs7s0GvtoUBiWxnOOarXd9vVlzt7kg/MfxrKa4LoeeeB1qCSQbeT+VSzojYs2k7FjuPA71ZuJhImc8AVko5HQ4pZJSUxkelJhKV2dJoxMkeN3ylsY/rXSW6osIwevrXM+G1AgZuCfbtW4sxUOqgEH1pIyvccbhlkdIxkdSfQVoeaGUEAcDjPpXOm5cS4VQATVp71UTA4bGD/jVpXFVaS0NY3pAfgkFeB6YrNnuwy7cY55PtWVNqD+YzbiFxtAHpUJuQxzkj3qmjKNt2bkUmyMMGACgkn0rPmuTIxPOMYFUJL0iNlViQeOarrc465HvSsUqnYnvJgvT7x71zOvTy3DRWlvzLJxn0960rybJyTxUHhu2+13sl02dudqn2HU1jJXdjqUtFY6Dw/Yx2FksEZBKDknuauXd2tpEy7C0zdT6Vft7ZY4g3DDGeepPasnVWQSqrMC2NxArSMUtEJSTZSVHjTcWOM5NMMhdizD5B7U15JJjyQFzjFVb2ZoYiicE8YrZWJqSaZXvtSXeYUZQR1A7VTicOp2gA55HrVOW23ysxOJG5zT7KOUSMIxuA5JPao1BWaujQtFw55I3HgCr3lAZ3dDRaQEbSTzj9atvFkKAufWrtYlSuZbR84/yanjhEqjdjPtVk2rk7tvy+1O+zvGx64qokTKEtqE5XvVK7LFcd+1bzofLwM5NZ11AdmW4x3quUhO+5y9/YxXkTR3EYIIwa4nWdCaxZZYQZYUPzIeqj145r00JuDKe/ANZ19bAtg4I/nW1KrKnsYVaakzydAgJVcS/wB0c+vX6+1Jwrs8YOSdqsWxz1z+PPtW34k0g2s7XNup2ZBZF/h561i3A2PhyJnVsgDng98/Tt2r0oTU1dHI1ZjVUlWVCpH3wMdsUgdixKKh3APyBzj+H6e3elYDJUIQ6sWAH936+tMmE6Iin5kwZUIHAHciquIePKaZY3jYBwOR1BJ5/H0Fen+I21mHU0t9O8K213p6RIttNLYNM7JtGNzE5z169K4LRbHTdQa4XVdSbT2ijDxskRkz68DoB+fNdATpLtj/AIWBqChsFT5MuB2/vVjUabX+TKic94gkvH1R3v7OPT7nYqPbxQ+SqjHBCn1/ve9FQa+LZtVlEGpPqcTRri7lDAswHIw3PtRW0XohM5eiiivljpCiiiiwBQKKKQC0UZooAKWjFFAxwrQ0K1N3q1tEAcbtx+grPXFemfDLQGVTqFyhAlGI1I/h9fxoirsNzT1HQzLpzHHO3NcxosxikaJjgq2BXr7RJJbNHjnB6968l1a1Nlq74Uj5s1VSNtUaxVjtNPugIh0xWpHchlALD8K4yyuWTAzkGti0uBwc81UWWtNTo4nTGM02TO4YHFZkVx+9BJ4zzWn5oKA5FXujTnsyTcFKbqnjlDNtA4qkTlck8ipYWwpb2pj5kTQqqzDecDtUlwAWAB57VUj+Zhu571I74OBye2ak1RcjUhc7qnEoHBIyTjjrVEygxHscjOaR5eC3HBqkZVGabyKVwCc5xTBKEPPb1rOE/mKVTqP0p7PuRTnirZzJalkMCc5H1qleXB2gFgeOlMWcom08gZwRVCeXj5j0Has3obcpL523j1oD5GM4NVWkGCD2oLADeDmpvcq7SNBSBwTjNRDDHb696pm5YkLirNodrAtz7U5W6Ecz6nbaFb7bZfnPPU1emkEZOAMn+KsvTr9YYFVmA7dKLjUcAgkHPFNomL0GXVyEkJ7t3rNuL07mI5J7+lQXk4kfC9vSsyWYhsZ4q4uxM5Git2SpzUT3TdQePSss3G0nnBqF7gkj070zNyNZbktg9qkWf0NY6vkEZ5qwsmF6/nSkOL1F1a6JQRRn95IdqgV2Phy2FtYRjjpgcdfWuI0SI6hq5myPJh4Ge7V3k8scEShWAAGKyjq7nWtku5tsV8oAHjHJrmbxYvtsxUggZAar6M82wB8g1iB8SzMxz1Aq0itkQGTb8o6/yqjdyYYgnkds1FdzlZSRkY71nzTF2UA7tx60JhPY2bGBJdoYEkn8q0fsYtp8FMtIQRjn6Cs7SpmhG/aCwGFB9TW3ayH7dBxvwpwD3cjqfpW72MY3TsacdmBGQFzxgc+nWnRWP7w4DEcfKan0uNmWLdkgHPPXYOmPqc1r7VD/AHeCDuwPuj1qLhflMmSzIjbhsA7Riqk1mxLEFmGP88V0sqrt2yBlKAEgfov1qpd26rGDn5zgnHahSsxKdzBeIIoD8+gPesq/AYEDpn866i7hKxk5ye4I/Kud1NArnPGegrRMzS1uc7KBGzc4HoaoTtuBb0rVu4snBHArJulZSfSnfQt6mddoJFG3qOaw5/D1tev5o3ROflZU+7+VbbuCQvAq7awFyCq4BFCquGzI9kpuxw114YvoMvbtHMQ2QuAvFYN1az2mY5rd4yGyN3Iwe31r2dLY7drD8aq3unLNGyTRxuhHQjIreGLe0gqYOyumeW6LoWpa3JMmj2vmtBhyDMqYU+m4jPIrTfwH4jyobT0IPzD/AEiPjPJH3qsar4UeGZJdJch1biF+Rye3+BrWvdI8I2H9sRS6dqVw+jvEtw/2rYZN5wzKMcYP51v7b+X+vxOX2dtzidU0680u5uLW/iEdxEFkKBlbAPQ5HHfpRVrxpYW2n6/LFYQ+TZmKKa1Jct5kbLuDEnnJzyPWit4zukzNqxxwpaSivmTpFooooAKKKKACgUUtAC0o60gpygk8UDNbw3ph1XVI4DkRA7pCP7vp+Ne8aNAsMSJGgVFAAA7CvPvhlYrFaG4ZSWmbrjoBXqlmo2qAOQKuOh00Yq12XBGjxY2DNeXeNLQR6hvAPlvxn3r1MFmUAAe1Zes6OmoWjxvGMnkMKcldFySWp5RCCmATyK0YHIAxUN5ZyWdy8EwO9DgY7inwYwRzWaZlc0ILnOATzWk0/wC64PP8651sq4btU63DFMZBPatVIk2orosByfercMxJwDxWDHNtA4571biuADkHihNlSkrm9E4UdabNLkkrx0NZi3Wfut0p4uF5BOQeKbZcJ2LRuCMg8jrU/mEKccjINZRlXHqe9TC4AXGecGlGRVR3LwmWOQ4I+apIpwV61hy3B3/Meop0N1gDmq5rnPexsSSBQSDx6VQuXBPpVSa7XqG781n3GoY3d6Ug5zSLE/ezintMAAv4VhjUNoPzdQKil1PaeG5JqL2G5Nm/vAYGpvtIVcg8iubXU1GSzZPSm/2juwAwwTz60yXNnWR6qA+A/OKkk1DK8n9a4pZyeVJB7c1IbiU5BbjtS5mVzI6iS+OCQ3Oaqy3eWz3rFWbj7x/GobnUFQHLcVSZm3dmtLc/OfWoxcEkAHvWEmoLK55GPWrUVxGp6g1VyNjeE4VAe9VL/UWCLFEczSEKoFYt3qyRg4IOKteGIXurk3txyo4j9ves5TcnZG0Fbc73RYFsrOCJSMk5Y+p71rXcyyLGow2fvViQzFimOOKf55CkHkluM1pFHUbUV39klVs8AH68isW5uiFOO1R3M6mVM81SmmLPn+HNWLmW4y8lLwMZOPaqNvud0KHgHP1FP1GUmP5D3qnbzFdoFQ9JE89zoonIdcHGR+lb+myF+e56k9hXKWzlnB7Y7ntWvaXAUABuDyfpXRdWMLu53VjMxChRggjaT+g/CtKJw0LybiSDgDHJx2/rXDJqbxjAbHp7VfttWfYqkMwNRa5bZ0huPkRGy0u7HuT3b8KcZdqFn2le4P6GuZfWNkwYswJGCR6VIdRFxtEZOc9W6KKLA2bFzOhhLA7XOOh+6O5rmtRnVm+Xr2z1qzc3JVCGLbn7Hv71iyuN27ccn+VWkRexHcSBlAPX1rBvpCHZs5U8VrXEy5PTPpWLfuGRj3FEnZCvqZrMTMMDjvXS6RGZMgKThc4/GuYJG8AfxEV3mhqIrBmwC7Hbz6D3rLd2NqW48IPLwQM+tQTwkA/KMY4q9GCQ2/A9qaZCyFMfWmtDsbOYvIixxtOT1wKd4it7yHXIWvW0o3Fxbpb3qzqTGydQJtvO4YByORVzUbaYv5sAbYhBZgMheeM/jWnqVrYapI91fWOsQXEozLHDb71c4wSCemaaqNO5zVqakjxHxr/aR8S3J1cQpcx7cJAP3flgDZsHddtFX/igXn8QG7e1e1iKJCkLcMiKoC5z6jvRXqUppxR5ko2Z5+KWkozXz5sFLSd6WgAooooAKWkpaAFq/pFk2oX8Nqmcuecdh3NUVGa9G+HGmrHD9tlX55OFJ7LQioq7sd94e01ba2ijRcIgAArrLWHLc8AD86x7F0RAC1bdi8bDlvmNUehCOhIVKDI+lWowhT5sUnkkEBjx1zVmKJSmQPampClGJyPi7w99tiM1uv75MkED7w9K85ZHilZXG1l4IPY1720KkAjkAVxXjHwwLqNrqzAW5Xkjsw96m13dGEonm7HJxn5arltpPqB1qSUOjvHIhjkTh0YYI/8ArVAmGBBJqlqZ7bk8cuRuJNJFdYY81nzu0eQDx2FUHudp5JFF7E7nU/asrweaT7UVyAcCuYXUQrjLVL/aSjILZp7iTaZ0H20k4yOakF4205PQZFcs2orjggUqamoX5jU2sXzHQG+yQQfxqEX+P4j9K5ybU1GcEVVk1Pk4PX0pkNo6SfUgobnj3rGn1jbnmsO5vnkPB4+tU2Ysck5pNk3NiXV3YkZ/Wq7apIeM1m0E4pBc0F1GUMDmpE1SRW3Zyay80ZoEb1trTR/eP1B9aurrq7ckiuUzS5ouB0c2uk5Cnisu41GWVic8Vn5NGabYF9L91OepqVtWlK4HH41l5ozSuBr6Y7XV2BI2F6kZr0jR3VLJVjxnGa8mgmaFwydq6nQtc4EcjYIGOtONhps9Js7jlRnjvVkyYy+SR2rlbLUEIADcg9c1ofa1O7DdenNbRehoplq4nYzAqMgHJNR3EuxSWIPpVGW42g7iORniqU975oGOOKXNY0u2Wb29UwjHUGm2b74gTjPXNYd7uAJ3fLVmzuSYto4OMVPM7kySWx1EUvynB9j9KtwSjdycD0rnra5KgA49DV+3lz3HXNXGTE2ka7TjGH59Ks29/mFlU8+lYUswyAOeafBNgqc4B6mr5ho3Y7r5QWYE45HWrlrcfIGGM+g71hwNlecZH61cSYKy4OABVKQm77mlcTZkLFsnpz3FUZHyW5HXNQyXILdcjtVWS56jIqubQVhZ5PnOOtY1y27IJPBq1NIcE+vSsu6n4PpWUpX0C1iS1ZWuFzyR2rtrC5ZrWKNV428455rg9MO+bA6scV2FuDFgpnms4y1OmjHS5qwq7IQrD/Cnujxg5YDjNVo7ryiSxG4nvTLm8QEorrkjJGea1ZtGVyF7tvLkjWRhHIQHVT97B44781t6lJFZXf2e48U6lHIAN4EZITIzgndXLSvGrBlPIOc+ldHcWv8AaqLeXuhTNcyANhLtYhcH+9sPPPtWTlqKra2hwvxQ0UfZNQvIdTl1C6sjE1wtxHhtjcK6nJ3LyKKx/HfimUpq1lNYeRqV66QzFiQIYY8bYlX6jkmivRwjfIeXVS5jyyiiivIGFOptFADqKBRQAUopKUUASwIZJkRersFH417Jo6La2sMEY5VQPwryPSlJ1G2A/vg17LoUJ2iRxy36U0a0ldnQWEBOAcetbMEaoD2x1rOtPlGeateZnPGc1djts2akN1GFKs5Qgd+lWYLh4MbvnXOQV71gl+cMBjvSRCeNg9vIdvoT1oSG4WR0zXO+MvC3I6qaijvFb93KMMfWsOK7JlxKpRh3FWWuIZ1CuwEg6E9TVcvYlOK92Rz/AI28PxX+Z7bEd0v3XHf2NeWTvJDO8UylJ0PKnv8ASvabklk6giuR8UaFFqVv5ygJOg+Vhxg0ODeq3MaiUTzuS53HnHHeqN2RjjFQaj51pcvBcqUkHfsaznuWAwGrO/c527bDp2IyQearG4cd6Y7knOetR5o2IuTfaH7nNIZmPeoqKLgOLMepNJn3puaM0ALRSZozSAXNFJRQAtFJRQAtFJRQAtFJRQAtFJRQAuaVWwcg4NNooA1LPVpYOGJIrXt9eyVL84rlKUGncdzuW1iOVcbuO1RC/jBPzZzXGh2HQkU4TSD+I0XHzM6q4vlMZGR61Hb6iuMZwa5kzOeppFkKtnNFxczO5gvFGDnmtGO9DDhsGuAgvCmPmq/Bf5PLVSkO9zuo594GTU8cuDya5K1vm3cNmtOG8BIBPJpplI6SK6ORg4Oas+bu4zmsOC4QkEngVYNyMqM4zVKQ7moznbk54qo0mWxUUl8oTBNZ1zeqnQ802xXZfubgKuM8/wAqw7+5CrjPzGoLvU1RSWPasdbwT3OWPfCiobJvqdfoLbAZG7dK6qLUY1jXPOa4aO9SCBY0Zc98etSx6kNo3n9alStsdUXodhdXgcFuoHFZr3XmSE5+ZeMg1gzasgGNxHHSqEurqu7nGablcanynSyaiFYE4fByRnrWp4nVdb1CXVLLWtNS2mCkG5uRG9twBtKnnjtivN47m8vDIunWlzdMgywhiaTbn1x0rMu9G124YtJo+pE/9er/AOFTcznWvsaHxA1a31jxXNc2MzTwxxRweeRjzyiBWfHuRmipPiDF9n8ToixCJls7XKhQuG8lc5HrnNFelhHamcctWchRilxRXByFCUooxS1NhhRRRSsAUtJTh2pWA6LwVZ/atYDMPkiG417JYRKpXcOPSvP/AIfWgjsDMw+aVs/h2rv4GwB6elNHXh4m7bhcHHT+dSFDn09qoWkpLAg8AVrJ+9TI6GtYq50S90o3EbBchSaqC4eJwD0H6VpXRZOucdMmsqX5JwcEZ7GlJGsLSWpdW5jlzu+V8fnWdey/KSo2sD1FNnKxnPO41VaXO4NyDVx0Oedh39pSJGBKSSD96nreiQbWwQayL59mcc4HHtWRaXzLe7GPXn6UnKzMd1qVPGmnxXMczYAkUEqc15k55r0rxPfBI5WYj7hx9a82dlLZUHpzk9T61nM5pbjaKKTNQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKYgooopDCiiigAooooAKKKKACiiigApQ3YGkooAsRXcid+K0rXVimN1YtFO4XOpTVQQCWHXNTtq2VGG5rkN2OlLuPqadxqTOok1PuWyPrVK51UMeDz7Vh7j3pM0J2Btss3F08h5Jx71EkzIwKnBFR9aKTEWfts398ilF/OOA5qrRSHdlk3kzA5aoWmdj8zE0yigVy7purahpbSNpt9c2hkwHMMhTdjpnFXf+Es8Q/8AQc1L/wACG/xqz4StLA2esapqlq97Fp0SMtqHKiR3cKCxHO0d/wAKt3Omad4i0mfUPDdsbPULRTJdabvLho/+esRPJA7qelAzn5r64vbhri/mlupnADPK24sBwOT6UVs+PLS2sNd+zWMSQ2/2W3lCL03NEpJ/EkmivQpVOWKSM2tTmBQRQKWs7XGJRiloqHEBMUUtFTyjExThzxSVa0yH7RfwRD+JxUuNgR6x4ZhEGnQIOyCuiicA8Vj6cPLtlAxxxVvzvLYemOayTPRoI3LSUhRgA5OK2IpGWNBj61gaaQ4Unr2rcXcMc8kZFdENjWqkx0+HAGcehrFuGUT4ySR1Nad7OQmNg4HODWDHGwlMsjE57elVJGS91EsxO3Ldv1qmqFstnj0qxNIrrj9KpST+WCvQGs72Yp/CZ19Kp3g9K499RWPUOWHy5/Cr3ifVPsySMrfMeBzXn0lxJI7Ozctyealy1OO/KrGn4h1M3sxVD8g9O9Y5NFJUXIDNFFJSAWikFGaAFooooAKKSloFYKKQ0UBYWiikzQAtFJS0AFFJRQFgzRSUUBYWjNFJQAtLSCjNAxaKQ0ZpiCjNBoFIBaKTNAoAWiikzQAtFJmjNMBaKQ0ZoAWikzQaAFpKM0lIYtJRRQBveEJddtr6W48O209w6psmjSDzkZD2dcEEHHerNhoHi2xv0vbHR9Wguo2Lq8dswKn8untWd4Y1e+0XWIbrTd7S52tCM4mU9UIHUEVpahb+JxLNcQ2mvW1mzFkRjK3lqTwN3fHrQMqeLrvVL7XJZtftzb6gUQPGYvKwAoCkr2yMUVkXE81xIZLmWSWU8bpGLNx7miuiL0JIxS0gpa0ixBiil7UlUwCiiipAK1/DEe/U1bH3Bmsit/wkQLmX1wKzqbFR3PRbWbbEoq0pDleeax7SXCdatRTYPPrXLE7absdPp58sDkAetaQuGDMMjjpmuchuF8rjgketTG7PATr35roi7I2UuY0Z5S6few3f/CqFxdtCyRkEluvtUMlzsX0J6GqTzbm3M1PmJky9NcKqA8Z61k31xtjLseaqz3uZNu35R3J61lave7bd9x6CovcxqOxy3ia7Mt0EByF5NYlPuJDLM7nuajqGcrCiikpCFpM0GkoAUUlLSUAFKKSloAD1ooNJQAUUUUALSUuaSgAooooAKKKKACiiigAooooAKKKKACiiigQUUUUAFFFFABRRRQAUUUUBYKKKKACiiigAooooGFFFFAHYfDycx/2vDY3dvZa1PAq2U8zBAPmG9VY8KxXoa0LfRfH8N0swvLuFgc+fJqKhPqSXwRWD4UsNPltNV1PWIpri00+ND9mifYZXdtqgt2UdzVzUNI07WtGm1Pwwk0Mlou680yWTzGjT/npG3Vk9c8igZU+IFxa3Xii4ls5IZvkjWaaEYjlmCASOo9C2aKTx3p9rpmvi2sI/Kg+y28m3JPzNErE8+pJoqkyWc9ThTKUGtoSEOooFFa3AKKKKlgFamgTiG85IGeKy6dGxSRXHUHNTNXQ07HoUEuxsZ4q9DMCAe/pmuVsL9ZogD1FXBd7R1/GuTY6E76nTxXI28HpU4ujxnFcql8R0YAVN/aPofwqky1I6SWcP1Y4qnNPgfezWOdSHdutUbzVFVc7ulVcHI05pgCSSMCuU17UPPbyozwDzior3VXkBWPj3zWWTnr1ouYznzCUtIaM1JmGaKSigBaSiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA1NA1u70O5llsxFIkqGOaCdA8cyddrKetQaXql3pepJfafL5FwhJUp056qQeo7YNa3g7S4byaa5uoPtMcLxwxW27aJ55DhFYjovBJx2HvW1aXr3urX+mypod7b26OY7eO0ES3ATllikUBlbAOCTzjvVJAct4j1m41/VH1C7jhjmZEjKwrtX5VCjA7dKKXxHp8Wnam0dq7SWkqJPbu/wB4xuoZc+4zg+4orRUxGVR3opO9QtGA8GlzTRSiuiLELQaKKGACiiimA6OR4zlSR7VcF+23DZzVEdRSjvWcqaeo7lpr1uxoN/JjAqkaBWFguyy15Kf4sVA8jP8AeYk000lAxaSiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUdxVpAdD4R1KGzkntbuZraGdo5Y7lV3eRPGco5HdeSD7H2rp9lpbzT3uzQdOeZWD30F6Z9oYEMYYAchiCcZHGe1ec9qcAM9K1jC4rmj4h1CPUdUeW2jMVrGiQW8bHJWNFCrn3wMn3NFZ1FdHLbQR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31750=[""].join("\n");
var outline_f31_0_31750=null;
var title_f31_0_31751="Basic principles of genetic counseling for the obstetrical provider";
var content_f31_0_31751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic principles of genetic counseling for the obstetrical provider",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31751/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31751/contributors\">",
"     Harry Ostrer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31751/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31751/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31751/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31751/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/0/31751/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling refers to the process of communicating information about genetic risks. It focuses on susceptibility to disease in individuals who are [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected of having a heritable disease.",
"     </li>",
"     <li>",
"      At risk because of their family history.",
"     </li>",
"     <li>",
"      Concerned about the possibility of having an affected child based upon personal or family history, age, or ethnicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As medical genetics increasingly permeates all fields of medicine, some genetic counseling will be provided by all physicians. Obstetricians, in particular, must take an ethnic history and a thorough three-generation genetic history at the first prenatal examination; they must be able to recognize women at risk of having an affected offspring and provide information",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral for prenatal diagnosis. The assessment should include evaluation for genetic diseases and multifactorial congenital malformations",
"    <span class=\"nowrap\">",
"     (www.marchofdimes.com/Your_family_health_historypreconceptionprenatal.pdf),",
"    </span>",
"    as well as familial diseases with a major genetic component (eg, premature atherosclerosis, diabetes mellitus, deafness, psychiatric disorders, epilepsy, rheumatoid arthritis).",
"   </p>",
"   <p>",
"    Obstetricians should have practical knowledge of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modes of Mendelian inheritance, multifactorial inheritance, polygenic inheritance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link\">",
"       \"Basic principles of genetic disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"       \"Overview of Mendelian inheritance\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"       \"Glossary of genetic terms\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"       \"Principles of molecular genetics\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penetrance, nonpenetrance, variable expression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link\">",
"       \"Overview of genetic variation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity of genetic tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How to take a comprehensive three-generation family history [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H3#H3\">",
"       \"Genetic counseling and testing\", section on 'Family history'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How and when to make referrals to genetic specialists or other specialist physicians who manage genetic conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"       \"Genetic counseling and testing\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROVIDERS OF GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal genetic counseling is provided by individuals who have trained at the master's level in this field and who have achieved certification by the American Board of Genetic Counseling (",
"    <a class=\"external\" href=\"file://www.nsgc.org/\">",
"     www.nsgc.org",
"    </a>",
"    ). Genetic counseling is also provided by physicians who have trained in residency programs accredited by the American College of Medical Genetics (",
"    <a class=\"external\" href=\"file://www.acmg.net/\">",
"     www.acmg.net",
"    </a>",
"    ) and have become certified by the American Board of Medical Genetics (",
"    <a class=\"external\" href=\"file://www.abmg.org/\">",
"     www.abmg.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetrical providers should know how and when to refer patients for formal counseling by a certified geneticist. Indications for genetic counseling include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A known or suspected hereditary disease in the patient or a family member; multiple family members with the same or similar disorders",
"     </li>",
"     <li>",
"      Family history of early onset cancer or earlier than expected age of onset of a nonmalignant disorder",
"     </li>",
"     <li>",
"      Consanguinity",
"     </li>",
"     <li>",
"      Diagnosis of a disorder in the less often affected sex",
"     </li>",
"     <li>",
"      Advanced parental age during a pregnancy",
"     </li>",
"     <li>",
"      Teratogen exposure during pregnancy",
"     </li>",
"     <li>",
"      Ethnic background associated with an increased prevalence of a heritable disorder (",
"      <a class=\"graphic graphic_table graphicRef54288 \" href=\"UTD.htm?18/58/19373\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Presence of birth defects, chromosomal abnormality, intellectual disability, developmental delay in a parent, a child, or the child of a family member",
"     </li>",
"     <li>",
"      Recurrent pregnancy loss",
"     </li>",
"     <li>",
"      Identification of one or more significant abnormalities during an antenatal sonogram",
"     </li>",
"     <li>",
"      Abnormal results on first or second trimester screening",
"     </li>",
"     <li>",
"      Growth abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much of the information can be obtained while taking a relatively detailed medical and family history from the patient",
"    <span class=\"nowrap\">",
"     (www.marchofdimes.com/Your_family_health_historypreconceptionprenatal.pdf).",
"    </span>",
"    Once obtained, information on the family history should be evaluated for signs of inherited risk. The goal is to identify families who are appropriate candidates for referral to a genetics center for more thorough evaluation, which can take several hours. However, it appears that the majority of pregnant women with an indication for referral for genetic counseling are either not identified or not referred [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H4#H4\">",
"     \"Genetic counseling and testing\", section on 'Collecting the information'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H6#H6\">",
"     \"Genetic counseling and testing\", section on 'Interpreting the history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, the family history should focus first (if applicable) on the history of present illness in the patient, inquiring whether other relatives have had similar signs and symptoms and whether precise diagnoses have been made for those individuals. While taking a family history, the provider should ask about all first-degree relatives (eg, the patient's parents, siblings, children), asking about their ages, state of health, and the age and cause of death of any who have died. The family history should include questions about second and third degree relatives, fetal or infant deaths and congenital anomalies or intellectual disability, which might otherwise be overlooked. If a medical condition is identified in one or more family members, it is important to confirm the diagnosis by examination of this person",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    review of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    medical record.",
"   </p>",
"   <p>",
"    Patients are generally considered at increased risk for ethnicity-based recessive disorders if their genetic background is made up of at least 25 percent of the ethnic group at risk. Below this level, their risk approximates that of the general population.",
"   </p>",
"   <p>",
"    As an example, the following case report illustrates several genetic counseling issues relevant to the patient's obstetrical and medical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Example of a clinical case",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 35 year old woman presented for genetic counseling with her 40 year old fianc&eacute; because they were concerned about risks to future offspring based upon her history of type 1 diabetes mellitus. While giving a complete medical and family history, the patient revealed that she and several of her sisters had asymmetric breasts and missing teeth, findings compatible with the diagnosis of X-linked hypohidrotic ectodermal dysplasia (XHED). Her fianc&eacute; also mentioned that he had neurofibromatosis 1 (NF1), an autosomal dominant condition that was diagnosed as a coincidental finding during an employment physical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=see_link&amp;anchor=H537377059#H537377059\">",
"     \"Risk factors for brain tumors\", section on 'Neurofibromatosis type 1'",
"    </a>",
"    .) The couple were not blood relatives (consanguineous). The woman was of Northern European descent and her fianc&eacute; was Ashkenazi Jewish. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We advised the couple that their risk of having a fetus with diabetic embryopathy was 10 to 20 percent based upon laboratory evidence of poor glycemic control (glycated hemoglobin value [A1C] of 10 percent). Offspring of a mother with type 1 diabetes have a 1 in 25 risk of developing type 1 diabetes if, at the time of pregnancy, the mother is less than 25 years of age, and a 1 in 100 risk if the mother is 25 years of age or older [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .) There was also a 50 percent risk of NF1 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/7\">",
"     7",
"    </a>",
"    ] and a more severe form of XHED could occur if the fetus was male [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommended that the woman improve her blood glucose level prior to conception (ideally A1C less than 7 percent) to reduce the risk of diabetic embryopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/9\">",
"     9",
"    </a>",
"    ]. We offered the couple genetic testing to identify mutations that cause NF1 and XHED and told them this information could be used for preimplantation or prenatal diagnosis, although in neither case would knowledge of the mutation predict the severity of the condition in the fetus.",
"   </p>",
"   <p>",
"    The risk of Down syndrome or other chromosomal abnormality was about 1:200 based upon the current maternal age (",
"    <a class=\"graphic graphic_table graphicRef75423 \" href=\"UTD.htm?16/60/17357\">",
"     table 2",
"    </a>",
"    ), therefore she might choose to have prenatal diagnosis by amniocentesis or chorionic villus sampling for detection of fetal aneuploidy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    .) Alternatively, she might choose to undergo serum and ultrasound screening for Down syndrome to better define her risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of having a child with a congenital anomaly may increase with increasing parental age. Issues related to parental age and fertility, pregnancy, and offspring outcome should also be reviewed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=see_link\">",
"     \"Effect of advanced paternal age on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, her Northern European ancestry gave her a 1:2500 chance for having a fetus with a cystic fibrosis, a 1:5000 chance of having a fetus with spinal muscular atrophy and a 1:4000 risk of having a fetus with fragile X syndrome. The risks of being a carrier for any of these conditions vary with ethnicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=see_link\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\"",
"    </a>",
"    .) Her fianc&eacute;'s ethnicity increases their risk for having a fetus with a series of other autosomal recessive disorders, including Tay-Sachs disease, Canavan disease, Gaucher disease, Bloom syndrome, Fanconi anemia, Niemann-Pick disease, mucolipidosis IV, familial dysautonomia, maple syrup urine disease, glycogen storage disease I, familial hyperinsulinism, lipoamide dehydrogenase deficiency, nemaline myopathy, and Usher syndrome types 1 and 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link\">",
"     \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic screening by DNA analysis was available for all of these conditions and could be performed most efficiently for the fianc&eacute;. If he were found to be a carrier for one of these conditions, then carrier testing could be performed on the woman to determine whether she is a carrier, based on her having cryptic Jewish ancestry. Alternatively, should the man be found to be a carrier for a lysosomal storage disease, prenatal diagnosis for this condition might be offered, based on specific enzyme analysis of fetal cells. Generally enzymatic carrier testing is recommended only for Tay-Sachs disease. For other conditions, enzyme tests lack both sensitivity and specificity and full gene sequencing can be offered as a carrier test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INFORMATION CONVEYED IN GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The informational components of the genetics consultation include discussion of the:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Likelihood of developing disease",
"     </li>",
"     <li>",
"      Impact of the disease",
"     </li>",
"     <li>",
"      Possibility of modification of either the impact or likelihood of disease",
"     </li>",
"     <li>",
"      Anticipated future developments in diagnosis or treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Likelihood of developing the disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The individual should be informed about the magnitude of risk for disease occurrence. Several factors contribute to this estimate. First, the condition may show a Mendelian pattern of inheritance, with the likelihood of inheriting disease genes based upon autosomal dominant (",
"    <a class=\"graphic graphic_figure graphicRef75203 \" href=\"UTD.htm?10/45/10974\">",
"     figure 1",
"    </a>",
"    ), autosomal recessive (",
"    <a class=\"graphic graphic_figure graphicRef65919 \" href=\"UTD.htm?17/32/17934\">",
"     figure 2",
"    </a>",
"    ), or an X-linked (",
"    <a class=\"graphic graphic_figure graphicRef56888 \" href=\"UTD.htm?12/46/13038\">",
"     figure 3",
"    </a>",
"    ) pattern of inheritance. Second, the risk is modified by information on disease penetrance (ie, likelihood of developing disease given inheritance of disease-causing mutation) and expressivity (ie, phenotypic variations in the way the disease is expressed). Lastly, the risk may be quantified more precisely by testing the individual at risk to determine whether she inherited disease-causing mutations.",
"   </p>",
"   <p>",
"    An empiric risk can be quoted in the absence of a known Mendelian pattern of transmission or an available genetic test. The empiric risk is estimated based upon the observed number of cases among individuals harboring specific risk factors; as an example, the empiric risk of having a fetus with birth defects among women with a history of pregestational diabetes mellitus and known A1C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Impact of the disease on the patient and family",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the disorders presented during a genetic counseling session are unfamiliar to the patient, and thus require that the counselor educates the patient about the natural history of the condition. Salient issues include whether the disorder may:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shorten longevity",
"     </li>",
"     <li>",
"      Require chronic hospitalization",
"     </li>",
"     <li>",
"      Require costly treatments",
"     </li>",
"     <li>",
"      Affect mental or physical development, including the ability to engage in normal, independent daily activities",
"     </li>",
"     <li>",
"      Impair reproductive performance, including possible infertility",
"     </li>",
"     <li>",
"      Have been inherited by other family members",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnosis of an index case in a family may lead to identification of multiple other affected family members. As an example, we diagnosed myotonic dystrophy (an autosomal dominant condition) in a patient and subsequently determined that eight of his nine children were also affected with this condition, with two showing clinical manifestations at the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Possibility of modifying the impact of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to prevention, intervention, and treatment of the disease must also be discussed. For an individual at risk for having an affected child, this might include exploration of artificial insemination by donor, ovum transfer from a surrogate, preimplantation genetic diagnosis by embryo biopsy, adoption, and prenatal diagnosis (eg, chorionic villus sampling, amniocentesis, or sonography). In addition, the risk of some congenital anomalies may be modified by avoidance of teratogens and by dietary interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link\">",
"       \"Genetic and environmental causes of birth defects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"       \"Principles of teratology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link\">",
"       \"Folic acid for prevention of neural tube defects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"       \"Nutrition in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the individual is the one at risk, the discussion might include the roles of diet, medication, and surgery; prophylactic organ removal (especially for those at risk for cancers such as ovarian, colon, and breast) or organ transplantation (eg, lung transplants for cystic fibrosis); and increased surveillance by physical examination, diagnostic imaging, or endoscopy.",
"   </p>",
"   <p>",
"    Anticipated developments in the diagnosis and treatment of the genetic disorder should be explored. Improved methods of genetic diagnosis or early surveillance of phenotypic manifestations may be in the pipeline. In addition, the genetic counselor may be aware of new treatments such as drug, enzyme-replacement, or gene therapy that are in development or clinical studies recruiting patients for investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENETIC TESTING AND INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals often come to a genetic counseling session with an imprecise estimate of their risk of having a genetic disease or having a child affected with a genetic disorder. They may have been misdiagnosed either by themselves or by their practitioners, because misunderstanding of genetic principles is common and knowledge of this area is advancing rapidly.",
"   </p>",
"   <p>",
"    As an example, a woman with an autosomal dominant trait, such as familial breast cancer or Huntington disease, may perceive herself to be doomed to develop the condition, whereas the highest risk is actually 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This risk can be further reduced by genetic testing. If a mutation in the BRCA1 or Huntington gene is present in the family, then failure to inherit this mutant allele by the individual at-risk will reduce her risk for developing disease to that of the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    .) A complete diagnostic evaluation, which includes family history, physical examination, and genetic testing, contributes to making a correct diagnosis and precise estimate of risk.",
"   </p>",
"   <p>",
"    Genetic testing performed in the absence of knowledge of a specific disease allele segregating in a family may still be useful for risk modification. Identification of the disease allele in the woman increases her risk for developing disease to the known penetrance for mutation carriers, while failure to identify a disease allele diminishes her risk. This is quantified by application of Bayes' theorem, which considers the likelihood of disease prior to genetic testing and incorporates the false positive and false negative rates for genetic testing to determine a new likelihood that the individual is a mutation carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Informed consent is the process of transmitting information about the utility and risks associated with a procedure. Informed consent has typically been associated with performance of an invasive procedure or a research protocol; however, many states now require that individuals provide informed consent prior to genetic testing. This is required in recognition of the sensitive nature of genetic testing, not because genetic testing is viewed as experimental. Genetic counseling is the best method for educating individuals prior to obtaining consent for genetic testing.",
"   </p>",
"   <p>",
"    The benefits and risks of genetic testing are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef61384 \" href=\"UTD.htm?35/41/36507\">",
"     table 3",
"    </a>",
"    ). Genetic testing methods are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef63290 \" href=\"UTD.htm?39/19/40252\">",
"     table 4",
"    </a>",
"    ). An overview of genetic testing and specifics of available genetic tests is available online at GeneTests (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 2008 Federal Genetic Information Non-Discrimination Act provides safe guides against unfair genetic discrimination in health insurance and employment. Many states have laws that protect against unfair genetic discrimination [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRENATAL GENETIC SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common genetic disorders for which prenatal screening may be offered are Down syndrome (trisomy 21), hemoglobinopathies, cystic fibrosis, fragile X, and a variety of disorders most common in the Ashkenazi Jewish population.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"       \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=see_link\">",
"       \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=see_link\">",
"       \"Cystic fibrosis: Prenatal genetic screening\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=see_link\">",
"       \"Prenatal screening and diagnosis for fragile X syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link\">",
"       \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening for spinal muscular atrophy is also widely recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small chromosomal deletions and duplications can be detected using array genomic hybridization (aGH) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PRENATAL GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is performed for definitive diagnosis when the offspring is at increased risk of a known heritable disease. It can be performed before birth using cells derived from the placenta (from 10 to 14 weeks of gestation), amniotic fluid (from 15 weeks of gestation to term), fetal blood (from about 18 weeks of gestation to term), or fetal tissue (from about 20 weeks of gestation to term), and sometimes from cell-free fetal nucleic acids in maternal blood (from about 9 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/16\">",
"     16",
"    </a>",
"    ]. It can even be performed before implantation, using cells derived from preimplantation blastocysts conceived in vitro.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"       \"Preimplantation genetic diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"       \"Chorionic villus sampling: Risks, complications, and techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"       \"Diagnostic amniocentesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"       \"Fetal blood sampling\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=see_link\">",
"       \"Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prenatal diagnosis of specific genetic disorders is discussed in individual topic reviews or within the topic review for the specific disease.",
"   </p>",
"   <p>",
"    Conventional karyotyping is the principal cytogenetic tool used for prenatal diagnosis. DNA microarrays to detect submicroscopic chromosomal abnormalities can be offered as an adjunct in prenatal cases with abnormal anatomical findings and a normal conventional karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31751/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. There are many additional techniques for genetic testing: testing may be DNA-based, cytogenetic, or metabolic, depending upon its purpose (",
"    <a class=\"graphic graphic_table graphicRef63290 \" href=\"UTD.htm?39/19/40252\">",
"     table 4",
"    </a>",
"    ). The best approach depends on the disorder that is being evaluated and should be determined in consultation with a genetic counselor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A glossary of genetics terms is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef72267 \" href=\"UTD.htm?24/6/24685\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two particularly useful sources of medical genetics information include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Online Mendelian Inheritance in Man (",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim\">",
"       www.ncbi.nlm.nih.gov/omim",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gene Tests (",
"      <a class=\"external\" href=\"file://www.genetests.org/\">",
"       www.genetests.org",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candidates for genetic counseling include individuals suspected of having a heritable disease, individuals at risk of developing a heritable disease because of their family history, and individuals concerned about the possibility of having an affected child based upon personal or family history, age, or ethnicity",
"      <span class=\"nowrap\">",
"       (www.marchofdimes.com/Your_family_health_historypreconceptionprenatal.pdf).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an obstetrical setting, referral for genetic counseling is appropriate for women of advanced maternal age, teratogen exposure during pregnancy, certain ethnic backgrounds (",
"      <a class=\"graphic graphic_table graphicRef54288 \" href=\"UTD.htm?18/58/19373\">",
"       table 1",
"      </a>",
"      ); presence of birth defects, chromosomal abnormality, or intellectual disability in a parent, a child, or the child of a family member; recurrent pregnancy loss, significant abnormalities during an antenatal sonogram, and abnormal results on first or second trimester screening. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic counseling should include information on the likelihood of developing the disease, the potential impact of the disease on the patient and family, and any options for modifying the impact of disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Information conveyed in genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common genetic disorders for which prenatal screening may be offered are Down syndrome (trisomy 21), hemoglobinopathies, cystic fibrosis, fragile X, and a variety of disorders most common in the Ashkenazi Jewish population. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prenatal genetic screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing can be performed before birth using cells derived from the placenta, amniotic fluid, fetal blood, or fetal tissue, and sometimes from cell-free fetal nucleic acids in maternal blood. It can also be performed before implantation, using cells derived from preimplanted blastocysts conceived in vitro. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prenatal genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Foundation-March of Dimes Symposium on Genetic Counseling, Genetic counseling, with particular reference to anticipatory guidance and the prevention of birth defects. Baltimore, Williams and Wilkins, 1970.",
"    </li>",
"    <li>",
"     Marks, JH. Genetic counseling principles in action: a casebook. White Plains, NY: National Foundation March of Dimes, 1989.",
"    </li>",
"    <li>",
"     Baker, DL, Schuette, JL, Uhlmann, WR. A guide to genetic counseling. New York: Wiley-Liss, 1998.",
"    </li>",
"    <li>",
"     Schuette, JL, Bennett, RL. Lessons in history: Obtaining the family history and constructing a pedigree. In: A Guide to Genetic Counseling, Baker, DL, Schuette, JL, Uhlmann, WR (Eds), Wiley-Liss 1998. p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/5\">",
"      Bernhardt BA, Haunstetter CM, Roter D, Geller G. How do obstetric providers discuss referrals for prenatal genetic counseling? J Genet Couns 2005; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/6\">",
"      Tyrala EE. The infant of the diabetic mother. Obstet Gynecol Clin North Am 1996; 23:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/7\">",
"      Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/8\">",
"      Clarke A. Hypohidrotic ectodermal dysplasia. J Med Genet 1987; 24:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/9\">",
"      Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 1990; 301:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/10\">",
"      Ostrer H. A genetic profile of contemporary Jewish populations. Nat Rev Genet 2001; 2:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/11\">",
"      Bloch M, Adam S, Fuller A, et al. Diagnosis of Huntington disease: a model for the stages of psychological response based on experience of a predictive testing program. Am J Med Genet 1993; 47:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/12\">",
"      Peshkin BN, Lerman C. Genetic counselling for hereditary breast cancer. Lancet 1999; 353:2176.",
"     </a>",
"    </li>",
"    <li>",
"     Young, Ian D. Introduction to risk calculation in genetic counseling. New York: Oxford University Press, 1999.",
"    </li>",
"    <li>",
"     file://ghr.nlm.nih.gov/spotlight/the-genetic-information-nondiscrimination-act-gina. (Accessed on January 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/15\">",
"      Salman M, Jhanwar SC, Ostrer H. Will the new cytogenetics replace the old cytogenetics? Clin Genet 2004; 66:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/16\">",
"      Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update 2009; 15:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/17\">",
"      ACOG Committee Opinion No. 446: array comparative genomic hybridization in prenatal diagnosis. Obstet Gynecol 2009; 114:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31751/abstract/18\">",
"      Hillman SC, Pretlove S, Coomarasamy A, et al. Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2011; 37:6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 461 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31751=[""].join("\n");
var outline_f31_0_31751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROVIDERS OF GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Example of a clinical case",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INFORMATION CONVEYED IN GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Likelihood of developing the disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Impact of the disease on the patient and family",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Possibility of modifying the impact of disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENETIC TESTING AND INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRENATAL GENETIC SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PRENATAL GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/461|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/45/10974\" title=\"figure 1\">",
"      Autosomal dominant pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/32/17934\" title=\"figure 2\">",
"      Autosomal recessive pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/46/13038\" title=\"figure 3\">",
"      X linked recessive pedigree",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/58/19373\" title=\"table 1\">",
"      Carrier testing for genetic disease based on ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/60/17357\" title=\"table 2\">",
"      Maternal age-related Down syndrome risk at 3 gestational ages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/41/36507\" title=\"table 3\">",
"      Risks benefits genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/19/40252\" title=\"table 4\">",
"      Methods of genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/6/24685\" title=\"table 5\">",
"      Genetic terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=related_link\">",
"      Cystic fibrosis: Prenatal genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=related_link\">",
"      Effect of advanced paternal age on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=related_link\">",
"      Huntington disease: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=related_link\">",
"      Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=related_link\">",
"      Prenatal screening and diagnosis for fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=related_link\">",
"      Prenatal testing for the hemoglobinopathies and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_0_31752="Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis";
var content_f31_0_31752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31752/contributors\">",
"     Amy McMichael, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31752/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31752/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/0/31752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H109567509\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female pattern hair loss (FPHL) is a common form of nonscarring hair loss that primarily occurs in adult women. The condition is characterized by the progressive loss of terminal hairs over the frontal and vertex regions of the scalp, resulting in a visible reduction in hair density (",
"    <a class=\"graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195 \" href=\"UTD.htm?36/26/37290\">",
"     picture 1A-C",
"    </a>",
"    ). Unlike many cases of androgenetic alopecia in men (male pattern hair loss), the loss of terminal hairs in affected areas is usually incomplete and the frontal hairline is often spared. &nbsp;",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of FPHL will be reviewed here. Androgenetic alopecia in men and other forms of hair loss are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"     \"Treatment of androgenetic alopecia in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=see_link\">",
"     \"Evaluation and diagnosis of hair loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=see_link\">",
"     \"Chemotherapy-induced alopecia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516820567\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the term &ldquo;androgenetic alopecia&rdquo; was the primary term used to refer to the appearance of the common, progressive loss of terminal hair on the frontal scalp",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vertex of the scalp in both men and women. The term &ldquo;andro&rdquo; signified a hormonal etiology and &ldquo;genetic&rdquo; signified a contribution of heredity to the clinical phenotype.",
"   </p>",
"   <p>",
"    Over the years, as more work on hair loss was published, &ldquo;female pattern hair loss&rdquo; became the preferred term for this form of hair loss in women. This newer terminology helps to distinguish the different clinical features of this process in women versus men and reflects the lack of evidence to support a hormonal contribution in all cases of the condition.",
"   </p>",
"   <p>",
"    Further, some authors use the terms &ldquo;androgen-dependent FPHL&rdquo; and &ldquo;androgen-independent FPHL&rdquo; to separate women with FPHL due to androgen excess from women with FPHL and normal androgen levels [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/1\">",
"     1",
"    </a>",
"    ]. The term &ldquo;female pattern alopecia&rdquo; has also been used in place of FPHL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109567516\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;FPHL is a common condition. In a series of approximately 1000 Caucasian women in the United States, the prevalence of FPHL was 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of FPHL appears to be lower in the Asian population than among Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/3\">",
"     3",
"    </a>",
"    ]. Little is known about the prevalence in women of African descent.",
"   </p>",
"   <p>",
"    Although FPHL can occur at any time in life beginning in puberty, the condition most commonly occurs following menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The age-related rise in FPHL was clearly demonstrated in the American series mentioned above; FPHL was detected in only 4 of 121 women between the ages of 20 and 29 (3 percent), but in 41 of 140 women between ages 70 and 89 (29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/2\">",
"     2",
"    </a>",
"    ]. In a British study of 377 women who presented to a general dermatology clinic with concerns unrelated to hair loss, 38 percent of women over the age of 70 years had FPHL [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109567523\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visible thinning of hair over the frontal scalp and vertex of the scalp in FPHL results from a progressive decrease in the ratio of terminal hairs to shorter, thinner vellus hairs in the affected areas, a process known as follicular miniaturization [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/7\">",
"     7",
"    </a>",
"    ]. As part of this process, the duration of the anagen (growth) phase of hair follicles shortens from a normal duration of a few years to only weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714520#H21714520\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Hair growth cycle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism through which follicular transformation occurs in FPHL is not completely understood. Although the crucial roles of androgens and genetic susceptibility in male androgenetic alopecia are well-accepted, the degree to which these factors contribute to FPHL in most women is less clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714534#H21714534\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432607103\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male androgenetic alopecia occurs as a consequence of the effects of dihydrotestosterone (a potent metabolite of testosterone) on susceptible hair follicles. Dihydrotestosterone binds to androgen receptors in hair follicles, resulting in the upregulation of genes responsible for the gradual transformation of terminal hair follicles to miniaturized hair follicles. The pattern of the hair loss, which typically spares the occipital scalp, reflects regional differences in the sensitivity of scalp follicles to androgens (",
"    <a class=\"graphic graphic_picture graphicRef83805 \" href=\"UTD.htm?39/47/40692\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714541#H21714541\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors have theorized that a similar process contributes to the development of FPHL [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/9\">",
"     9",
"    </a>",
"    ]. This concept is supported by the observation that women with disorders of hyperandrogenism (eg, polycystic ovarian syndrome, ovarian hyperthecosis, or adrenal or ovarian androgen-secreting tumors) may develop early-onset FPHL as a feature of these diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/10\">",
"     10",
"    </a>",
"    ]. However, androgen levels are normal in most women with FPHL, indicating that our understanding of the pathogenesis of this disorder remains incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In a series of 109 women with moderate to severe FPHL, laboratory evidence for hyperandrogenism was present in only 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Proposed theories on the mechanisms through which women with normal androgen levels could develop FPHL include increased sensitivity of hair follicles to androgens and an influence of estrogens on the development of this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. The age-related increase in FPHL, with the highest rates in postmenopausal women, suggests the possibility of a role for estrogen. However, studies have demonstrated conflicting evidence on whether estrogens stimulate or inhibit hair growth [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432607110\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is known that genetic susceptibility influences the development of male androgenetic alopecia, relatively little is known regarding the genetic basis and inheritance pattern of female pattern hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/8\">",
"     8",
"    </a>",
"    ]. An Australian gene-wide association study of Caucasian women suggested that the aromatase gene (",
"    <em>",
"     CYP19A1",
"    </em>",
"    ) may contribute to FPHL [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/13\">",
"     13",
"    </a>",
"    ]. However, no definitive familial inheritance has been identified. Multiple genes may contribute to susceptibility to FPHL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714548#H21714548\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109567558\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;FPHL is a nonscarring form of hair loss that presents as a progressive reduction in the density of terminal scalp hairs in a characteristic distribution (",
"    <a class=\"graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195 \" href=\"UTD.htm?36/26/37290\">",
"     picture 1A-C",
"    </a>",
"    ). The frontal scalp and vertex of the scalp are the primary sites of involvement. Although diffuse involvement occasionally occurs, the occipital scalp is usually relatively spared.",
"   </p>",
"   <p>",
"    The exact pattern of hair loss varies among women. In some patients, the frontal scalp thinning is most prominent, resulting in the visualization of a &ldquo;Christmas-tree&rdquo; like pattern when the hair is parted at the midline [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], whereas in others, diffuse central thinning is the most pronounced feature [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/16\">",
"     16",
"    </a>",
"    ]. The frontal hairline is usually relatively spared, though women frequently exhibit mild bitemporal thinning [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/9,17,18\">",
"     9,17,18",
"    </a>",
"    ]. A combined pattern that resembles male androgenetic alopecia (fronto-temporal recession and vertex loss) is infrequently seen [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scarring, inflammation, and scale are not clinical features of FPHL. If these features are seen in a patient with hair loss, another scalp disorder may be present in conjunction with FPHL or may be solely responsible for the clinical findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=see_link\">",
"     \"Evaluation and diagnosis of hair loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of methods have been used to classify the clinical features of FPHL. The Ludwig scale is one of the most commonly used grading scales (",
"    <a class=\"graphic graphic_figure graphicRef87190 \" href=\"UTD.htm?8/30/8677\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/16\">",
"     16",
"    </a>",
"    ]. Other scales that have been used to describe the severity of FPHL include the Sinclair (",
"    <a class=\"graphic graphic_picture graphicRef87210 \" href=\"UTD.htm?7/33/7697\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/7\">",
"     7",
"    </a>",
"    ] and Savin [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/14\">",
"     14",
"    </a>",
"    ] scales.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605925860\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352182082\">",
"    <span class=\"h2\">",
"     Psychosocial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with FPHL experience negative psychosocial effects related to the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. As an example, in a questionnaire-based study that included 96 women with FPHL and 56 female control subjects, 70 percent of the affected women reported that they were very upset to extremely upset about their hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/21\">",
"     21",
"    </a>",
"    ]. Women with hair loss experienced more feelings of negative body image, poorer self-esteem, less of a sense of control over their lives, and had a less satisfying quality of life than the control group. A separate study in which 58 women were interviewed about the effects of FPHL on their quality of life also found that hair loss frequently was accompanied by negative psychosocial effects. In this study, 88 percent of women felt that the hair loss negatively influenced daily life [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adolescent girls with FPHL may also experience psychosocial dysfunction. Girls with FPHL may suffer from poor self-esteem and impaired functioning at home, school, or work and in interpersonal relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When managing patients with FPHL, clinicians should remain cognizant that the clinical assessment of the severity of FPHL may not be consistent with the patient&rsquo;s perception of the severity of hair loss and the psychosocial impact of the condition. In a questionnaire-based study of 104 women with FPHL, telogen effluvium, or alopecia areata, the patient perception of the severity of hair loss tended to be greater than the perception of the examining dermatologist [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, the patients&rsquo; severity ratings correlated more closely with the effects of hair loss on patient quality of life than the severity ratings given by the dermatologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432607899\">",
"    <span class=\"h2\">",
"     Associated medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medical disorders may be associated with FPHL. In addition to causes of hyperandrogenism (eg, ovarian or adrenal tumors, polycystic ovarian syndrome, adrenal hyperplasia), links between FPHL and insulin resistance, role limitations due to physical health, and hypertension have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Further study is necessary to clarify whether the associations between FPHL and these conditions are valid. Of note, cardiovascular risk factors have been associated with androgenetic alopecia in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714612#H21714612\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109567572\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of female pattern hair loss is usually made clinically. Scalp biopsies are helpful aids for diagnosis when concomitant disorders of the scalp confound the clinical findings or the diagnosis is unclear. Laboratory tests to assess for hyperandrogenism are performed when clinical findings suggestive of hyperandrogenism are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605925949\">",
"    <span class=\"h2\">",
"     Patient history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient history can provide clues to support or negate a diagnosis of FPHL and to identify an underlying hyperandrogenic state. We typically inquire about the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age of onset, duration, and rate of progression of hair loss",
"     </li>",
"     <li>",
"      Presence of signs of virilization (hirsutism, deepening of voice, clitoral enlargement)",
"     </li>",
"     <li>",
"      Gynecological and obstetrical history (menstrual irregularities, difficulty conceiving)",
"     </li>",
"     <li>",
"      Presence of other medical disorders, significant changes in health status, medication list",
"     </li>",
"     <li>",
"      Use of hormonal or nutritional supplements that may contain androgens",
"     </li>",
"     <li>",
"      Family history of male and female hair loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A rapid onset of diffuse hair loss may suggest acute telogen effluvium, particularly when the history suggests a change in health status (eg, serious illness, pregnancy, significant weight loss) or medication changes within the preceding several months. Of note, telogen effluvium may coexist with FPHL, and an episode of telogen effluvium may unmask underlying FPHL. The gynecological history and assessment for signs of virilization help to identify women for whom an evaluation for hyperandrogenism is indicated. (See",
"    <a class=\"local\" href=\"#H432606918\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonscarring hair loss\", section on 'Telogen effluvium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with FPHL may first notice their hair loss as the progressive thinning of a ponytail or as increasing visibility of the scalp through the hair in the frontal and vertex areas of the scalp. These features are typically noted over the course of months to years. Although the onset and progression of FPHL is often insidious, occasional patients describe noticing specific episodes of increased hair loss prior to a noticeable change in terminal hair density. Women may also complain of an increased propensity for sunburns on the scalp as hair coverage diminishes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605925941\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A full skin examination that includes evaluation of the scalp, face, body, and nails is advised in patients who present with a new complaint of hair loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=see_link&amp;anchor=H638362#H638362\">",
"     \"Evaluation and diagnosis of hair loss\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The examination of the scalp and scalp hair should focus on identifying the distribution of hair loss and the caliber of hairs within the involved areas. Findings consistent with FPHL include the detection of terminal hair loss that is primarily localized to the frontal scalp",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vertex of the scalp and miniaturized hairs (shorter and thinner hairs or vellus hairs). The use of a sheet of paper as a contrasting background can facilitate visualization of individual hairs.",
"   </p>",
"   <p>",
"    Comparing the part width in the frontal or vertex scalp to the occipital scalp, which is usually relatively spared, provides a visual aid for the assessment of the reduction in hair density. Even in patients who develop diffuse hair loss from FPHL, hair thinning usually remains most prominent in the frontal and vertex areas [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/9,26\">",
"     9,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The examination of the scalp should also focus on the detection of clinical features such as inflammation, scarring, or scale. The presence of these features strongly suggests that the hair loss is caused by a different disease or that FPHL coexists with another scalp disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=see_link\">",
"     \"Evaluation and diagnosis of hair loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The examination of other body sites may result in the identification of features useful for diagnosis and patient management. For example, patients with diffuse alopecia areata may have nail abnormalities and patchy hair loss on other body sites, findings that are not associated with FPHL. In addition, the presence of hirsutism, acne, and obesity suggest the possibility of a hyperandrogenic state related to polycystic ovarian syndrome or another hormonal abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hair pull tests, which can identify increased shedding of telogen hairs, may be positive in early hair loss on the central scalp, but are typically negative in patients with long-standing FPHL [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/17\">",
"     17",
"    </a>",
"    ]. A positive hair pull test suggests the possibility of active telogen effluvium or alopecia areata. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=see_link&amp;anchor=H638534#H638534\">",
"     \"Evaluation and diagnosis of hair loss\", section on 'Hair pull test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605926128\">",
"    <span class=\"h3\">",
"     Dermoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermoscopy of the scalp (also known as trichoscopy) may be useful for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Dermoscopic features of FPHL and male androgenetic alopecia include hair diameter diversity, perifollicular",
"    <span class=\"nowrap\">",
"     pigmentation/peripilar",
"    </span>",
"    signs, and yellow dots [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/28\">",
"     28",
"    </a>",
"    ]. Focal atrichia may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352182242\">",
"    <span class=\"h2\">",
"     Scalp biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although scalp biopsies usually are not needed to diagnose FPHL, biopsies can be helpful in cases in which the clinical evaluation does not provide a definitive diagnosis. Examples of scenarios in which a biopsy may be particularly useful include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distinguishing FPHL from telogen effluvium or diffuse alopecia areata",
"     </li>",
"     <li>",
"      Distinguishing FPHL from scarring alopecia when the clinical differentiation between scarring and nonscarring alopecia is difficult",
"     </li>",
"     <li>",
"      Identifying coexisting scalp disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Scalp biopsies should be performed within an affected area and should extend into the subcutaneous fat. It is best to avoid the bitemporal area, since follicular miniaturization in this area is common in individuals without hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 4 mm punch biopsy usually provides sufficient tissue for histological examination. We typically perform two 4 mm punch biopsies so that one specimen can be processed with vertical sectioning and the other with horizontal sectioning [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Doing so allows the pathologist to examine the hair follicles in both longitudinal and cross-sections. Many dermatopathologists prefer to receive two specimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714576#H21714576\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical histopathological features of FPHL are identical to those of male androgenetic alopecia. They include [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased number of miniaturized hair follicles and reduced size of sebaceous glands",
"     </li>",
"     <li>",
"      Decreased anagen to telogen ratio",
"     </li>",
"     <li>",
"      Increased number of follicular stelae",
"     </li>",
"     <li>",
"      Perifollicular inflammation around the upper portion of the hair follicle with or without perifollicular fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714576#H21714576\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432607982\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no serological tests provide a definitive diagnosis of FPHL, such tests are helpful for identifying an underlying hyperandrogenic state. Testing for hyperandrogenism is performed in women with FPHL when the clinical features suggestive of hyperandrogenism are present (eg, hirsutism, irregular menses, moderate to severe acne, treatment-refractory adult acne, acanthosis nigricans, or galactorrhea). We typically obtain a free",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total testosterone level and dehydroepiandrosterone sulfate (DHEAS) level as initial screening tests [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/17\">",
"     17",
"    </a>",
"    ]. Oral contraceptives should be discontinued for at least two months prior to androgen testing [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/33\">",
"     33",
"    </a>",
"    ]. Additional tests for specific disorders of hyperandrogenism are added as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of premenopausal women with hirsutism\", section on 'Biochemical testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432607989\">",
"    <span class=\"h2\">",
"     Adjunctive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional procedures that may be utilized for the evaluation and follow-up of FPHL include trichograms and phototrichograms. A trichogram is a technique in which 25 to 50 hairs are grasped with a needle holder and plucked from the scalp followed by an examination of the proximal ends of the hair to assess for the proportion of hairs in telogen. Trichograms are now seldom used in the diagnosis of FPHL. The results of one retrospective study suggest that dermoscopy (trichoscopy) is more useful for the diagnosis of FPHL than trichograms [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H605926128\">",
"     'Dermoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Phototrichograms are imaging techniques used to closely examine the features of hair loss for diagnosis and follow-up. A small area of hair is trimmed and followed with imaging for the proportion of regrowing (anagen) hairs, resting (telogen) hairs, and shed hairs, as well as the rate of growth, and hair density [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/35\">",
"     35",
"    </a>",
"    ]. Computerized techniques for performing phototrichograms have been developed (TrichoScan and Folliscope) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. Phototrichograms are primarily utilized in clinical studies and specialized hair clinics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=see_link&amp;anchor=H93848306#H93848306\">",
"     \"Evaluation and diagnosis of hair loss\", section on 'Trichograms and phototrichograms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432606918\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple hair and scalp disorders may present with clinical features that resemble FPHL [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/41\">",
"     41",
"    </a>",
"    ]. Careful review of the patient history, physical examination findings, and biopsy (when necessary) is of value for differentiating these disorders from FPHL. Of note, since FPHL is a common condition, the coexistence of FPHL with other disorders must also be considered when patients present with features that are not entirely consistent with FPHL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Telogen effluvium",
"      </strong>",
"      &ndash; Telogen effluvium is the disorder that may be most difficult to distinguish from FPHL. Patients present with acute or chronic noninflammatory, diffuse hair loss [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/42\">",
"       42",
"      </a>",
"      ]. The clinical history is often of value for identifying this diagnosis. For example, a major illness, severe psychological trauma, significant weight loss, childbirth, and certain medications may precipitate an episode of acute telogen effluvium that begins a few months after the insult. In telogen effluvium, hair loss occurs in all areas of the scalp, although the hair loss may be most evident in the temporal area (",
"      <a class=\"graphic graphic_picture graphicRef76636 \" href=\"UTD.htm?9/36/9792\">",
"       picture 4",
"      </a>",
"      ). A hair pull test often demonstrates increased shedding of telogen hairs in patients with active telogen effluvium. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link&amp;anchor=H5#H5\">",
"       \"Nonscarring hair loss\", section on 'Telogen effluvium'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diffuse alopecia areata",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The rare diffuse form of alopecia areata is characterized by diffuse reduction in hair density (",
"      <a class=\"graphic graphic_picture graphicRef87197 \" href=\"UTD.htm?11/30/11750\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/41\">",
"       41",
"      </a>",
"      ]. Due to the preferential loss of pigmented hairs, adult patients may complain of rapid graying of the hair. Though not always present, a personal or family history of alopecia areata, the detection of circumscribed areas of complete hair loss, and nail abnormalities offer support to this diagnosis. A biopsy is useful for confirming the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of alopecia areata\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Central centrifugal cicatricial alopecia",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Central centrifugal cicatricial alopecia is a scarring alopecia that most commonly occurs in women of African descent [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/43\">",
"       43",
"      </a>",
"      ]. The classic location on the vertex of the scalp contributes to the potential for confusion of this diagnosis with FPHL (",
"      <a class=\"graphic graphic_picture graphicRef87198 \" href=\"UTD.htm?37/17/38168\">",
"       picture 6",
"      </a>",
"      ). The detection of loss of follicular ostia indicates the presence of scarring. Pustules or inflammation may be detected in early disease. Biopsies are used to confirm the diagnosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Frontal fibrosing alopecia",
"      </strong>",
"      &ndash; Frontal fibrosing alopecia is an uncommon scarring alopecia that is usually characterized by frontotemporal recession, perifollicular erythema and follicular hyperkeratosis [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31752/abstract/44\">",
"       44",
"      </a>",
"      ]. Eyebrow loss may also occur. The detection of clinical and histological signs consistent with a lymphocytic scarring alopecia aid in diagnosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Traction alopecia",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Traction alopecia is a form of hair loss that occurs as a result of chronic tension on the hair shaft and follicle (",
"      <a class=\"graphic graphic_picture graphicRef60331 \" href=\"UTD.htm?37/36/38468\">",
"       picture 7",
"      </a>",
"      ). Tight braiding of the hair is a common cause of this condition. Hair loss due to traction alopecia is often located at the hairline. Although the hair loss is reversible initially, hair loss may become permanent if tension on the hair follicles continues. The patient history is useful for diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452176536\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Female pattern hair loss (FPHL) is a common, nonscarring form of hair loss that most commonly occurs in adult women. The highest prevalence of FPHL is found in postmenopausal women. (See",
"      <a class=\"local\" href=\"#H109567516\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although hormonal factors and genetic predisposition are believed to contribute to FPHL, the mechanism through which these factors lead to FPHL is not entirely clear. The majority of women with FPHL do not have abnormal levels of serum androgens. (See",
"      <a class=\"local\" href=\"#H109567523\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classically, FPHL presents with a slow, progressive transition of terminal hairs on the frontal scalp",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertex of the scalp to shorter, thinner hairs and vellus hairs. The process results in a visible reduction in hair coverage on the scalp (",
"      <a class=\"graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195 \" href=\"UTD.htm?36/26/37290\">",
"       picture 1A-C",
"      </a>",
"      ). The occipital scalp and frontal hairline are often relatively spared. (See",
"      <a class=\"local\" href=\"#H109567558\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although FPHL does not cause physical discomfort or physical disability, the hair loss can contribute to significant psychological distress. (See",
"      <a class=\"local\" href=\"#H352182082\">",
"       'Psychosocial dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of FPHL is usually made clinically, based upon the patient history and physical examination. The diagnosis is suggested by the detection of a reduction in hair density in the characteristic distribution and an increased prevalence of miniaturized hairs. Skin biopsies are not usually performed, but can be helpful when the diagnosis is uncertain or when a concomitant scalp disorder is suspected. (See",
"      <a class=\"local\" href=\"#H109567572\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of FPHL includes several types of nonscarring and scarring hair loss. Telogen effluvium, central centrifugal cicatricial alopecia, and traction alopecia are examples of relatively common disorders that share features with FPHL. (See",
"      <a class=\"local\" href=\"#H432606918\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/1\">",
"      Atanaskova Mesinkovska N, Bergfeld WF. Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin 2013; 31:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/2\">",
"      Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001; 27:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/3\">",
"      Wang TL, Zhou C, Shen YW, et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol 2010; 162:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/4\">",
"      Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011; 164:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/5\">",
"      Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. Br J Dermatol 2010; 163:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/6\">",
"      Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001; 144:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/7\">",
"      Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol 2006; 155:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/8\">",
"      Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 2011; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/9\">",
"      Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003; 8:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/10\">",
"      Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988; 19:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/11\">",
"      Schmidt JB, Lindmaier A, Trenz A, et al. Hormone studies in females with androgenic hairloss. Gynecol Obstet Invest 1991; 31:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/12\">",
"      Camacho-Mart&iacute;nez FM. Hair loss in women. Semin Cutan Med Surg 2009; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/13\">",
"      Yip L, Zaloumis S, Irwin D, et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 2009; 161:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/14\">",
"      Olsen EA. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol 1999; 40:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/15\">",
"      Olsen EA. Female pattern hair loss. J Am Acad Dermatol 2001; 45:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/16\">",
"      Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/17\">",
"      Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/18\">",
"      Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol 1988; 18:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/19\">",
"      Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999; 141:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/20\">",
"      Van Der Donk J, Hunfeld JA, Passchier J, et al. Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica. Soc Sci Med 1994; 38:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/21\">",
"      Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 1993; 29:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/22\">",
"      Price VH. Androgenetic alopecia in adolescents. Cutis 2003; 71:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/23\">",
"      Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 2012; 66:e97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/24\">",
"      Arias-Santiago S, Guti&eacute;rrez-Salmer&oacute;n MT, Buend&iacute;a-Eisman A, et al. Hypertension and aldosterone levels in women with early-onset androgenetic alopecia. Br J Dermatol 2010; 162:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/25\">",
"      Hirsso P, Rajala U, Laakso M, et al. Health-related quality of life and physical well-being among a 63-year-old cohort of women with androgenetic alopecia; a Finnish population-based study. Health Qual Life Outcomes 2005; 3:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/26\">",
"      Kang H, Kang TW, Lee SD, et al. The changing patterns of hair density and thickness in South Korean women with hair loss: clinical office-based phototrichogram analysis. Int J Dermatol 2009; 48:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/27\">",
"      Zhang X, Caulloo S, Zhao Y, et al. Female pattern hair loss: clinico-laboratory findings and trichoscopy depending on disease severity. Int J Trichology 2012; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/28\">",
"      Inui S. Trichoscopy for common hair loss diseases: algorithmic method for diagnosis. J Dermatol 2011; 38:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/29\">",
"      Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/30\">",
"      Headington JT. Transverse microscopic anatomy of the human scalp. A basis for a morphometric approach to disorders of the hair follicle. Arch Dermatol 1984; 120:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/31\">",
"      Horenstein MG, Jacob JS. Follicular streamers (stelae) in scarring and non-scarring alopecia. J Cutan Pathol 2008; 35:1115.",
"     </a>",
"    </li>",
"    <li>",
"     Messenger AG. Androgenetic alopecia. In: Hair diseases: Medical, surgical, and cosmetic treatments, McMichael AJ, Hordinsky MK (Eds), Informa Healthcare, New York 2008. p.108.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/33\">",
"      S&aacute;nchez LA, P&eacute;rez M, Centeno I, et al. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil Steril 2007; 87:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/34\">",
"      Galliker NA, Tr&uuml;eb RM. Value of trichoscopy versus trichogram for diagnosis of female androgenetic alopecia. Int J Trichology 2012; 4:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/35\">",
"      Dhurat R. Phototrichogram. Indian J Dermatol Venereol Leprol 2006; 72:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/36\">",
"      Riedel-Baima B, Riedel A. Use of the TrichoScan to assess female pattern hair loss. Dermatol Surg 2009; 35:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/37\">",
"      Lee BS, Chan JY, Monselise A, et al. Assessment of hair density and caliber in Caucasian and Asian female subjects with female pattern hair loss by using the Folliscope. J Am Acad Dermatol 2012; 66:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/38\">",
"      Van Neste D, Tr&uuml;eb RM. Critical study of hair growth analysis with computer-assisted methods. J Eur Acad Dermatol Venereol 2006; 20:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/39\">",
"      Gassmueller J, Rowold E, Frase T, Hughes-Formella B. Validation of TrichoScan technology as a fully-automated tool for evaluation of hair growth parameters. Eur J Dermatol 2009; 19:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/40\">",
"      Saraogi PP, Dhurat RS. Automated Digital Image Analysis (TrichoScan&reg;) for Human Hair Growth Analysis: Ease versus Errors. Int J Trichology 2010; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/41\">",
"      Chartier MB, Hoss DM, Grant-Kels JM. Approach to the adult female patient with diffuse nonscarring alopecia. J Am Acad Dermatol 2002; 47:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/42\">",
"      Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002; 27:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/43\">",
"      Summers P, Kyei A, Bergfeld W. Central centrifugal cicatricial alopecia - an approach to diagnosis and management. Int J Dermatol 2011; 50:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31752/abstract/44\">",
"      MacDonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a review of 60 cases. J Am Acad Dermatol 2012; 67:955.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15679 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31752=[""].join("\n");
var outline_f31_0_31752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H452176536\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109567509\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H516820567\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109567516\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109567523\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432607103\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432607110\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109567558\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H605925860\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352182082\">",
"      Psychosocial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432607899\">",
"      Associated medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109567572\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605925949\">",
"      Patient history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605925941\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H605926128\">",
"      - Dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352182242\">",
"      Scalp biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432607982\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432607989\">",
"      Adjunctive tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H432606918\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452176536\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15679|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/30/8677\" title=\"figure 1\">",
"      Ludwig scale for female pattern hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15679|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/58/21411\" title=\"picture 1A\">",
"      Female pattern hair loss 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/22/15719\" title=\"picture 1B\">",
"      Female pattern hair loss 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/10/3238\" title=\"picture 1C\">",
"      Female pattern hair loss 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/47/40692\" title=\"picture 2\">",
"      Androgenetic alopecia extensive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/33/7697\" title=\"picture 3\">",
"      Sinclair scale for female pattern hair loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9792\" title=\"picture 4\">",
"      Telogen effluvium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/30/11750\" title=\"picture 5\">",
"      Diffuse alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/17/38168\" title=\"picture 6\">",
"      Central centrifugal cicatricial alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/36/38468\" title=\"picture 7\">",
"      Traction alopecia hairline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=related_link\">",
"      Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=related_link\">",
"      Chemotherapy-induced alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=related_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=related_link\">",
"      Evaluation and diagnosis of hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=related_link\">",
"      Nonscarring hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=related_link\">",
"      Overview of dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=related_link\">",
"      Treatment of androgenetic alopecia in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_0_31753="Fibrillary glomerulonephritis light";
var content_f31_0_31753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrillary glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in fibrillary glomerulonephritis shows diffuse expansion of the mesangium by amorphous, acellular material (arrows). Electron microscopy and Congo red staining are necessary to distinguish this light microscopic appearance from amyloidosis or light chain deposition disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31753=[""].join("\n");
var outline_f31_0_31753=null;
var title_f31_0_31754="Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children";
var content_f31_0_31754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31754/contributors\">",
"     Deborah P Merke, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31754/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31754/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31754/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/0/31754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/0/31754/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/0/31754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 95 percent of cases of congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This conversion is mediated by 21-hydroxylase, deficiency of which is caused by mutations in the CYP21A2 gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children is reviewed here. The pathophysiology, genetics, and clinical manifestations of 21-hydroxylase deficiency, the treatment of 21-hydroxylase deficiency in adults, and the clinical presentation and treatment of nonclassic (mild) congenital adrenal hyperplasia (CAH) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"     \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of 21-hydroxylase deficiency is directed toward providing glucocorticoid in sufficient doses to reduce the associated excessive corticotropin-releasing hormone (CRH) and corticotropin (ACTH) secretion and hyperandrogenemia, so that growth, sexual maturation, and, later, reproductive function, are normal. In patients with the salt-losing form of the disorder, mineralocorticoid is given to restore serum electrolyte concentrations and extracellular fluid volume to normal. These goals can be difficult to achieve without overtreatment, and its attendant risk of growth retardation and other clinical manifestations of Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An Endocrine Society Clinical Practice Guideline on the diagnosis and treatment of 21-hydroxylase deficiency in children and adults is available [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. Guidelines regarding comprehensive care are also available based on a conference attended by pediatric endocrinologists, medical endocrinologists, reproductive endocrinologists, pediatric",
"    <span class=\"nowrap\">",
"     urologists/surgeons,",
"    </span>",
"    endocrine nurses, psychologists and affected individuals and their families [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRENATAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis of 21-hydroxylase deficiency was originally undertaken to provide parents with information regarding the disease status of the fetus. Prenatal diagnosis also has been performed if prenatal therapy is contemplated. However, because prenatal therapy may have adverse effects (on the fetus and mother) and long-term risks are unknown, the decision to treat should be made in consultation with a highly experienced team in a research setting [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Prenatal diagnosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The rationale for prenatal therapy is that suppression of fetal pituitary ACTH secretion by exogenous glucocorticoid would prevent or reduce virilization of the external genitalia of affected females. Very early diagnosis is required because virilization of affected female fetuses begins as early as four weeks of gestation. Rapid genotyping of fetal cells obtained by chorionic villus sampling at 8 to 10 weeks of gestation appears to be the best approach, but therapy must be started at the time of the first missed menstrual period, well before the molecular diagnosis is available. Circulating cell-free fetal DNA can be detected in the maternal circulation at five weeks gestation and represents a noninvasive accurate method of determining fetal sex [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/5\">",
"     5",
"    </a>",
"    ]; however, this test is not routinely available. &nbsp;",
"   </p>",
"   <p>",
"    Prenatal treatment consists of maternal administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , which is not degraded by the placenta and crosses into the fetal circulation. This treatment is most effective in preventing abnormal genital development in affected female fetuses when it is initiated as soon as pregnancy is recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. If treatment cannot be begun by nine weeks of gestation, it should not be given at all [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 85 percent of prenatally treated female infants are born with normal or slightly virilized genitalia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatment failures have been attributed to early cessation of therapy, late start of therapy, nonadherence, suboptimal dosing, or differences in",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    metabolism. Treatment is discontinued if genetic testing reveals a male fetus or an unaffected female. Since the risk of having an affected female fetus is one in eight when both parents are known carriers, seven in eight fetuses will receive treatment who in retrospect are not affected females. Adverse effects for the mother include increased appetite, early and excessive weight gain, edema, striae, and signs and symptoms of Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prenatal treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may have some adverse effects on the fetus. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 15 fetuses with congenital adrenal hyperplasia and 28 unaffected fetuses exposed to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in utero, five unaffected and three affected fetuses had postnatal failure to thrive, psychomotor developmental delay, or other adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, the only adverse effect of in utero exposure to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      among 26 fetuses was increased internalizing behavior, such as shyness [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive and motor development was similar among 487 children with intrauterine exposure to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (48 with congenital adrenal hyperplasia [CAH]) and 313 unexposed children (195 with CAH) up to 12 years old whose mothers completed age-appropriate standardized developmental questionnaires [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 26 children 7 to 17 years old suggests that prenatal treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      may have negative effects on some neuropsychological functions and school performance [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/17\">",
"       17",
"      </a>",
"      ]. Eight children with CAH who were treated prenatally performed less well on tests measuring verbal processing speed as compared to age- and sex-matched healthy controls. Thirteen other children who did not have CAH and therefore had a shorter prenatal treatment course also performed less well on a test measuring verbal working memory, and had reduced self-perception of scholastic competence and increased self-reported social anxiety. There were no differences in intelligence, memory encoding, or long-term memory between the prenatally treated children and the healthy controls.",
"     </li>",
"     <li>",
"      In rhesus monkeys, prenatal exposure to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      was associated with a deficit in hippocampal neurons at 24 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multicenter case-control study, maternal corticosteroid use during pregnancy was associated with a moderately increased risk of cleft lip and palate [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      was shown to induce germ cell apoptosis in cultured human fetal ovaries [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/20\">",
"       20",
"      </a>",
"      ], suggesting the possibility of a previously unrecognized effect of in utero dexamethasone exposure. Fertility has not been evaluated in dexamethasone treated females.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of prenatal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    use for the prevention of virilization in pregnancies at risk for classic CAH found very few studies evaluating outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/21\">",
"     21",
"    </a>",
"    ]. Although dexamethasone reduces virilization of CAH-affected females and no important permanent side effects were observed for the mothers, long-term effects have not been adequately studied and remain unclear.",
"   </p>",
"   <p>",
"    Taken together, these studies indicate that the long-term safety of the treatment has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/17,21-23\">",
"     17,21-23",
"    </a>",
"    ]. Given these unresolved questions, several groups have concluded that prenatal therapy should be regarded as experimental, parents should be fully informed regarding potential adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2,13,24\">",
"     2,13,24",
"    </a>",
"    ], and treatment should only be managed by an experienced team and pursued through protocols approved by Institutional Review Boards [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13,24,25\">",
"     13,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT IN NEONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn infants with congenital adrenal hyperplasia (CAH) may be identified through prenatal diagnosis, neonatal screening programs, because they are noted to have ambiguous genitalia on physical examination (females), or because of an adrenal crisis (hyponatremia, hyperkalemia, dehydration) at approximately 10 to 20 days of life. Every newborn with ambiguous genitalia or a suspected diagnosis of CAH should be evaluated by a pediatric endocrinologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ambiguous genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with ambiguous genitalia require urgent medical attention. The initial evaluation should include history, physical examination, pelvic ultrasonography to evaluate internal genitalia (uterus) and possibly adrenals, karyotype or fluorescence in situ hybridization (FISH) for sex chromosome (SRY probe) material (if not available from prenatal testing), and rapid and reliable measurement of 17-hydroxyprogesterone and serum electrolytes. This evaluation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"     \"Evaluation of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with genital ambiguity and nonpalpable gonads should be presumed to have CAH and empirically treated for CAH until the diagnosis is confirmed or excluded.",
"    <strong>",
"     After",
"    </strong>",
"    the blood sample for 17-hydroxyprogesterone is obtained, treatment doses of glucocorticoid and mineralocorticoid and sodium chloride supplementation should be initiated in",
"    <strong>",
"     all",
"    </strong>",
"    infants in whom CAH is a consideration to prevent the potentially life-threatening manifestations of an adrenal crisis. While awaiting laboratory results, therapy should be initiated with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    divided thrice daily,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    100 mcg (0.1",
"    <span class=\"nowrap\">",
"     mg)/day,",
"    </span>",
"    and one gram or 4",
"    <span class=\"nowrap\">",
"     mEq/kg/day",
"    </span>",
"    of sodium chloride divided in several feedings. Higher doses of hydrocortisone (ie, 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day)",
"    </span>",
"    may be used for initial reduction of markedly elevated adrenal hormones, but it is important to rapidly reduce the dose when target hormone levels are achieved. Doses of hydrocortisone that exceed 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    in infancy have been associated with growth suppression and shorter adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of the infant with ambiguous genitalia\", section on 'Initial stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The birth of an infant with ambiguous genitalia is a psychosocial emergency for the family. Careful and complete evaluation by an experienced team of endocrinologists, geneticists, and surgeons, aided by individuals capable of sophisticated psychosocial support, is necessary before an appropriate therapeutic plan can be developed with the full, informed participation of the parents. The parents and family may need some time to adjust to the diagnosis before they are capable of making decisions regarding management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of the infant with ambiguous genitalia\", section on 'Family coping'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical management of children born with ambiguous genitalia is complex. Girls with classic CAH typically undergo reconstructive surgery, usually clitoroplasty and vaginoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. This surgery requires medical teams with experience and expertise in children with 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Clitoral reduction should preserve the neurovascular bundle, the glans, and the preputial skin related to the glans. The timing and type of surgery is controversial, and depends on a number of patient-specific considerations, as discussed in consensus statements and a separate topic review [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link\">",
"     \"Management of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adrenal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent medical therapy is necessary for infants who present in an adrenal crisis, which appears to be occurring less frequently in the era of mandatory newborn screening for CAH (secondary to 21-hydroxylase deficiency) in the United States. A rapid overview guiding the recognition and treatment of an adrenal crisis is shown in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef61357 \" href=\"UTD.htm?22/54/23405\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The initial goals are treatment of hypotension and dehydration, reversal of electrolyte and glucose abnormalities, and correction of cortisol deficiency. Normal (0.9 percent) saline solution or 5 percent dextrose in normal saline should be infused intravenously as quickly as possible. An intravenous bolus of 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of normal saline should be administered. An intravenous bolus of 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of 10 percent dextrose should be considered if there is significant hypoglycemia. Hypotonic saline",
"    <strong>",
"     should not be used",
"    </strong>",
"    because it can worsen the hyponatremia; the same is true of 5 percent dextrose without the addition of normal saline. Hyperkalemia should be corrected with the administration of glucose and insulin if necessary, although it typically improves rapidly as a result of the potent mineralocorticoid action of high-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (see below).",
"   </p>",
"   <p>",
"    After a blood sample is obtained for steroid hormone measurements (most importantly 17-hydroxyprogesterone), stress doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    should be administered. An initial dose of hydrocortisone of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    should be administered as an IV bolus (typical neonatal dose is 25 mg), followed by hydrocortisone at a dose of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV per day divided every six hours. Stress doses of hydrocortisone should be continued until the patient is stable and feeding normally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During treatment with stress doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , mineralocorticoid replacement is unnecessary. If the diagnosis of classic 21-hydroxylase deficiency is confirmed, infants should receive glucocorticoid and mineralocorticoid therapy and salt supplementation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Management in children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Positive newborn screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn screening for CAH is routinely performed in all 50 US states and at least 40 other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. A positive newborn screening test for CAH must be confirmed by a second",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    sample. The urgent medical issue is identification of infants with the salt-losing form before they develop an adrenal crisis. Symptoms of salt-losing, including vomiting, poor feeding with failure to thrive, lethargy, hypovolemia, dehydration, hyponatremia with hyperkalemia, hypoglycemia, and cardiovascular collapse can occur within the first few weeks of life if CAH is not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13,29\">",
"     13,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As soon as CAH is suspected on the basis of a positive newborn screen, a sample of blood should be obtained for confirmatory steroid hormone measurements (most importantly, 17-hydroxyprogesterone), and serum electrolytes should be measured.",
"    <strong>",
"     After",
"    </strong>",
"    the confirmatory blood sample is obtained, treatment doses of glucocorticoid and mineralocorticoid should be initiated in",
"    <strong>",
"     all",
"    </strong>",
"    infants in whom CAH is a consideration, to prevent the potentially life-threatening manifestations of an adrenal crisis. While awaiting laboratory results, we suggest initiating therapy with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    divided thrice daily,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    and one gram of sodium chloride divided in several feedings. If the physician chooses not to initiate treatment while awaiting confirmatory steroid hormone measurements, serum electrolytes should be measured daily. These patients should be managed by a pediatric endocrinologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT IN CHILDREN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Glucocorticoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid replacement is necessary in children who have classic 21-hydroxylase deficiency and in symptomatic children with nonclassic 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/1,13,29\">",
"     1,13,29",
"    </a>",
"    ]. The goal of therapy is to replace deficient steroids while minimizing adrenal sex hormone and iatrogenic glucocorticoid excess [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"     \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoid in infants and children is usually administered as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (cortisol) in a dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ], divided into three doses, although higher doses are sometimes needed and treatment should be individualized. This dose range exceeds the daily cortisol secretory rate of normal infants and children, which is estimated to be 7 to 9",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    in neonates and 6 to 7",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. It is important to use the lowest effective glucocorticoid dose because excessive dosing reduces linear growth. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    For older adolescents and adults, long-acting glucocorticoids such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    are often the preferred treatment due to the convenience of less frequent dosing. However, the longer duration of action and greater potency may increase the risk of overtreatment, restricting linear growth if given prior to epiphyseal closure [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/6,33,34\">",
"     6,33,34",
"    </a>",
"    ]. Dexamethasone is given once daily at a dose of 0.25 to 0.50 mg, preferably at bedtime. A glucocorticoid that is inactivated by the placenta (eg, prednisone) is preferred in sexually active women. Prednisone is given at a daily dose of 5 to 7.5 mg, divided into two doses. Similar to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , higher doses are sometimes needed and treatment should be individualized.",
"   </p>",
"   <p>",
"    Because the results of therapy are frequently suboptimal in terms of eventual adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/35-39\">",
"     35-39",
"    </a>",
"    ], long-acting glucocorticoids such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    have raised particular concerns (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Growth'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Menstrual cycle'",
"    </a>",
"    below). However, some studies suggest that treatment with these drugs does not necessarily limit growth. One study of 26 children treated with dexamethasone (average dose 0.27",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every morning) for an average of seven years demonstrated normal growth and control of androgen secretion with normal sexual maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/40\">",
"     40",
"    </a>",
"    ]. Similarly, nine children with adrenal insufficiency had normal short-term (six months) growth velocity when receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    at a dose of 5:1 relative potency to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/41\">",
"     41",
"    </a>",
"    ]. It is possible that the doses used in these studies were sufficiently low to avoid the growth-suppressing effects. However, because of ongoing concerns about growth, hydrocortisone remains the glucocorticoid of choice and the standard of care during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mineralocorticoid and sodium chloride",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mineralocorticoid replacement is recommended in all patients who have the classic form of CAH, whether or not it is the salt-losing form. Although mineralocorticoid deficiency may only appear clinically apparent in the salt-losing form, aldosterone secretion has been shown to be impaired in the simple-virilizing form [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] and mineralocorticoid treatment has been associated with improved height outcome in patients with classic CAH [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The need for mineralocorticoid replacement should be periodically reassessed, since sensitivity to mineralocorticoids may vary over time [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mineralocorticoid is given as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    , in a dose sufficient to restore normal serum sodium and potassium concentrations, and plasma renin activity should be maintained within the normal range. Excessive dosing can induce hypertension, hypokalemia, and possibly, impaired growth [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/46\">",
"     46",
"    </a>",
"    ], while underdosing also can lead to poor growth with failure-to-thrive. This may be in part because inadequate mineralocorticoid replacement increases the glucocorticoid replacement requirement, impairing growth [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In addition, inadequate mineralocorticoid replacement may lead to increased adrenal androgen production. This is because patients may be chronically volume-depleted, which is clinically inapparent but results in persistent overproduction of renin and angiotensin II. Angiotensin II stimulates vasopressin and ACTH, leading to higher adrenal androgen synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/48\">",
"     48",
"    </a>",
"    ]. For all of these reasons, mineralocorticoid therapy appears to benefit patients with either the classic salt-losing form or the classic non-salt-losing (simple virilizing) form of 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/49\">",
"     49",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The usual pediatric dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    is 50 to 200 mcg per day (0.05 to 0.20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. Infants require higher doses of fludrocortisone and also require sodium chloride supplementation of 1 to 3 g per day (about 17 to 51 mEq per day or 4",
"    <span class=\"nowrap\">",
"     mEq/kg/day)",
"    </span>",
"    distributed in several feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13\">",
"     13",
"    </a>",
"    ]. Fludrocortisone doses typically require dose reduction after 6 to 12 months of age because sensitivity to mineralocorticoid increases as the kidneys mature in the first year of life; dose reduction should be guided by measurement of plasma renin activity and blood pressure. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Salt",
"    <span class=\"nowrap\">",
"     tablets/solution",
"    </span>",
"    can be discontinued as the child begins to eat table food and the taste for salty food increases. Additional salt intake may be needed with exposure to hot weather or with intense exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitoring therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy should be evaluated monthly in the first three months of life, every three months in the neonate and infant, and every three to six months thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13\">",
"     13",
"    </a>",
"    ]. More frequent monitoring is sometimes clinically indicated. Response to therapy is monitored by measuring serum 17-hydroxyprogesterone, androstenedione, plasma renin activity or direct renin, as well as growth velocity, blood pressure, and the rate of skeletal maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/26,50-53\">",
"     26,50-53",
"    </a>",
"    ]. Measurement of testosterone is sometimes useful in patients whose disease is not well controlled. Decreased mineralocorticoid sensitivity is present in the first few months of life; thus, it is essential to reassess mineralocorticoid status and adjust the replacement dose as needed during the first year. Blood samples for monitoring therapy should be obtained at a consistent time in relation to glucocorticoid dosing, optimally in the morning to reflect peak",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    concentrations but before the glucocorticoid dose is taken [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/1,13,29\">",
"     1,13,29",
"    </a>",
"    ]. Normative laboratory data for age and sexual maturation should be used in the interpretation of all laboratory tests; normative data may vary depending upon the laboratory.",
"   </p>",
"   <p>",
"    Appropriate target ranges are a serum 17-hydroxyprogesterone concentration of 400 to 1200",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (12 to 36",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and serum androstenedione concentrations appropriate for the patient's age and sex [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/1\">",
"     1",
"    </a>",
"    ]. Adrenal androgen secretion should not be completely suppressed; normal levels of 17-hydroxyprogesterone generally indicate overtreatment. These serum tests serve as markers of the adequacy of treatment and of patient adherence to it, and along with the growth record provide the basis for adjustments in the doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    . Simply adjusting the glucocorticoid dose to normalize the serum 17-hydroxyprogesterone value is insufficient because of the risk of iatrogenic Cushing syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/3\">",
"     3",
"    </a>",
"    ] and since androgen excess may persist because of avid adrenal conversion of 17-hydroxyprogesterone to androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Plasma renin activity should be in the normal range for age. In patients with salt-losing and continued androgen excess,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    and the exogenous salt dose should be adjusted to normalize renin before increasing the glucocorticoid dose.",
"   </p>",
"   <p>",
"    Patients with significant elevations of androstenedione or testosterone levels due to poor compliance may respond more rapidly to a limited 7- to 10-day course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    administered in supraphysiologic doses, followed by the standard replacement doses. It is essential that the high-dose course be brief to avoid compromising growth and increasing weight.",
"   </p>",
"   <p>",
"    Alternative measurements include urinary metabolites (pregnanetriol) or salivary hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13,56\">",
"     13,56",
"    </a>",
"    ]. The measurements of bone age and growth rate reflect long-term control; bone age should be obtained at least once a year after two years of age or every six months if advanced for chronologic age [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. Ideally, treatment should be modified well before there is evidence of reduced growth rate or advanced bone age [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/57\">",
"     57",
"    </a>",
"    ]. In practice, however, this may not be a simple matter. As an example, in a randomized trial in 26 children,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    at a dose of 25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day caused significant slowing of growth over the course of one year, compared with 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/55\">",
"     55",
"    </a>",
"    ]. However, at the lower dose there was often incomplete suppression of androgen secretion. Thus, the patient's symptoms and signs of androgen excess, steroid measurements, and growth and development all need to be considered.",
"   </p>",
"   <p>",
"    Patients with CAH are at risk for early central puberty. Central precocious puberty is most likely to develop when the diagnosis of CAH is delayed or when adrenal androgen secretion is poorly controlled; such patients may benefit from treatment with a gonadotropin-releasing hormone analog [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/58\">",
"     58",
"    </a>",
"    ]. In boys with CAH, the onset of central puberty has been closely linked to a bone age of 12 years to 12 years 6 months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/59\">",
"     59",
"    </a>",
"    ], but no clear association has been identified in girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adrenal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine illnesses may become life-threatening in children with CAH unless their glucocorticoid regimen is appropriately modified. A rapid overview guiding the recognition and treatment of an adrenal crisis is shown in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef61357 \" href=\"UTD.htm?22/54/23405\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment of illnesses in children with fever or gastroenteritis who have adequate oral intake requires doubling or tripling the oral dose of glucocorticoids for the duration of illness; changes in",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    dose are not usually required [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. If a patient is unable to tolerate oral medication,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    should be given intramuscularly, and medical advice should be promptly sought. Increased doses of glucocorticoids are not required for mild illnesses without fever, emotional stress (eg, school examinations), or before physical exercise.",
"   </p>",
"   <p>",
"    Illnesses that are associated with diarrhea or vomiting and impaired oral intake require assessment by a medical team, and possibly the administration of parenteral glucocorticoids, saline, and glucose until resumption of adequate oral intake. Patients with CAH and febrile illnesses are at risk for hypoglycemia, especially in young children and if oral intake is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents should be instructed in the techniques for IM administration of glucocorticoids and not rely solely on rapid access to an emergency center. Patients with nausea and vomiting who are unable to take oral medications should receive IM",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    sodium succinate (Solucortef) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/26\">",
"     26",
"    </a>",
"    ]. In the preferred two-chamber Act-o-vial formulation, this medication has a shelf-life of five years unopened. The optimal IM dose and frequency depends upon the patient's size and the severity of the intercurrent illness. As a general rule, 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </span>",
"    or triple the patient's usual daily dose with a maximum dose of 100 mg may be used. The parents' knowledge of indications for and techniques of emergency treatment should be assessed at each clinic visit.",
"   </p>",
"   <p>",
"    Patients who have severe illness or major surgery should receive intravenous glucocorticoids as indicated below. The recommended bolus is followed by a continuous intravenous infusion at stress doses for children of various ages as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &le;3 years &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      (25 mg IV x one dose, followed by 25 to 30 mg per day)",
"     </li>",
"     <li>",
"      &gt;3 years and &lt;12 years &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      (50 mg IV x one dose, followed by 50 to 60 mg per day)",
"     </li>",
"     <li>",
"      &ge;12 years of age &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      (100 mg IV x one dose, followed by 100 mg per day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stress doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    should be tapered rapidly according to the clinical improvement, generally by reducing the dose by 50 percent each day until the patient is receiving their usual glucocorticoid daily dose.",
"   </p>",
"   <p>",
"    Every patient should wear a medical identification (MedicAlert&reg;) bracelet or necklace and carry an Emergency Medical Information Card [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Both should indicate the diagnosis \"adrenal insufficiency\" (not CAH), and the clinician to call in the event of an emergency. Patients can enroll in MedicAlert&reg; by calling (800) 432-5372 or through the internet at",
"    <a class=\"external\" href=\"file://www.medicalert.org/\">",
"     www.medicalert.org",
"    </a>",
"    (United States) and",
"    <a class=\"external\" href=\"file://www.medicalert.ca/\">",
"     www.medicalert.ca",
"    </a>",
"    (Canada).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should be offered counseling as soon as the diagnosis is established. Children should be informed of their condition by both their clinicians and parents; the information should be provided in a manner that is appropriate to the age and developmental status of the child and should be repeated at regular intervals beginning at a young age [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13,60-63\">",
"     13,60-63",
"    </a>",
"    ]. Adolescent girls should receive reassurance and independent counseling should be considered if warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/26,64\">",
"     26,64",
"    </a>",
"    ]. Patients and parents may find helpful information at the following Web sites [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.caresfoundation.org/productcart/pc/index.html\">",
"       CARES Foundation",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.aboutkidshealth.ca/En/HowTheBodyWorks/SexDevelopmentAnOverview/CongenitalAdrenalHyperplasiaCAH/Pages/default.aspx\">",
"       The Hospital for Sick Children",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OUTCOME OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of therapy for 21-hydroxylase deficiency can be measured by evaluating growth, bone density, and, in women, menstrual function. In addition, children with 21-hydroxylase deficiency are at risk for obesity in part due to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult height achieved in treated patients is usually less than that in reference groups [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/65\">",
"     65",
"    </a>",
"    ]. A meta-analysis of studies of height outcome in 561 patients revealed a mean final height SD score of -1.4, or 10 cm below the population mean [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/66\">",
"     66",
"    </a>",
"    ]. The mean weighted final height SD score was closer to normal in those treated before versus after 1 year of age (-1.1 versus -1.6). No difference was found between males and females or by year of study publication (1977 to 1997). Similarly, a meta-analysis of 35 studies of patients treated for congenital adrenal hyperplasia (CAH) reported a final height SD score of -1.03; mineralocorticoid users had a better height outcome compared to nonusers [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective studies have shown that final height of patients with CAH is independent of the degree of control of adrenal androgen concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/38,67-69\">",
"     38,67-69",
"    </a>",
"    ], suggesting that both hyperandrogenism and hypercortisolism contribute to the observed short stature. Several studies have suggested that treatment during the first two years of life and during puberty are the most important factors influencing height outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/69-72\">",
"     69-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best established approach to optimizing linear growth is judicious glucocorticoid and mineralocorticoid dosing and close monitoring; heights approximating target height have been reported in patients treated with thrice-daily doses of medication and monitoring every three months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2,73,74\">",
"     2,73,74",
"    </a>",
"    ]. Experimental therapies to improve linear growth in patients with CAH include sex steroid blockade, growth hormone,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gonadotropin releasing hormone agonists. These treatments can be considered for patients with CAH and severe growth failure (predicted adult height -2.25 SD), in the setting of a controlled research trial [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Experimental medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect on bone mineral density depends upon the age of the patient studied. In 30 younger patients (mean age 17.5 years) in one study, for example, those treated with glucocorticoid therapy for a mean of 15 years did not have decreased bone mineral density, as compared with age, sex, and weight-matched normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/75\">",
"     75",
"    </a>",
"    ]. However, another report of 32 older adults who had been treated since childhood found significantly lower bone density compared with a reference population, most likely because of overtreatment with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the apparently low risk for reduced bone mineral density in children with CAH who are treated with appropriate treatment doses of glucocorticoids, routine evaluation of bone mineral density is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"     2",
"    </a>",
"    ]. However, adults with CAH tend to have low bone mineral density and should be monitored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\", section on 'Bone density'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Menstrual cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found that among 16 adult women (mean age 22 years), menarche occurred at a mean age of 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/65\">",
"     65",
"    </a>",
"    ]. However, only 10 of 24 had reasonably regular menses, while eight had irregular menses [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Testicular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic adrenal tissue located in the testes (testicular adrenal rest) is commonly found in males with CAH and can interfere with testicular function resulting in infertility. In one study of 19 men with classic CAH, eight (42 percent) had evidence of testicular adrenal rest on ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/76\">",
"     76",
"    </a>",
"    ]. In a study of 18 men with classic CAH, nine had testicular rests; most of these had the salt-losing form of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/77\">",
"     77",
"    </a>",
"    ]. Higher dose glucocorticoid therapy may decrease testicular adrenal rest and reverse infertility, but side effects consistent with Cushing syndrome may occur.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    0.75 mg daily and dexamethasone 0.5 mg given twice daily have been shown to restore fertility in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Testis-sparing surgery is rarely indicated, but may be considered in patients when medical therapy fails. However, in one study of eight adult men with CAH, testicular adrenal rest, and infertility, testis-sparing surgery successfully removed the tumors but did not restore fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\", section on 'Male reproduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17653863\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a complication in glucocorticoid-treated patients with 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. In one study, 37 children with CAH (26 classic, 11 nonclassic) were compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/85\">",
"     85",
"    </a>",
"    ]. Children with classic CAH had more fat mass than controls, whereas children with nonclassic CAH had more lean mass but higher insulin levels, suggesting that glucocorticoid therapy plays a role in the development of obesity in CAH. In the largest review of 89 children from Germany with 21-hydroxylase deficiency (ages between 0.2 and 17.9 years), 17 percent of patients were obese as defined by a body mass index (BMI) that was &gt;2 SD from the mean BMI for age [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/81\">",
"     81",
"    </a>",
"    ]. There was no difference in incidence of obesity based upon either gender or clinical form of 21-hydroxylase deficiency (simple virilizing and salt-losing forms). All patients received glucocorticoid therapy and there was a positive correlation between BMI and the dose of medication prescribed. The BMI of normally growing children with CAH has been found to increase throughout childhood more than the expected age-related increase [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/83\">",
"     83",
"    </a>",
"    ]. Children with an obese parent were at increased risk for developing obesity. In a second study, elevated blood pressure was associated with increased BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/84\">",
"     84",
"    </a>",
"    ]. These results suggest that obesity is common in children and adolescents with 21-hydroxylase deficiency and may be associated with higher glucocorticoid dose and parental obesity. In addition, elevated blood pressure is also seen in obese patients. These children and their families should be closely monitored and participate in weight management programs if appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality is increased threefold in patients aged 1 to 4 years, often because of an adrenal crisis after an infection; improved parent education about congenital adrenal hyperplasia and its treatment, especially during episodes of acute illness (eg, infection), may reduce mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/86\">",
"     86",
"    </a>",
"    ]. Mortality rates in older patients are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative therapeutic approach designed to minimize the effects of excess androgens while reducing the glucocorticoid dose was evaluated in a randomized trial of 28 children with classic 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/87\">",
"     87",
"    </a>",
"    ]. A four-drug regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    (an antiandrogen), testolactone (to inhibit aromatization of androgen to estrogen, which stimulates premature epiphyseal closure), reduced-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (average 8.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day),",
"    </span>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    was compared with a control regimen of hydrocortisone (average dose 13.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day)",
"    </span>",
"    and fludrocortisone. Although serum androgen concentrations remained high in the experimental group because of the lower glucocorticoid dose, these children had a rate of normal linear growth and bone maturation after two years of therapy.",
"   </p>",
"   <p>",
"    Because short stature commonly occurs in spite of good adrenal hormonal control during childhood and puberty, exogenous growth hormone therapy has been given to improve final adult height in these patients. In some cases, gonadotropin releasing hormone agonist therapy has been added to block excess androgen activity that exacerbates premature epiphyseal fusion. This is illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 20 children who received growth hormone therapy for two years (eight of whom also received gonadotropin releasing hormone agonist therapy for precocious puberty) were compared to historical control children receiving glucocorticoid replacement only [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/88\">",
"       88",
"      </a>",
"      ]. Growth hormone-treated patients had increased growth rate and predicted height, and decreased height deficit for bone age, as compared to the historical controls [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were seen in a study of 14 children with 21-hydroxylase deficiency who received a combined therapy of growth hormone and a gonadotropin releasing hormone agonist for four years [",
"      <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/89\">",
"       89",
"      </a>",
"      ]. Treated patients had improved final height SD score compared to historical controls who only received glucocorticoid therapy (-0.4 SD versus -1.4 SD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    New treatment approaches that aim to achieve physiological cortisol replacement are being developed and might achieve improved adrenal androgen control with less daily glucocorticoid exposure. As examples, infusion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    in a circadian fashion to poorly controlled congenital adrenal hyperplasia (CAH) patients achieved reduction in adrenal hormone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]; a modified-release oral form of hydrocortisone designed to mimic physiologic cortisol secretion also has been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/92\">",
"     92",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SURGICAL ADRENALECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been some reports of total bilateral adrenalectomy for severe 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. The major potential benefit of this procedure lies in obviating the need to administer glucocorticoids at doses required to suppress adrenal androgen secretion. Reported long-term (average of five years) follow-up of 18 patients with congenital adrenal hyperplasia (CAH) who underwent bilateral adrenalectomy revealed improved signs and symptoms of hyperandrogenism and less obesity after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?31/0/31754/abstract/96\">",
"     96",
"    </a>",
"    ]. A minimum dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    of 11",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    was necessary in most patients to prevent hyperpigmentation and the activation of ectopic adrenal tissue.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44549?source=see_link\">",
"     Fludrocortisone",
"    </a>",
"    therapy is also required. A possible increase in susceptibility (secondary to combined loss of adrenocortical and adrenomedullary tissue) to an adrenal crisis and sudden death must be considered for patients considering this controversial surgical option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/56/19330?source=see_link\">",
"       \"Patient information: Congenital adrenal hyperplasia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5151201\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 95 percent of cases of congenital adrenal hyperplasia (CAH) are caused by autosomal recessive deficiency of 21-hydroxylase (due to mutations of the CYP21A2 gene), which ultimately leads to defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol and diminished or absent production of cortisol. Variable degrees of salt-loss are observed in the classic form. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"       \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link&amp;anchor=H1#H1\">",
"       \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Introduction'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Therapy of 21-hydroxylase deficiency is directed toward providing glucocorticoid in sufficient doses to reduce the associated excessive corticotropin-releasing hormone (CRH) and corticotropin (ACTH) secretion and hyperandrogenemia, so that growth, sexual maturation, and, later, reproductive function, are normal. Mineralocorticoid is given to normalize serum electrolyte concentrations, extracellular fluid volume, and plasma renin activity. Treatment with mineralocorticoid permits lower glucocorticoid dosing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For parents who are carriers of classic CYP21A2 gene mutations, prenatal treatment consisting of maternal administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      can be considered. This treatment may prevent abnormal genital development in affected female fetuses, but only if it is initiated in very early pregnancy (eg, before nine weeks of gestation), which is before a molecular diagnosis of 21-hydroxylase deficiency can be made. Because prenatal therapy may have adverse effects and long-term consequences are unknown, the decision to treat should be made in consultation with a highly experienced team in a research setting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prenatal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborn infants with CAH may be identified through prenatal diagnosis, neonatal screening programs, because they are noted to have ambiguous genitalia on physical examination (females), or because of an adrenal crisis (hyponatremia, hyperkalemia, dehydration) at 10 to 20 days (males). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management in neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborn infants with ambiguous genitalia require urgent medical attention to prevent an adrenal crisis if CAH is the cause, and to advise and support the family. In addition to steroid hormone measurements listed below, a karyotype should be urgently performed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ambiguous genitalia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"       \"Evaluation of the infant with ambiguous genitalia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Newborn infants with classic CAH are at risk for an adrenal crisis, which is characterized by hypotension or shock, and electrolyte abnormalities (hyponatremia, hyperkalemia, metabolic acidosis, and hypoglycemia) (",
"      <a class=\"graphic graphic_table graphicRef61357 \" href=\"UTD.htm?22/54/23405\">",
"       table 1",
"      </a>",
"      ). Infants with a suspected adrenal crisis should be urgently treated with fluid replacement. Stress doses of glucocorticoids should be given",
"      <strong>",
"       after",
"      </strong>",
"      a blood sample is obtained for steroid hormone measurements (most importantly, 17-hydroxyprogesterone) to confirm the diagnosis of CAH. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Adrenal crisis'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      For newborns with a positive newborn screen suggesting CAH, a sample of blood should be obtained for confirmatory steroid hormone measurements (most importantly, urgent measurement of serum electrolytes and 17-hydroxyprogesterone).",
"      <strong>",
"       After",
"      </strong>",
"      the confirmatory blood sample is obtained, treatment doses of glucocorticoid and mineralocorticoid and sodium chloride supplementation should be initiated in",
"      <strong>",
"       all",
"      </strong>",
"      infants in whom CAH is a consideration. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Positive newborn screen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid replacement is necessary in all infants and children who have classic 21-hydroxylase deficiency. In infants and children, this is usually administered as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (cortisol) in a dose of 10 to 15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      body surface",
"      <span class=\"nowrap\">",
"       area/day.",
"      </span>",
"      In the early phase of treatment, infants may require 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      of hydrocortisone, but stress doses of up to 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      may be needed temporarily to reduce markedly elevated adrenal hormones. Longer acting glucocorticoid preparations increase the risk for growth failure but may be used in some adolescents and adults. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Positive newborn screen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mineralocorticoid replacement is necessary in all pediatric patients who have classic 21-hydroxylase deficiency. Mineralocorticoid replacement can often be tapered after infancy. Dosing should be guided by measurement of plasma renin activity and blood pressure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mineralocorticoid and sodium chloride'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Response to therapy is monitored by measuring serum 17-hydroxyprogesterone, androstenedione, plasma renin activity or direct renin, as well as growth velocity (measured by serial measurements of height) and the rate of skeletal maturation. Laboratory and clinical monitoring should be performed every month in the neonate and infant, and every three to six months thereafter. Bone age should be measured at least annually after two years of age until skeletal maturity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children with classic CAH are at risk for developing an adrenal crisis, which is characterized by hypotension or shock, and electrolyte abnormalities (hyponatremia, hyperkalemia, metabolic acidosis, and hypoglycemia) (",
"      <a class=\"graphic graphic_table graphicRef61357 \" href=\"UTD.htm?22/54/23405\">",
"       table 1",
"      </a>",
"      ). Adrenal crisis can be triggered by significant physical stress or illness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonadherence to treatment. To avoid an adrenal crisis, patients with CAH should be treated with stress doses of glucocorticoids when they become ill with fever or gastroenteritis, or undergo surgery with general anesthesia or trauma. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Adrenal crisis'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Adult height in patients with classic 21-hydroxylase deficiency is modestly decreased as compared with reference groups. The best established approach to optimizing linear growth is judicious dosing of glucocorticoid and mineralocorticoid dosing and close monitoring to avoid under- and over-treatment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Growth'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/1\">",
"      Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/2\">",
"      Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:4133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/3\">",
"      Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002; 136:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/4\">",
"      Auchus RJ, Witchel SF, Leight KR, et al. Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative. Int J Pediatr Endocrinol 2010; 2010:275213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/5\">",
"      Fern&aacute;ndez-Mart&iacute;nez FJ, Galindo A, Garcia-Burguillo A, et al. Noninvasive fetal sex determination in maternal plasma: a prospective feasibility study. Genet Med 2012; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/6\">",
"      Miller WL. Clinical review 54: Genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1994; 78:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/7\">",
"      Forest MG, B&eacute;tuel H, David M. Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr Res 1989; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/8\">",
"      Mercado AB, Wilson RC, Cheng KC, et al. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995; 80:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/9\">",
"      Evans MI, Chrousos GP, Mann DW, et al. Pharmacologic suppression of the fetal adrenal gland in utero. Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia. JAMA 1985; 253:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/10\">",
"      David M, Forest MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 1984; 105:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/11\">",
"      Migeon CJ. Comments about the need for prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1990; 70:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/12\">",
"      New MI, Carlson A, Obeid J, et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001; 86:5651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/13\">",
"      Joint LWPES/ESPE CAH Working Group.. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002; 87:4048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/14\">",
"      Lajic S, Wedell A, Bui TH, et al. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998; 83:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/15\">",
"      Pang S, Clark AT, Freeman LC, et al. Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 75:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/16\">",
"      Meyer-Bahlburg HF, Dolezal C, Baker SW, et al. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 2004; 89:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/17\">",
"      Hirvikoski T, Nordenstr&ouml;m A, Lindholm T, et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007; 92:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/18\">",
"      Uno H, Eisele S, Sakai A, et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 1994; 28:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/19\">",
"      Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197:585.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/20\">",
"      Poulain M, Frydman N, Duquenne C, et al. Dexamethasone induces germ cell apoptosis in the human fetal ovary. J Clin Endocrinol Metab 2012; 97:E1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/21\">",
"      Merc&egrave; Fern&aacute;ndez-Balsells M, Muthusamy K, Smushkin G, et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 73:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/22\">",
"      Seckl JR, Miller WL. How safe is long-term prenatal glucocorticoid treatment? JAMA 1997; 277:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/23\">",
"      Nimkarn S, New MI. Prenatal diagnosis and treatment of congenital adrenal hyperplasia. Horm Res 2007; 67:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/24\">",
"      Hirvikoski T, Nordenstr&ouml;m A, Wedell A, et al. Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint. J Clin Endocrinol Metab 2012; 97:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/25\">",
"      Clayton PE, Miller WL, Oberfield SE, et al. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002; 58:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/26\">",
"      White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/27\">",
"      Hendren WH, Donahoe PK. Correction of congenital abnormalities of the vagina and perineum. J Pediatr Surg 1980; 15:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/28\">",
"      Premawardhana LD, Hughes IA, Read GF, Scanlon MF. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 1997; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/29\">",
"      Speiser PW. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Endocrinol Metab Clin North Am 2001; 30:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/30\">",
"      Kerrigan JR, Veldhuis JD, Leyo SA, et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 1993; 76:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/31\">",
"      Metzger DL, Wright NM, Veldhuis JD, et al. Characterization of pulsatile secretion and clearance of plasma cortisol in premature and term neonates using deconvolution analysis. J Clin Endocrinol Metab 1993; 77:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/32\">",
"      Linder BL, Esteban NV, Yergey AL, et al. Cortisol production rate in childhood and adolescence. J Pediatr 1990; 117:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/33\">",
"      Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1987; 27:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/34\">",
"      Young MC, Hughes IA. Dexamethasone treatment for congenital adrenal hyperplasia. Arch Dis Child 1990; 65:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/35\">",
"      Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987; 316:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/36\">",
"      Klingensmith GJ, Garcia SC, Jones HW, et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977; 90:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/37\">",
"      Richards GE, Grumbach MM, Kaplan SL, Conte FA. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 47:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/38\">",
"      DiMartino-Nardi J, Stoner E, O'Connell A, New MI. The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinol Suppl (Copenh) 1986; 279:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/39\">",
"      Young MC, Ribeiro J, Hughes IA. Growth and body proportions in congenital adrenal hyperplasia. Arch Dis Child 1989; 64:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/40\">",
"      Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics 2000; 106:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/41\">",
"      Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. J Pediatr 2003; 143:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/42\">",
"      Frisch H, Battelino T, Schober E, et al. Salt wasting in simple virilizing congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2001; 14:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/43\">",
"      Nimkarn S, Lin-Su K, Berglind N, et al. Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/44\">",
"      Muthusamy K, Elamin MB, Smushkin G, et al. Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010; 95:4161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/45\">",
"      Balsamo A, Cicognani A, Baldazzi L, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 2003; 88:5680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/46\">",
"      Lopes LA, Dubuis JM, Vallotton MB, Sizonenko PC. Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? J Pediatr Endocrinol Metab 1998; 11:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/47\">",
"      Jansen M, Wit JM, van den Brande JL. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth. Acta Paediatr Scand 1981; 70:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/48\">",
"      Schaison G, Couzinet B, Gourmelen M, et al. Angiotensin and adrenal steroidogenesis: study of 21-hydroxylase-deficient congenital adrenal hyperplasia. J Clin Endocrinol Metab 1980; 51:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/49\">",
"      Simpoulos AP, Marshall JR, Delea CS, Bartter FC. Studies on the deficiency of 21-hydroxylation in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1971; 32:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/50\">",
"      Pang S. Congenital adrenal hyperplasia. Curr Ther Endocrinol Metab 1994; 5:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/51\">",
"      Shimon I, Kaiserman I, Sack J. Home monitoring of 17 alpha-hydroxyprogesterone levels by filter paper blood spots in patients with 21-hydroxylase deficiency. Horm Res 1995; 44:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/52\">",
"      Appan S, Hindmarsh PC, Brook CG. Monitoring treatment in congenital adrenal hyperplasia. Arch Dis Child 1989; 64:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/53\">",
"      Hughes IA. Management of congenital adrenal hyperplasia. Arch Dis Child 1988; 63:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/54\">",
"      Cutler GB Jr, Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1990; 323:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/55\">",
"      Silva IN, Kater CE, Cunha CF, Viana MB. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch Dis Child 1997; 77:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/56\">",
"      Gr&ouml;schl M, Rauh M, D&ouml;rr HG. Cortisol and 17-hydroxyprogesterone kinetics in saliva after oral administration of hydrocortisone in children and young adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2002; 87:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/57\">",
"      Hughes IA. Monitoring treatment in congenital adrenal hyperplasia. Arch Dis Child 1990; 65:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/58\">",
"      Soliman AT, AlLamki M, AlSalmi I, Asfour M. Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog. Metabolism 1997; 46:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/59\">",
"      Flor-Cisneros A, Leschek EW, Merke DP, et al. In boys with abnormal developmental tempo, maturation of the skeleton and the hypothalamic-pituitary-gonadal axis remains synchronous. J Clin Endocrinol Metab 2004; 89:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/60\">",
"      Kuhnle U, Bullinger M, Schwarz HP. The quality of life in adult female patients with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients life. Eur J Pediatr 1995; 154:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/61\">",
"      Meyer-Bahlburg HF. Gender and sexuality in classic congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/62\">",
"      Servin A, Nordenstr&ouml;m A, Larsson A, Bohlin G. Prenatal androgens and gender-typed behavior: a study of girls with mild and severe forms of congenital adrenal hyperplasia. Dev Psychol 2003; 39:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/63\">",
"      Pasterski VL, Geffner ME, Brain C, et al. Prenatal hormones and postnatal socialization by parents as determinants of male-typical toy play in girls with congenital adrenal hyperplasia. Child Dev 2005; 76:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/64\">",
"      J&auml;&auml;skel&auml;inen J, Tiitinen A, Voutilainen R. Sexual function and fertility in adult females and males with congenital adrenal hyperplasia. Horm Res 2001; 56:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/65\">",
"      J&auml;&auml;skel&auml;inen J, Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1996; 45:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/66\">",
"      Eugster EA, Dimeglio LA, Wright JC, et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001; 138:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/67\">",
"      Brook CG, Zachmann M, Prader A, M&uuml;rset G. Experience with long-term therapy in congenital adrenal hyperplasia. J Pediatr 1974; 85:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/68\">",
"      Urban MD, Lee PA, Migeon CJ. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978; 299:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/69\">",
"      New MI, Gertner JM, Speiser PW, del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatr Jpn 1988; 30 Suppl:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/70\">",
"      Rasat R, Espiner EA, Abbott GD. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. N Z Med J 1995; 108:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/71\">",
"      Young MC, Hughes IA. Response to treatment of congenital adrenal hyperplasia in infancy. Arch Dis Child 1990; 65:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/72\">",
"      Bonfig W, Pozza SB, Schmidt H, et al. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab 2009; 94:3882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/73\">",
"      D&ouml;rr HG. Growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2007; 68 Suppl 5:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/74\">",
"      Hoepffner W, Kaufhold A, Willgerodt H, Keller E. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience. Horm Res 2008; 70:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/75\">",
"      Mora S, Saggion F, Russo G, et al. Bone density in young patients with congenital adrenal hyperplasia. Bone 1996; 18:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/76\">",
"      Avila NA, Premkumar A, Merke DP. Testicular adrenal rest tissue in congenital adrenal hyperplasia: comparison of MR imaging and sonographic findings. AJR Am J Roentgenol 1999; 172:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/77\">",
"      Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:3070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/78\">",
"      Collet TH, Pralong FP. Reversal of primary male infertility and testicular adrenal rest tumors in salt-wasting congenital adrenal hyperplasia. J Clin Endocrinol Metab 2010; 95:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/79\">",
"      Claahsen-van der Grinten HL, Otten BJ, Sweep FC, Hermus AR. Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil Steril 2007; 88:705.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/80\">",
"      Claahsen-van der Grinten HL, Otten BJ, Takahashi S, et al. Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. J Clin Endocrinol Metab 2007; 92:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/81\">",
"      V&ouml;lkl TM, Simm D, Beier C, D&ouml;rr HG. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 2006; 117:e98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/82\">",
"      Knorr D, Hinrichsen de Lienau SG. Persistent obesity and short final height after corticoid overtreatment for congenital adrenal hyperplasia (CAH) in infancy. Acta Paediatr Jpn 1988; 30 Suppl:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/83\">",
"      Cornean RE, Hindmarsh PC, Brook CG. Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998; 78:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/84\">",
"      Roche EF, Charmandari E, Dattani MT, Hindmarsh PC. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol (Oxf) 2003; 58:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/85\">",
"      Williams RM, Deeb A, Ong KK, et al. Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010; 72:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/86\">",
"      Swerdlow AJ, Higgins CD, Brook CG, et al. Mortality in patients with congenital adrenal hyperplasia: a cohort study. J Pediatr 1998; 133:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/87\">",
"      Merke DP, Keil MF, Jones JV, et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/88\">",
"      Quintos JB, Vogiatzi MG, Harbison MD, New MI. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/89\">",
"      Lin-Su K, Vogiatzi MG, Marshall I, et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005; 90:3318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/90\">",
"      Bryan SM, Honour JW, Hindmarsh PC. Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. J Clin Endocrinol Metab 2009; 94:3477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/91\">",
"      Merza Z, Rostami-Hodjegan A, Memmott A, et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006; 65:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/92\">",
"      Verma S, Vanryzin C, Sinaii N, et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010; 72:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/93\">",
"      Gunther DF, Bukowski TP, Ritz&eacute;n EM, et al. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. J Clin Endocrinol Metab 1997; 82:3324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/94\">",
"      Bruining H, Bootsma AH, Koper JW, et al. Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/95\">",
"      Gmyrek GA, New MI, Sosa RE, Poppas DP. Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. Pediatrics 2002; 109:E28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/0/31754/abstract/96\">",
"      Van Wyk JJ, Ritzen EM. The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88:2993.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5800 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31754=[""].join("\n");
var outline_f31_0_31754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5151201\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRENATAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT IN NEONATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adrenal crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Positive newborn screen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Glucocorticoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mineralocorticoid and sodium chloride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitoring therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adrenal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OUTCOME OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Testicular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17653863\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EXPERIMENTAL MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SURGICAL ADRENALECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5151201\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5800|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/54/23405\" title=\"table 1\">",
"      Rapid overview adrenal crisis in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=related_link\">",
"      Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=related_link\">",
"      Management of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/56/19330?source=related_link\">",
"      Patient information: Congenital adrenal hyperplasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_0_31755="Path features HCV";
var content_f31_0_31755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathologic features in recurrent hepatitis C and acute cellular rejection following orthotopic liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathologic feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute rejection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurrent hepatitis C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lobular necroinflammation",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interface hepatitis",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bile duct damage",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apoptosis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoid aggregates",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central vein endotheliitis",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steatosis (fat)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrosis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31755=[""].join("\n");
var outline_f31_0_31755=null;
var title_f31_0_31756="Tuberculin skin test interpretation";
var content_f31_0_31756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretation of tuberculin skin test",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tuberculin skin test reaction size (mm)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Situation in which reaction is considered positive*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       &ge;5",
"      </td>",
"      <td>",
"       HIV infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Close contact of active contagious case",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal chest x-ray with fibrotic changes consistent with old TB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunosuppressed patients: TNF-alpha inhibitors, chemotherapy, organ transplantation, glucocorticoid treatment  (equivalent of &ge;15 mg/d prednisone for &ge;1 month)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       &ge;10",
"      </td>",
"      <td>",
"       Persons with clinical conditions that increase the risk of reactivation, including silicosis&bull;, chronic renal failure requiring dialysis&bull;, diabetes mellitus, some malignancies (leukemias, lymphomas, carcinoma of the head, neck, or lung), underweight (&ge;10 percent ideal body weight), jejunoileal bypass, injection drug users",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Children less than 4 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Foreign born from countries with incidence &gt;25/100,000 &Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Residents and employees in high risk settings, such as prisons, jails, healthcare facilities, mycobacteriology labs, and homeless shelters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;15",
"      </td>",
"      <td>",
"       Healthy persons with low likelihood of true TB infection &loz;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The goal of testing for latent tuberculosis infection is to identify individuals who are at increased risk for the development of tuberculosis and therefore would benefit from treatment of latent TB infection. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive (see text).",
"     <br>",
"      &bull; The US Centers for Disease Control and Prevention (CDC) recommends a 10 mm induration definition for patients with silicosis or chronic renal failure. However, population based studies demonstrate that the relative risk for development of active tuberculosis in this category is high (&ge;10x that of healthy individuals). For this reason, many favor a lower threshold for a positive test (&ge;5 mm).",
"      <br>",
"       &Delta; The US Centers for Disease Control and Prevention (CDC) indicates that only those foreign born individuals who immigrated within the past 5 years should be tested (regardless of age), although others do not favor this practice since most recently arrived foreign born with positive TST have old (not recent) infection.",
"       <br>",
"        &loz; Persons with a low likelihood of true TB infection should not be tested routinely unless they are entering a high risk setting such as starting employment at a healthcare facility. A threshold of 15 mm is used in the US, and is appropriate for healthy individuals with low likelihood of true TB infection and high likelihood of exposure to non-tuberculous mycobacteria (eg, Southern US). However, Canadian guidelines use a threshold of 10 mm for healthy individuals given the lower likelihood of exposure to nontuberculous mycobacteria. (See \"Epidemiology of nontuberculous mycobacterial infections\").",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31756=[""].join("\n");
var outline_f31_0_31756=null;
var title_f31_0_31757="Preferred and alternative regimens for ART-naive patients";
var content_f31_0_31757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preferred and alternative regimens for antiretroviral therapy-na&iuml;ve patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        Selection of a regimen should be individualized based on virologic efficacy, toxicity, pill burden, dosing frequency, drug-drug interaction potential, resistance testing results, and comorbid conditions. The regimens in each category are listed in alphabetical order.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Preferred regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (Regimens with optimal and durable efficacy, favorable tolerability and toxicity profile, and ease of use.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        The preferred regimens for nonpregnant patients are arranged by order of FDA approval of components other than nucleosides, thus, by duration of clinical experience.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         NNRTI-based regimen",
"        </strong>",
"        <ul>",
"         <li>",
"          EFV/TDF/FTC&Delta; (AI)",
"         </li>",
"        </ul>",
"        <hr/>",
"        <strong>",
"         PI-based regimens",
"        </strong>",
"        <em>",
"         (in alphabetical order)",
"        </em>",
"        <ul>",
"         <li>",
"          ATV/r + TDF/FTC&Delta; (AI)",
"         </li>",
"         <li>",
"          DRV/r + TDF/FTC&Delta; (AI)",
"         </li>",
"        </ul>",
"        <hr/>",
"        <strong>",
"         INSTI-based regimen",
"        </strong>",
"        <ul>",
"         <li>",
"          RAL + TDF/FTC&Delta; (AI)",
"         </li>",
"        </ul>",
"        <hr/>",
"        <strong>",
"         Preferred regimen&loz; for pregnant women",
"        </strong>",
"        <ul>",
"         <li>",
"          LPV/r + ZDV/3TC&Delta; (AI)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <strong>",
"         Comments",
"        </strong>",
"        <hr/>",
"        <p>",
"         <strong>",
"          EFV",
"         </strong>",
"         should not be used during the first trimester of pregnancy or in women trying to conceive or not using effective and consistent contraception.",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          TDF",
"         </strong>",
"         should be used with caution in patients with renal insufficiency.",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          ATV/r",
"         </strong>",
"         should not be used in patients who require &gt;20 mg omeprazole equivalent per day.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Alternative regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (Regimens that are effective and tolerable but have potential disadvantages compared with preferred regimens. An alternative regimen may be the preferred regimen for some patients.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         NNRTI-based regimens",
"        </strong>",
"        <em>",
"         (in alphabetical order)",
"        </em>",
"        <ul>",
"         <li>",
"          EFV + (ABC or ZDV)/3TC&Delta; (BI)",
"         </li>",
"         <li>",
"          RPV/TDF/FTC&Delta; (BI)",
"         </li>",
"         <li>",
"          RPV + ABC/3TC&Delta; (BIII)",
"         </li>",
"        </ul>",
"        <hr/>",
"        <strong>",
"         PI-based regimens",
"        </strong>",
"        <em>",
"         (in alphabetical order)",
"        </em>",
"        <ul>",
"         <li>",
"          ATV/r + (ABC or ZDV)/3TC&Delta; (BI)",
"         </li>",
"         <li>",
"          DRV/r + ABC/3TC&Delta; (BIII)",
"         </li>",
"         <li>",
"          FPV/r + either [(ABC or ZDV)/3TC&Delta;] or TDF/FTC&Delta; (BI)",
"         </li>",
"         <li>",
"          LPV/r + either [(ABC or ZDV)/3TC&Delta;] or TDF/FTC&Delta; (BI)",
"         </li>",
"        </ul>",
"        <hr/>",
"        <p>",
"         <strong>",
"          INSTI-based regimen",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          RAL + ABC/3TC&Delta; (BIII)&nbsp;",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Comments",
"         </strong>",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <hr/>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          RPV",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Use RPV with caution in patients with pretreatment HIV RNA &gt;100,000 copies/mL",
"         </li>",
"         <li>",
"          Use of proton pump inhibitors is contraindicated with RPV",
"         </li>",
"        </ul>",
"        <p>",
"         <strong>",
"          ABC",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          ABC should not be used in patients who test positive for HLA-B*5701",
"         </li>",
"         <li>",
"          Use ABC with caution in patients with high risk of cardiovascular disease or with pretreatment",
"          <br/>",
"          HIV RNA &gt;100,000 copies/mL",
"         </li>",
"        </ul>",
"        <br/>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The following combinations in the recommended list above are available as fixed-dose combination formulations: ABC/3TC, EFV/TDF/FTC, LPV/r, RPV/TDF/FTC, TDF/FTC, and ZDV/3TC.",
"    <br>",
"     <div class=\"footnotes\">",
"      3TC: lamivudine; ABC: abacavir; ATV: atazanavir; ATV/r: atazanavir/ritonavir; DRV: darunavir; DRV/r: darunavir/ritonavir; EFV: efavirenz; FPV: fosamprenavir; FPV/r: fosamprenavir/ritonavir; FTC: emtricitabine; INSTI: integrase strand transfer inhibitor; LPV: lopinavir; LPV/r: lopinavir/ritonavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleos(t)ide reverse transcriptase inhibitor; PI: protease inhibitor; RAL: raltegravir; RPV: rilpivirine; RTV: ritonavir; TDF: tenofovir; ZDV: zidovudine.",
"      <br>",
"       Rating of Recommendations: A = Strong; B = Moderate; C = Optional Rating of Evidence: I = data from randomized controlled trials; II = data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = expert opinion.",
"       <br>",
"        &Delta; 3TC may substitute for FTC or vice versa.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         For more detailed recommendations on ARV use in an HIV-infected pregnant woman, refer to the Perinatal guidelines available at file://aidsinfo.nih.gov/guidelines.",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"      Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, October 14, 2011. United States Department of Health and Human Services.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31757=[""].join("\n");
var outline_f31_0_31757=null;
var title_f31_0_31758="Fatty cast polarized";
var content_f31_0_31758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fatty cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 218px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADaAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5wpfxpKWgBMc0oFJR2oAKBQaB1oAKKO1FAAOtJS0UAJS0lLQAUUdqKADtS4pAKUUAIKBS0lAAKDSikoAPxo704U2gBQKQ0oo70AJiiiigANAHXmigdaAA0tJRQAdqKKWgBDS+lFGOlAB2pKWgigBKKWkoACKKD1pQKAEopcdKTHNABil9KTFOxQA2iiigAHWjFA60uKAA0tJRQAd6KKWgBKQUp60goAWkpaO1ACelFLSCgAo9aB3ooAUUHrSdqO9AC9qO1LR9aADHBNIozQKAetACjqaQ4zSjvSUAFFKRmkHWgBRSd6WkNACUvpS44pO9ACZo70UvegA70hpaD0oAQ9OtLRR6UAHelPalPWj0oATFB6UtBoATtSU7saTHNAAaMcUtKBQAhpBjJqTbyKUocZ7UARUuOBSkgYAGaQ5oAaRikpelB60AHeg9aB1ooAKXtSUvagBCelKKSgUABoHWg0DrQAUdqQ0vagApKUUnWgAFL35oHWjuaAFzR3pAKXHNAB60opO1LQAg70ADuaUdaQA5yKAFGM0HqKAOaVh0oAQdaQ0o6UmeaAFFIetKtIcZoATpml70Gl9qAGmjvSn0pO9AC8ZpD0oAzS44560AJS+lB7UoFABRilPWj0oAKQ0vagDgUALik7U7FGCTgAk+1ACYzWt4c0O98Qava6ZpcBmvLhtiIOMn3NQ6MLT+1rQaiWWzMqiYr1C55/Svq7TPEXwk8PXFlfeH/s4u7deJUDAgEYO4t1P0oA838P8Awag0TxPawfES8hs7CVC0flTD96/93OOK9F+Lvw38JWvw78/T/sulpZoXjcIDJcMeApYnJq/8Q/FXw01/w8+qaneJd3McTLbIjOJVbsFHQc9zXnXw3+GWp/ECzGseKNUu4dFGVtUL73cZ7A9BQB5B4c0TTrrxHaWes332Oydh5k4GcCtL4iaN4a03WTa+F9Ta9gRQGdh1bvg96h+Juhy+GvElxpyrOtpG58kzLhmX1rkwqsCd2CPXvQBDLHskZBgkVGPpTj161OkluLR0aJmuCRh92AB9KAIBjNIetLg+lHFADaX60lL2oAKO1J3pRQAhoFBoHUUAB6UdR1oNHagBcYpO9KKSgA70opB1pR3oAXNJ0oxQOtAC9jQOlIe9KBQAtIKXpSLzQADP4Up60g60p60AApGxjilFIOtAAM0h60vbik70AHal7daVsdqMcUANJJHtQvXmlBwKF65oACDxR2pTSUAL2pfqaD0oAyKADqaWgDApW6UAIAadjHWnxKCQOSx7CrN5p1zbuqzwPGSMgOMHBoAqlcJkEVY0zUZ9Pld7fZl12ksoPH416L4F+C/ijxXCLiOBbG0YZWa6yoYewxk1ynjbwfqHhLW59O1BQzxHHmR5Kt9DQBS1nVYtSggjhsYLZox8zpnLn1NGg+H9W1yVotJs7i6dRuIjQnArS8JeFLrU7u3nuIHXTRIPNl7bRyefpX2b8Odc8JXGhyf8I9Ha2Fpa/unDBYycDqe5+poA+H9a/tC1MdhqCNEbfIEZXBBPrXrnwU+Ldp4YsJ7fxLc3ksNsn+hwxjco65GO31rG/aI1Hw9deMSfDc8VypTM7x8qZM84bvXkmCcnNAHdfEjxnqfxJ8TJcNbKAP3VvDCnIXPGe5Nc94i8Nar4dmji1e0ktpHUMquO1bHwv8RJ4a8QwahJ5W2A7wHTduPoK7b4keL9W+LF/awaJoJjtrVSV2LuY+pZugHHSgDyjSNKn1OZora3mmmAyEjUniptDtrFPEVvHrjNFZrIPOAHOPSp7PXNS0C5mFhO1vcMDHI6HkjuKwp5XmleSVizMcknvQB6N8QLfw9exJP4bkjigjTHl4wc15setOBJ4ycU0rzQA2lpDS0AJQKKUUABpB1pW9qRetAB2pQKD0ooAKQCnCm9zQADrThSClGaADtQKAPWjHNABjrQuO9L2owKAF7HvTVHenL1NAFABijoKXGTSMCDzQAmaQGlFIMbuaAAUHqKdxQRzQAgHrQMUGgfSgANApcHvRigBOtKBxQABSgUAJg0uKdjpUgQnGKAGFaTYSeASav21vLMwjt4mllbgBVzXe3/AMLvGOg+GJNevLCOCyCBn3Ou9VPQleo7UAct4Mura3vxDLZwS3MzKkctw2Eh55Y13uneIdG07x3Bf+KAdXjtJQoaAAxYHQgdwKn/AGf/AAJonjTVNQl8Q3WFtguy2SQI0hOefoMdvWvcvi18PtMn+HL2WlRW+nw2A84FYslgB0JAySaAO/8ACfiHT/FGixano7O1m5KoXTYeODxXnH7Q3ifQtL8G3VhOtndarc/JDFhWaL1c+lfNNp8Q/EuhaAdC0vVpILHLfLGAGGevzdRXV/Cj4Sal8QLY61fXyQ2Im2kyEs8uOWx/iaAMjRviPqVn4Wm0aS1ha02FUKoAQT3Jrz5J7y5naK3Mm6Q42KTzX2t44+HGnHwPPpfhbQbA3hULG74Uj1Yt1Jr43nS88LeI5Y7uHZeW0hVkPOCDQBm6lp13YShL2CSJuvzriqLEZOK9A8ffEQeKdHtLMaVb288ePNufvPJjoPYV59gc80AdX8MYtJm8aaYniGaKHTfMHmvKCVx719taTD4Pu9HnttHksBZOmx2t2CqR9Rx3r8/QT68V7r8KvAXijx14LZIdajsdHjlKpG2SXbv07UAee/FXSdM0Lx5fWmmSJcWCSArsk3cdcZ9axLxrXUJUOn2S28YAG0tkk1e+InhO/wDB/iC40zUnSSVMHehyGB6Guat2YSKIwxbOAB60Ae9/Bn4SaDr+hX+seK7x4oYW2iOOQIFAGSzGuT1LR/AEWo3UdvqV00KSuqHGcqCcdvSsm90jxraeGi9xp2o2uknDMzRsqtnufWuGO7JznNAEVApe9LjFADKUdKO9KOlACHpSL1p3akHWgA7GjtSnoaO1AAKQd6djikxQAmOfalFGMk0oFABzQOBSimH71AD8AgnNJgU0dalJQkHGKAGClHNPIAPXOaao70ALkA+tJkMeBzRgnnFPQbck0ARjrT1jyDgc00/Kc4p6P6rigCMcHmjtQMl6djBoAtHTL9dPS/axuhYuSq3Jiby2IOCA2MHn3qpjH1rU0jxBq2hsW0fU72xJ+99nmZA31AOD+NbH/CZy3YH9u6Nouq56vLaiCU+/mQFGJ92zQByfNB69K65D4O1JgDBrejTNxmJkvo8+yny2A/4Ex+te2eNP2dLFdHtJPD2rx22qx26CaC9fEdw4UbmU9UJOTjkfSgD5oiiMgJHAFC9cCtTWdF1Lw9qMmnavavbXK8lWIII9VYZDD3BIqtY2ct1dRwW8bSyyNtVVGST6UARRR55PQVf06xu9UuktdNtZZ53OFSJSzH8BXfaV8JvEEvirR9Iv7KS3+2fvGL8BYxyxOPQV9a+DfAnh/wAHo/8AYlgkMzjDzMSzkemT0FAHlf7PENr4XtJNG8Q6XNYa9dz7ovtFuQ0qY4AOOMc16z45Xw7c6JLZ+LLm3isJBuZJZ/L3Y+hBNUfib4cm13QxPpt29lqunk3FrOhxhgOQfY18S+LvEOra9qJm1vUp72dTtzI2QAPQdBQBbvtSstE8cyah4ZBbTrW6324kP3lDZGfWu28ffHbXfFWmvp1tbRafYyrtnWIlmkHcbj0FeRZUuABVu7haCNABjf1JFAFK5dZJGdE2AnhQc4r0b4NeMb3S/EFhpt3rtzp3h9pt9wqNwR6e2elek6J8E/Cl54JW8g1w3mqzW3mIUlQRq5GcbevB45r5yv4XsL+aBipaJipKnIyPegD6p+Ifx/tND1EWnhaK21KER/NM+4Kre3rXzD4l12517V7rUb/a1zcOXcgYGT6Cs2WUOo457mpdLt0urxIZGIDnAwMnNAFRsZGaGZc8DArd8Q6DLo0m2+imhYgFFkTaWB749K589aAFyeK63wd488SeFR5ehalPbxM24wg5Qn3B4rl2EPkIVdjKTyMcD8aSN2jYMhww70AavivWtV1/Vpr/AFud5rublmbj8hVLTL59N1C1vLZQZoJFkXcMjIORxVeWWSZhvJYjjmn28pt5dzRKzDoG6UAfRC/tFyzeE7q21fSY7rVJlKLwFhAIxkjkmvnua7eWZ5CFBZi2AOBmku7yW7YGTaAowAowBVagA70VsaH4b1jXWcaTp9zdlOW8qMtj8qo6hY3On3L297BJBMhwySKQR+FAFPvSjpR3AooAO1IOtL2pF5NAC9qUdKQ8ZpR0oADmhT60ZPekzQAd6cBkEimnmgE9AaAH8CmlcnignHWgHmgBQMA0enFIOc05V4560AAoXpk9KaDzTxyDmgBeg5BA9+9JuycUjMznLEkAYye1NUEsDjgUASAc0h607NIOtAAKWg0mDQAuKXk/SnIDTwhJ6UARMMUgWpmQgZxTJBtUHjJ7UAIkZJz2r6O+CWreCo9G0nS7bSnvPFksxcyGLO1geDuPQAV83KxY9cV6X8K/BfjLVZBq3hOF0EL7PtXmBAp74J69ecUAfTXiJ7Ky14eJNa1pbO60yMqtqjj5wRyMHk5qva/HTwZLbtJPdTwOv8BiJJ+mK8g+MHw3vfDmlW2t6xrs2qX1w4SWPaeuM8HJyB9BXidw/wAxxER9aAPoj4lfH9bzT5tP8J27xrMhR7qYfMARg7V7fU14l4J8LXHjLXhZQXUEDkFi8zYB9h6n2rAinMIY4UlhjHap9Inu7a+hubJnWZXBUpxg54oA7n4ifCzWPBNnFqNw0L2UjhEYP8xOM9K4/TbzT/MkOtQ3FwAuI0jfaAfevorSPhb4s8cWtnL451uWLTdokjt0OX5HHBGB+Oa4DU/g5cab8R7LSrwXMOhXU+yO8baSyD6cA/WgDyX7fcQM4tJpoY2yMK5HFUG5bJYmvcvjr8NvD/hS2sj4bnup7pyfNhZhJhcfeyBxXhsud2NuCOKAB8ADFWNLnkttQhmty3mIwKketVHUg896sWAnW5QwIWfPAxmgDt/HRvdTsINX1nUIZLl1CrCzlpMf0FeetjPFXdTmnmnZpxg55AGBVE9aAAdqnt5ViOWQPUCjJp4GBnIoAmnc3MpaKPaMdFqVbOeWAukLYXkkZJNJb3phhaNVAB4JUcn8abHf3EMbpBI0auMNtPJHpQBX6ZGaKQUYFAH0b8CPi9oPhbw+dJ1qA22GL/aIkyX+orj/ANoLx3oXjXWLOXQbVlECFZLh0CtISfT2ryQtzTSc0AGD97tSDtmkpR0oAO1AHIo4ozzxQAdqUdKFHFSACgBmKSnkZ7U0KByaAEHXpSijgnigUAIQaNpz6U/AxRwO2aAEQYPNKTzxTRwTS0AB60q80q9aXFACKBk0pOOBTlHalK8cUAR0Dr71IEPpUcpxxQArMWICjJpuSODUtsq7tz5pZ9gGVHXqaAJLZCSCK7nwd8P/ABB4m1GxS2064SyuJAhvGiPloO7Z9q4OymRbmIzhjCGBKqcEivuv4XeP/D/iixtdP8OxXKG1t18yJosLAAMYLdD+HWgDzDx78C9D0DwXe6lBqlybm0i8xjMFCSH0AA4z25NfM10gyxUEnoK/QHx54i8OaDpyjxU0TW8xOyGSLzPMI7BcV8WfEPWdH1jxncXWi6d/Z2nlgEgUAE+rYHAz6UAciZUNqkIgAkByZO9e8fA/4mXGiNpnhS1+yyWk8+57mdSPJ3fexg8/jXjusWztD9riVEhdtiqWBfp6V6l8Hvg1rms3Vlqupo+n6RIpcS7h5jjHG1ff1NAHtXjf4yeFNBvZbGaM6pOif8sAroSf4ST0/WvmoaXqPxH8XXI8NaVtaZjIY0wscS57noBXY/Hz4f6Z4LFjLor3cvn7jL53zbOmCWAHXniqn7PvxFtfB+oXdnqNuHt71lzMvDIR/Mc0AP8AEXwK1nw9pMepalfWL2yMPPWMtmMHv05/CmvH4c8IWhuNOuYL64Z0kgkkiIVGByQAetfRnjvx/wCHNC8Otc38sN5HOmEt1KsXyO49K+JfEmq/2rfTSodkJkZkjHAUE8ACgD650343+GF8Jwahqd4P7Q2YktYozuZvbtj8a5Dwp8Q9c+JnjP7PaaXEumW6s2zdgop43FvX6V4F4I0HUfFOsxaTplss91P0LnAQDqx9BX1r8J/hRZ+DbFpdRZbrVpD80kTsEVewA4z+NAFubxF4X8Kw31vdTRRXqR5l80ZJOOAM9a+JfEFwtxrF3NEylHkZgVGBya9v/aX8NXdl4nOo2tpdtpssal5iC0av3Gf8a8DugAAVXigCJ23LjHTvV7QLlbbUI3nMgi77OprNJycVdnv1m0+K28hVeM/6wHkj0xQBe8Wa6+tXUZNvBBHCojRYkC5A7nHU1hFuMYFPH0/OkON3SgBY8Y5oO09M0jEEjAxQOgoAQ+1IRzQaKAAdaKKMUALS4zT4DGJkMwJTPzAdSK33to9VuUXRtPl2/dwAWJNAHOHrQOlX9W0u70u5aC+t3glHVXGDVAHigBO1IOtOx8tIBzxQBPDgDJFez/B74JSeOtGOs6hqX2KwZ2jjWNN7uR1PXAFeJ5rvfh38UNf8ERPDptwXtGJb7PIcoG9cUAXfi/8ADC9+HuowK063Wn3RIt5xwTjqGHY81xmvaDc6NHZvcyQv9pjEqiN9xUHsfQ1r+PPHmu+N72K41y68wQgiKNFCon0A/nXMTXU04UTOzKvQGgBqjHGCTjoBTV5PUc9q2dG1LUtMtry8sYoxDKvkyO0atgHsM1iF8uWbqeTigCQ4HXgUFh0SiNomlTzt3lg/NjrirV9c27Xe/Tbc28QGAC24n3JoAqD0pcYGMU1H+c7+akJGNwoAZ/EMiplaMjADZrpPB3gnUvFJ3WijZnaOeWPoBUvi3wJ4i8FvDNrOmyQ28j4jkfBVyO3B/SgDS+Hfwx17xys8ulQRpawkBpp32Lk9h3Ncj4hsJNF1i60+ZkeW3kMbmNgwyDjg969d0X4g6xpemWMmqTxQaHftslhsQsbso4bGORxXF/Fe88G3eowHwPY3lvEFzNJcOf3jH0BJx+dAHC7mLDIIz2phBEmcdK9l8D/AfX/Ffhy31k3tpaRXC7oEmLFmXseAcCvP/G/g7VfB2tnTdXjVZ8BgUbcGU9CDQBhm5MmVES7iMVDOjqBvXFOnj2Nlc49fWhXecLG2MA9TQAwwyIiuVIU967n4afEXWPAk9y2jCB1uFAljmXcrY6Hse5rj7j93FtDZzUCts5RscUAdd4+8fa341vYrjWroOYgRHHGoVEB9BXIGR2l37iW9TTTk9jUphaJisyFWxnmgBVdvNG4s+PevrD4FfFyHUNKfTvFN5p2nrp8CRwPIxRpQBjkk44AHSvk+NghOMVYt8Kpcq7qOpC8CgD6N+LfxssNc0+/8NeHdO+3C4PlC6k5U89UXGfoTXBaL8MtS0pU1nxTaNbWEDKzQswDSjrjrXnctvf2ttFqC2dxBAW/dzlCFJ9jXqnw78ReGtZE8nxJ169njtkAt7Vi5VvXkfy4oA6XxR4D1Dxx4ZfxBBZafoulWts8ttBDlpJlHdvTpXzdJ8rlfQ4r0Xxh8Rr+5N5pPh+8ubLw0WZIbYOeY/Q/4V57sVju3ZJoA6j4d+M9R8E68uqaYsUkoQxskwyrKeo/SvsfR/iVoz+ALXxFquoWUTtDvlhjkGRJ/cCk5zXwojLGvA/OpBICvLZX0zQB7t8Xfjpb+J/D0ui6JYyQQz48+acgnA7KB/Ovn4uSNvH1qWZgwwBioSoxy2aAGFRySw+lHbsKH4GRTccc0AOIwtMI60Z4xSetADhjAoHTk0gHHSl44oAaaKKD1oAB1pT9aSl59qADvXaeE/H+oeGdJmsrCOFRKdxk2DePxrjTjFN6igDQ1rV7zWLxrm/naWRjklqoKpPA5PpSqM/hViwm+z3CvtB+ooAryAjhl2kURoXbap5rudI8Ean4rUSaPbtKx+92A/GuT1rTp9G1aayuFKTwEo4z0NAFKRChw1OTYE5znNEMUlzOkUSl5HOAB3NXNV0e/0iZYtStZbd2GQHUjI9qANTw34a1HxTdi00OwmupwMkRqTgep9Ko+INEvdDvXtNRtpbedDhkkXBFe6/sv+O9D8OWWq6drtzb2Pmss0c8gPz4GCpIrmf2g/iNZeONZgtNFt1NlZ5Vbkr88xPf2X0FAHjpZ/L2lvkHO3NNKnG7aQvrU9m8cVxuni8xQeVzUl7KlzPmGMxp2TOcUAU+p46U9SUbK9qVcowyAMetP37WbG1s/7PSgCNDwc45pyAkEUxl9uKsx7FClVYkfez0oA634f+MW8HS3VxFame9ZQIJC5AhPcgdzVfxb4x1zxfKJtevprnZ/qo2OFT6AcVgQgswAI3McCvpnwL+zta+Rp+pa/qrTSNsna2hj+Qg4O0sTz6dKAPmeJJYWjkmiMkanIVs4roNWvNEv9FhhtbGf+2d43Sq+IgvoFxX3B4s8PabeeFL+xGj29yv2dkhgSJQd23C7fTnHNfCni3wxrXha68rWLGeyeTlFcY3D2PQ0Adbovjrx94M0KAW+pPFpykxQxSlXC9ztBzxXMax4lutVmkv9YuJL6/mOWeQ9K5+6u5riGJJpHbYMKD0AqCORYZUbAkA5Kt0oAfK5lcsAAOuKhCuQzL0HU1IHEkjO2FB5wBwKJFhC/K5J9MUAOljURqQ2T3qbS9PutSvI7PTreS5uZThY0XJP4VT+prV8M63qHhvV4dT0icwXUWdr4zQBHrGk3+iX7WWrWs1rcpjdHIu0iqZGTlmJPua1fFviXU/FesSalrVx5124CltoAAHQACsZWPfpQA9gd2AK7nT/AIhXVr4Pk8P/ANk6c8TKF84wgPwc5z3PvXCl8mnBznrigD1Hxp8Xda8UeEbfw81lZ2ljGiK5jUln29OvT8K8w3bW+ZRSb3GME0hOcE8tQA99z4bHHakCkAEmk3YHWkDZoAHbPFSKo2Zzk1qeFfDWp+J9Yj0/SLSW5nblhGudi92PoK9H8XfAvxD4d0FtVikW7RCN8ESMZFHrgDpQB5CxwOajOccdKlmV1ZlcFWHUEVCx5xQAjc03n0pT160UAIB3NIetKeucUnr2oAP4aB1o9KXNACH1pDQelHagBR2pf89KTHtRQAuMUqjikrovAXhqXxd4osdGguIrdrl9plk6KO59/pQBz6KSwVepr0D/AIVhq58Kxa0nlvC43YVuQK7j4q/Ac+EPDR1jStTa8itxm5WZQhA9V5/SvIT4p1j+zF08X862a8CMMQKAOi0X4ieIPC+kTaPpsiQo2QzBcsPoa4e7nlvLmSe4kLyudzMx5JpquWcs7HJ6k0xiN3FAFnSb6TTdQhu4ceZEwZc+orpPHPjjUvGlzZyaoIwtsnlosa449TXKbflz3rtfg/p/hzUfGECeMLoW+lopc5JAdh0UkdBQBykkqGLai4qCOTyzu3HcOgr6U+KVl8I4fDtxdaY0S6k0Wy2is2ONwPVh/jXzNLt8xvLJK9iaAPU/hlH4CutC1A+M2niuky0LRZG7jpwK84uhbi6uGtJGEIc+WGHJXPFUg7BcBjj0q3pNlcajepbWcZlnfhVHegCu4+b5skV6F4dstFPgTULy7tJBcq4VJA1c5qnhnU9Nwl/ayQSsNwVxjIqpBaX72MhST/R43wU39T9KAGzWxtp4p5raVbaTlN4+8PamQWdxqFyyafazSAnIjjUuQPwqcXCXMZW9mlyi4QdefT2FfTv7OPjHwxZ+F7bRYLeSLWmkbzdkJYzEng7h7YGD0oA+b9a8N614ftbSbVtOns47ob4WkGCwFe5eDvjhfP4WstDstN3ahbwiI3ksuVwOAcY644617r4y8FaD4zsng1q1WSRRtWVWxJET6Gvmr4m/CY+EdEu9Q029JtoZAAWOGYfh3zQB9I+Bb+7Twst74knigmdi7PLIFCjA656V4J+05498P6/Ba6PpLJe3NrIXa6j5Rc9VU9/rXhl3ruqXVskF3qFzLAvCo0hIH4VTDqR2x6mgCpyW5ol+TgHOanaZRkKMj1xVR2JcsaAJBA5iDjkVJHbgwu7SKrL/AAnvUSSttC5O30qW8ZAVEb7jjkigCFMngAZ9amRAPUmmRJ8me9SZOPlOGoAa/B6Uwn1p+Tgbjk0hwaAIwM1YSPK5HaotvOaXJxjOKAAnmlU+1N20E7W5NAEgA3fNTeCflGKQSA8U44wMUAdl8LvHeoeBNeN1YPGIbgLFcB4w+U3AnHvXv/jT9o3RrS0MfhW1lvrp14lnXZHGfp1b9K+TcgdKkzxxQBY1i/n1PUJ7y6IM87l3IGBknJ4rPYCnuwPemA0AN70Yp2Kb060ADjaBg800d80r8kGm0AL+FLjp1pM9hThkigBpHFJS84NA7GgApaCTu7UZ9qACp7WeW2mSa3kaOVTlWU4INQUooA6fW/HXiXW9LTTtU1i7uLJOkLyErx6+tcw1L3o7UAMNTWUqQXcUssSyohBKN0PtUWDg0gBzQB3Pi/XPDur6Da/YdOa01dTh/KAWLb9OpNcW3yYKmmY96OaAHGRmPzEn61GTknPFKPTFAUlgGOPegBg61b068nsLyO4tZGjmQ5VgcGoJVWOTCOHHrRGGeTjrQB3N8NavIY9X18XX2aQAJK4PzD2zSax4ca28Kw64l9bRR3EhSO0EmZj/ALRHYVj6t4p1jUNOtrC8uGe3twBGp7Csh7ueQqHYlV6CgD3D4VfDXTdU8J6hda/aXLXs8ZaykDbYk4PLHp19a8jhvrjQdXlNrOyyxOV3QyEA4PqK9O1342TX3w+sfDNjpqWKxxJDPMr5LKox8o7Z79a8gvzbmcGzZ2U8ncO9AG9F4316C4llttSuYfNO51SVgGPvzzT/ABT4+1/xNbx2+q38kluihRGOFOO5Hc1zPlOx3NgCo8DPFAD5GUoAKaFZlxnAHNIoyamLAcYoAhKsBwcigK8hO44HrT+c8UpLEUAN8jkc8U0R4bg81KuSQKSVwjbUGSOpoAQEqCOtGO9Ism44YDPrSt1oASkGCaU03oaAHGmHOacDTguaAGn7orZ8J+GrzxNqItbLG7qSTishsYq5o+p3mmXAewnaKRuMqcUAL4j0qTRNUmsZj+8iODVBDkDip9VmmuLp5bmUyTNyzE5JqspIwAM5oAd0pc8UjDFFADG69KTPOKcaaRnnFAAxzxnFJxilIOaU9M0AM4ApcZJNG3POaTJ7UALjBozjGKTdml9KAEPIoo9aSgBaOKKXigA70tM707PFACk80Cm96O1ACsfeheppO1APNAD6M009KM8GgBwYjpTWOeaSjPNAAi571NGfLOR1qHdjpTlPJoAnd945NIrHtUIbBp245oAk2g9TTxhV6VCGIp27IOTQAGQn6VLDCXGR0qsV4qaG4KLtoARhsbFJTWbc2TQDQA8E0E03OO/NIw3Dg0ATR8gkHkVFAVEuZeV70gJWkKbskGgCSYoZv3XShjg+9MT5Pr60E85P50AKScUmcmkOfWkzzQA/uMU5c4qMGrUDKFOetADAme1RspzxX1z8Ivgp4eTwzY6r4it/7Rvb2BZvLdiI41YZAAHU4Iryn9ob4aw+CtWt7/SFC6RekhIy2TE46r9OeKAPGQhLc08nAxmhs5zTCaAFzjrRkEccUw9BmgdOKAHZppxmg5pD1oAcxxTVOfekPWgdaAHdRimHINKeOKQmgA6mnbjgU0U7pigBD0NJRRQAueaCeaO9GaAE70tB60CgBO9KOlIaXtQAUg60HvQOtAC9qOoo7UDoaADFIKUUDrQAgBpw75pzD5KZ3FADu3tSikP3aO4oAXPFLmkNIOtADs4po5NOPSk7UAKBwaQUtC0ALg0hpTSUAKozwaC5GVWlTrTU/wBZQAm4jOacRwDUb/fb61KfuigBnag8mihaAAU8dD600U+P7woA9p+HXx31nwtoY02+tl1OCJAlt5jbTEB2yByK4r4jfEDWvHeopcavIqwRZEMEYwkYPp7+5rjLgneB2pF+7QAjHk1HTj978KPSgAIyKb9KePu1H2oAXtTc040g60AIaKVqRetACGkPWlPanJ1NADelKx6UsnWk7CgBOxooooAO9B69aXuKbQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing fatty cast under polarized light. The fat droplets have a characteristic \"Maltese cross\" appearance (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31758=[""].join("\n");
var outline_f31_0_31758=null;
var title_f31_0_31759="Needle position";
var content_f31_0_31759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Relationship of motor unit action potential (MUAP) amplitude to needle position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Of all MUAP parameters, amplitude is most dependent on needle position. Only muscle fibers very close to the needle contribute to amplitude, as opposed to duration, wherein most muscle fibers contribute. Note change in amplitude as needle is moved to different locations within the same motor unit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Preston, DC, Shapiro, BE. Electromyography and neuromuscular disorders, Butterworth-Heinemann, Boston 1998. Copyright &copy; 1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_0_31759=[""].join("\n");
var outline_f31_0_31759=null;
